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ABSTRACT
Upon entry into the host, pathogens must overcome innate immunity in order to 
cause disease. The innate immune system is a fast-acting initial line of defense to 
prevent infection. In order to withstand innate defenses, bacterial pathogens like the 
Gram-positive bacterium Staphylococcus aureus produce a wide array of virulence 
factors that can inhibit innate immune cell recruitment and antimicrobial activity, or 
directly target and kill phagocytic leukocytes thereby facilitating pathogenesis. Infection 
with S. aureus can cause disease in virtually any tissue site and is a significant burden 
to human health. In this thesis, we sought to understand how S. aureus counters the 
host innate immune system to cause disease. Macrophages are professional 
phagocytic leukocytes that are central to innate defenses. As such, we hypothesized 
that S. aureus must be able to overcome macrophage inflammatory responses to aid in 
its pathogenesis.  
Data from a forward genetic screen using S. aureus cell free supernatants 
derived from a transposon mutant library uncovered that a mutation in the gene 
encoding the lipoic acid synthetase (LipA), which is required for the de novo synthesis 
of the cofactor lipoic acid, resulted in enhanced TLR2-dependent activation of 
macrophages. We found that the hyper-inflammatory response elicited by a DlipA 
mutant correlated with the absence of lipoylation on the E2 subunit of the pyruvate 
dehydrogenase complex (E2-PDH). In wild type cells, the release of lipoyl-E2-PDH 
occurred during exponential growth and required the major staphylococcal autolysin Atl. 
 
      xxii 
Purified S. aureus lipoyl-E2-PDH prevented TLR1/2 activation by triacylated 
lipopeptides. Moreover, the absence of lipoyl-protein production in vivo resulted in the 
recruitment of activated inflammatory macrophages that are better able to restrict S. 
aureus growth through production of bactericidal reactive oxygen and nitrogen species. 
Despite enhanced antimicrobial immunity upon primary infection with a DlipA mutant, we 
found that the host fails to mount an improved recall response to secondary infection. 
Overall, data in this thesis indicate that S. aureus lipoylated E2-PDH moonlights 
as a novel immune evasion protein by suppressing TLR-mediated macrophage 
activation. Our data also suggest that lipoic acid synthesis in S. aureus promotes 
bacterial persistence during infection through limitation of reactive oxygen and nitrogen 
species generation by macrophages. Broadly, this work furthers our understanding of 
the intersections between bacterial metabolism and the immune response to infection. 
Furthermore, work in this thesis provides a potential therapeutic target for S. aureus that 
can cripple bacteria replication and promote host immunity.  
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CHAPTER ONE
REVIEW OF LITERATURE 
Section 1: Staphylococcus aureus and Human Health 
Nearly 140 years have passed since Sir Alexander Ogston first isolated an 
infectious bacterium from a patient’s leg abscess and named it Staphylococcus aureus 
(1, 2). S. aureus is a Gram-positive coccus which causes a significant amount of human 
disease. Up to one-third of humans are asymptomatic carriers of S. aureus where it 
mainly resides in the nasal cavities, but recent data demonstrates that other sites of the 
body can be colonized as well (3-9). In addition to these carriers, a large proportion of 
people are transiently colonized with S. aureus (3-5). The pool of asymptomatic and 
transient carriers contributes to a large carrier population. Though S. aureus is highly 
pathogenic and potentially lethal, it is considered to be part of normal bacterial flora in 
asymptomatic carriers (5). Moreover, these carriers may facilitate the transmission of S. 
aureus throughout the population both in healthcare and community settings (10).  
S. aureus Disease and Morbidity. 
The most common manifestation of S. aureus disease is skin and soft-tissue 
infections such as impetigo, boils, scalded skin syndrome, or abscesses, and atopic 
dermatitis. Though the skin is the most common infection site of S. aureus, the 
bacterium can breach skin barriers and colonize almost every tissue site in the host. 
Upon access to these other tissues of the host, S. aureus infections lead to more severe
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diseases including osteomyelitis, pneumonia, toxic shock syndrome, necrotizing 
fasciitis, food borne illness, endocarditis, bacteremia, and sepsis. 
S. aureus is an opportunistic pathogen. Immunocompromised individuals, as well 
as those undergoing device implantations or procedures like catheterization are all at 
higher risk of contracting a severe S. aureus infection (11). In 2013, the Centers for 
Disease Control and Prevention (CDC) estimated an incidence of 80,000 severe 
infections and 11,000 deaths caused by S. aureus (12). Alarmingly, a recent report cites 
that the number of reported severe infections has increased to just under 200,000 cases 
and around 20,000 deaths (13). A contributing factor to the mortality of patients with 
severe infections is the inability to treat S. aureus infections due to antibiotic resistance.  
Antibiotic Resistance in S. aureus. 
The first successful antibiotic to treat S. aureus infections was penicillin. 
However, resistance by S. aureus to penicillin quickly appeared (14, 15). In 1960, a 
synthetic derivative of penicillin, named methicillin, was created as an alternative aimed 
to treat penicillin-resistant S. aureus infections. However, after only one year of use the 
first incidence of methicillin-resistant S. aureus (MRSA) was identified (16). Resistance 
to methicillin is conferred by the presence of the mecA gene which is mobilized by a 
mobile genetic element called the staphylococcal cassette chromosome mec (17). The 
presence of methicillin resistance on a mobile genetic element leads to robust horizontal 
transfer between different S. aureus strains (18). A large number of genes that encode 
antibiotic resistance mechanisms and virulence factors are found on mobile genetic 
elements which are transferred by phage transduction (19). Transduction by phage is 
the most common route for gene transfer as S. aureus is not naturally competent. 
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Though resistance to methicillin is considered a dangerous adaptation, MRSA can still 
be treated with the antibiotic vancomycin. Similarly, as with methicillin, the emergence 
of vancomycin resistance in S. aureus isolates appeared quickly after its implementation 
(20, 21). Despite its high level of antimicrobial resistance, there are several antibiotics in 
use or in development that can still control this pathogen. Derivatives of vancomycin 
such as telavancin, dalbavancin, and oritavancin all can kill S. aureus in vitro (22, 23). In 
the clinic, the cephalosporins ceftobiprole and ceftaroline were shown to be effective 
against skin and soft-tissue infections (24, 25). In summary, the emergence of antibiotic 
resistant isolates of S. aureus highlights the adaptability of this human pathogen.  
Epidemiology of S. aureus. 
There are many different infectious strains and isolates of S. aureus that have 
been characterized over the years. Three main typing methods such as multilocus 
sequence typing (MLST), staphylococcal protein A gene (spa) typing, and pulsed-field 
gel electrophoresis (PFGE) have been used to molecularly classify the different types of 
S. aureus isolates (26). MLST is a sequence-based genotyping method based on single 
nucleotide variations of seven S. aureus housekeeping genes that lead to distinct 
profiles known as sequence type (ST) (27, 28). Furthermore, S. aureus genomes are 
categorized into clonal complexes (CC) based on MLST, of which four CC cover 90% of 
all known S. aureus genomes (29, 30). spa typing is based on the variable tandem 
repeats in the spa gene (31). Lastly, PFGE incorporates fragmentation of the DNA with 
restriction enzymes followed by separation of the fragments PFGE. In the United States, 
PFGE was chosen as a standard over other typing methods and classified eight 
different lineages designated as pulsed-field types USA100 through USA800 (32).  
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Although infections occur on a global scale, a global pandemic strain has never 
emerged, rather infectious strains tend to only regionally dominate. A recent example of 
a strain that emerged in the healthcare setting was CC30 in North America and Europe 
(33, 34). In focusing on current predominant strains in the United States, USA300 is the 
most common strain of S. aureus that spreads mainly in the community causing skin 
and soft-tissue infections (35). USA300 first emerged in 2000 as a cause of skin and 
soft-tissue infections among college football players in Pennsylvania and prisoners in 
Missouri (36, 37). Since 2000, it has continued to spread among the community in the 
United States and was isolated from cases of severe infections (38). The spread of 
USA300 is attributed to virulence characteristics like resistance to numerous antibiotics 
such as methicillin, erythromycin, levofloxacin, mupirocin, and tetracycline (35). Though 
USA300 is a dominant strain in the United States, it has been isolated in Europe, South 
America, and Australia (39-41). 
With the first report of MRSA in 1961, that bacterium was believed to be 
transmitted in the healthcare setting. However, in the 1990s, cases of MRSA were 
beginning to be reported in the community in individuals that had no prior hospitalization 
leading to both healthcare-associated (HA) and community-associated (CA) infections 
(42). MRSA and methicillin-susceptible S. aureus (MSSA) infections are dominant in 
both the healthcare and community setting (43, 44). As such, in 2013 MRSA was 
classified as a serious threat to public health due to widespread infections and 
associated morbidity in the United States (45). Although a recent report by the CDC 
details a steady decline in the incidence of HA-MRSA infections from 2005-2012, 
between 2013-2016 this decline has slowed (13). Furthermore, CA-MRSA infection 
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rates have decreased at a much slower rate (13). Alarmingly, the rates of HA-MSSA 
infections have not decreased and CA-MSSA infections are still steadily increasing (13). 
The severity of infections caused by S. aureus and the continued dominance in hospital 
and community settings, underscore the need to find ways to treat S. aureus infections 
that do not rely on antibiotics or lead to resistance. 
Section 2: Host Defense Against S. aureus 
 The success of S. aureus as a human pathogen is aided by its ability to 
overcome host defenses such as the innate immune system. In this section, we will 
introduce components of the innate immune system that S. aureus faces upon invasion 
of the host focusing most heavily on macrophages. This will be followed by a section 
detailing how the innate immune system can recognize S. aureus. Then we will describe 
ways in which the innate immune system controls S. aureus during infection. After 
introducing how the host innate immune system interacts, recognizes, and controls S. 
aureus infection we then will cover the myriad adaptations of S. aureus that function to 
overcome the host response to infection.  
Physical and Chemical Barriers to S. aureus Infection. 
 The most common manifestation of S. aureus infection is skin and soft-tissue 
infection. Therefore, the first line of defense that S. aureus must overcome to cause 
disease is the host skin layer. The skin layer acts as physical barrier to prevent S. 
aureus from accessing deep tissues of the host. In the skin, epithelial cells linked 
together by tight junctions form a barrier to prevent S. aureus entry into the body. 
Besides these physical components, chemical components of the skin also work to 
defend against S. aureus infection. The skin is free of infection due to its slight acidic pH 
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and antimicrobial lipid composition (46). In saliva and tears, antibacterial enzymes 
including lysozyme and secretory phospholipase A2 function to kill S. aureus (47, 48). In 
addition, skin cells produce more than 20 different types of antimicrobial peptides 
(AMPs) such as defensins or cathelicidins, and make antibacterial fatty acids to prevent 
S. aureus infection (46, 49, 50). 
Cellular Arm of the Innate Immune System. 
When chemical and physical barriers to infection fail, the spread of a pathogen is 
countered by an innate inflammatory response mediated by recruited effector 
leukocytes and associated molecules. These leukocytes are derived from the myeloid 
lineage of cells which include macrophages, monocytes, neutrophils, dendritic cells, 
mast cells, eosinophils, and basophils. Though non-myeloid derived cells such as 
natural killer cells and gd T-cells also have innate-like functions. Cells that comprise the 
innate immune system are characterized by their ability to recognize microbes and 
mount fast responses to infection. The majority of innate immune cells are present in 
the blood and can access almost any tissue site during an infection. All of these innate 
immune cells are described to interact with S. aureus in some capacity and are outlined 
below.  
Eosinophils, Basophils, and Mast Cells. 
 Eosinophils, basophils and mast cells are highly granular cells of the innate 
immune system that have many overlapping functions. All of these cells contribute to 
responses in allergic inflammation. Eosinophils produce a wide range of cytokines, 
though their production of cytotoxic granule proteins such as major basic protein, 
eosinophil peroxidase, eosinophil cationic protein, and eosinophil-derived neurotoxin 
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(51, 52). Granule proteins produced by eosinophils aid in host control of helminth 
infections. Eosinophils can also respond to inflammatory signals and release 
mitochondrial DNA forming traps with granule proteins that are known to have 
antibacterial activity (53).  
Like eosinophils, basophils facilitate host defense to parasites. Basophils have 
little proliferative capacity, but upon activation produce histamine in addition to 
interleukin (IL) 4 and IL-13 all of which are potent mediators of allergic responses (54). 
Mast cells have many overlapping functions with basophils including the production of 
granule proteins such as histamines, but they also produce IL-5 and IL-13 upon 
activation (55). Again, mast cells are widely recognized for their role in allergic 
responses but can also aid in control of bacteria or viruses.  
While the role of eosinophils, basophils, and mast cells in facilitating host 
defense to S. aureus infection is not well understood, there are numerous studies that 
describe activation of these granular cells in response to S. aureus exposure. S. aureus 
can exacerbate allergic diseases like atopic dermatitis (56). In atopic dermatitis the 
functions of these granular cells contribute to the pathology associated with disease. 
Eosinophils were found to be targeted and killed by a S. aureus toxin in the supernatant 
called alpha-hemolysin (57). The S. aureus mediated killing of eosinophils is proposed 
to increase tissue injury during allergic disease (57). Moreover, Staphylococcal protein 
A, which binds to Fc regions of antibodies, is reported to bind and crosslink IgE and IgG 
on the surface of basophils causing the release of histamine (58). Lastly, mast cells can 
recognize the presence of S. aureus and activate inflammatory responses such as 
production of IL-8 and tumor necrosis factor-a (TNFa) (59). Interestingly, S. aureus can 
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invade and persist in mast cells (60). While S. aureus can activate mast cells in vitro, 
mice lacking mast cells were not more sensitive to S. aureus infection (61). In summary, 
while there is a small amount of published work related to how granulocytes such as 
eosinophils, basophils, and mast cells interact with S. aureus, the biological relevance 
of these interactions needs to be further explored. 
Dendritic Cells. 
 Dendritic cells are aptly named for their stellate morphology, when first described 
in the 1970s (62, 63). They are a heterogenous population of cells with distinct functions 
and subsets that are present in peripheral tissues. A main function of dendritic cells is 
their proficient ability to ingest matter through phagocytosis, micropinocytosis, and 
receptor-mediated endocytosis (64). Upon engulfment of a pathogen or activation by 
pro-inflammatory signals, dendritic cells can migrate from the tissue into secondary 
lymphoid organs and undergo a maturation event culminating in antigen presentation 
(64, 65). In antigen presentation, the internalized pathogen is processed and broken 
down into small components or antigens that are then presented on major 
histocompatibility class I or II (MHC) to activate naïve T cells (64, 65). In addition to 
antigen presentation on MHC, T cells also require co-stimulation which is provided by a 
variety of surface expressed molecules on dendritic cells including cluster of 
differentiation (CD) 40, CD80 and CD86 (66). Furthermore, dendritic cells secrete 
cytokines such as IL-12 that are involved in differentiation and activation of Th1 cells 
(67). In mice, dendritic cells are usually defined by the expression of an integrin named 
CD11c and high levels of MHC-II. A subset of dendritic cells that respond to viral 
pathogens are known as plasmacytoid dendritic cells. Relevant to S. aureus are the 
 
      
9 
classic/conventional dendritic cells, which secrete cytokines and chemokines necessary 
for establishing protection against S. aureus (68).   
 Dendritic cells also interact with S. aureus in different ways that can have major 
consequences for the innate and adaptive immune system. For example, wall teichoic 
acid of S. aureus drives dendritic cell maturation and activation in vitro (69). Without 
proper dendritic cell activation, they do not efficiently present antigen nor activate T 
cells. EsxA/EsxB are virulence factors of S. aureus and were found to be important for 
dendritic cells to condition the Th1/Th17 response to S. aureus (70). Conditional 
knockout of dendritic cells in mice during infection with S. aureus led to higher bacterial 
loads, inflammation, and mortality (71). A recent example of S. aureus interaction with 
dendritic cells revolves around the S. aureus toxin LukAB, which can kill dendritic cells 
and interfere with their activation of T cells (72). All together, these examples highlight a 
few of the interactions between S. aureus and dendritic cells that can influence the host 
response to infection. 
Neutrophils. 
 Neutrophils are the most abundant cell of the innate immune system (73-75). 
Neutrophils are mainly present in the blood, though they can be found in the bone 
marrow, spleen, lung and the liver (76, 77). Because of their unique multi-lobulated 
nucleus, neutrophils are termed polymorphonuclear leukocytes (PMNs), which include 
other innate immune cells such as basophils and eosinophils. An additional 
characteristic of neutrophils is their large abundance of granules and secretory vesicles 
present in the cytoplasm (78, 79). Neutrophils are considered to be short-lived cells, but 
during inflammation their longevity is expanded (76, 80). Upon invasion of S. aureus or 
 
      
10 
other pathogenic microbes into host tissues, neutrophils are rapidly recruited from the 
vasculature to site of infection by extravasation (81). During extravasation, P- and E-
selectin on the surface of endothelial cells in blood vessels bind to glycosylated ligands 
on the surface of neutrophils, causing free-flowing neutrophils to tether to the 
endothelium (82). The flow of circulating blood causes neutrophils to roll along the 
endothelium until they adhere via binding to integrins (83). Neutrophil specific 
chemokine gradients on the endothelium promote the crawling of neutrophils during 
extravasation (84). Finally, this process culminates upon transmigration of neutrophils 
through the endothelial cell layer and into the tissue by either paracellular or 
transcellular routes (85). 
 Neutrophils are considered to be highly pro-inflammatory cells with potent killing 
capacities. Though less proficient than macrophages and dendritic cells, neutrophils 
also phagocytose extracellular material. In mice, neutrophils are characterized by 
surface expression of the integrin CD11b and the protein Ly6G. It is unknown if there 
are different subsets of neutrophils like dendritic cells and macrophages. 
In the context of S. aureus infection, neutrophils are critical to infection control, as 
their absence leads to a higher susceptibility to infection (86, 87).  During MRSA 
infection, distinct types of neutrophils were isolated from mice, based on their surface 
expression of proteins and production of cytokines, that either resisted or were 
susceptible to infection (88). The neutrophils isolated from resistant mice were more 
mature and displayed pro-inflammatory characteristics in contrast to the anti-
inflammatory phenotype of neutrophils from susceptible mice (88). It is unknown if there 
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are different lineages of neutrophils that arise during infection with S. aureus or if 
neutrophils change functions based on diverse signals.  
Macrophages. 
 Described by their ability to phagocytose bacteria and apoptotic cells over 100 
years ago, macrophages have long been considered to be important cells of the innate 
immune system (89). In the host, macrophages have critical immune roles in pathogen 
defense and are major mediators in a multitude of host homeostatic functions. In 
addition to engulfment of pathogens and cellular debris, macrophages secrete an 
abundant array of cytokines and chemokines that function to regulate other innate 
immune cells and regulate the adaptive immune response to infection (90).   
Tissue resident macrophages. Nearly every tissue in the body has a resident 
population of macrophages, including immune privileged sites such as the brain and 
testes (91). In these tissues, macrophages can orchestrate critical functions in tissue 
development, sense damage, and mediate tissue repair. Originally, these tissue 
resident macrophages were thought to be populated by circulating blood monocytes 
that can differentiate into macrophages. However, we now understand that this is not 
the case. Instead these tissue resident macrophages are derived from the yolk sac and 
fetal liver, with only a small component derived from hematopoietic stem cells in the 
bone marrow (92, 93). These resident macrophages are then maintained by continuous 
self-renewal (94-96). Moreover, tissue resident macrophages have distinct tissue-
specific transcriptional and epigenetic profiles that highlight their heterogenous tissue 
specific functions based on the anatomical location in which they reside (97-100). Brief 
examples of the diverse functions of tissue resident macrophages are the following: 
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osteoclasts, bone macrophages, are highly specialized cells that can remodel bone 
(101); microglia present in the central nervous system contribute to brain development 
and function (102); lung alveolar macrophages clear surfactants produced by lung cells 
in addition to inhaled particulates and microbes (103); Kupffer cells in the liver remove 
harmful metabolites and pathogens (104); splenic red-pulp macrophages remove 
senescent red blood cells from circulation and recycle heme and iron (105).  
Peritoneal macrophages. A large reservoir of tissue resident macrophages is 
present in the peritoneal cavity. Peritoneal macrophages comprise two major subsets, 
the large and the small peritoneal macrophage (106). These two macrophages 
populations were first separated based on high surface levels of the integrin CD11b and 
the surface glycoprotein F4/80 in the large peritoneal macrophages compared to the 
small peritoneal macrophages (107). Large peritoneal macrophages are thought to 
originate from the yolk sac and self-renew in contrast to small peritoneal macrophages 
which have bone-marrow origins (108). During an infection in the peritoneal cavity, 
small peritoneal macrophages increase in number and are derived from recruited 
monocytes (107). Furthermore, small peritoneal macrophages are more phagocytotic 
and produce oxidative molecules to a higher extent than large peritoneal macrophages.  
Recruitment of macrophages during infection. During the course of acute 
inflammation or infection, macrophages are recruited to facilitate the host immune 
response. Macrophages that are present at the site of infection or inflammation can be 
from the tissue resident cells or derived from circulating monocytes. Monocytes 
originate from hematopoietic stems cells derived from the bone marrow and themselves 
have important functions in innate immunity (109, 110). However, monocytes infiltrate 
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the site of inflammation or infection where they differentiate into macrophages or 
dendritic cells (111). In response to environmental stimuli, these monocyte-derived 
macrophages can accentuate inflammatory responses or dampen the inflammatory 
response. These recruited monocytes are innate effectors that can kill pathogens 
through phagocytosis, produce a range of antimicrobial reactive oxygen species, and 
secrete inflammatory cytokines (112). In contrast, monocytes can promote angiogenesis 
to facilitate wound healing (113). Monocyte recruitment is driven by two main 
chemokines, the monocyte chemotactic protein 1 (MCP-1/CCL2) and CX3CL1 that bind 
to receptors, CCR2 and CX3CR1 (114, 115). These chemokines are produced by 
fibroblasts, epithelial cells, and endothelial cells in response to inflammation and thus 
facilitate the recruitment of monocytes to the site of inflammation.  
M1 and M2 macrophages. Macrophages are grouped into two main categories 
based on polarization states in response to various stimuli, M1 or classically activated 
macrophages and M2 or alternatively activated macrophages (116). The dogma is that 
M1 macrophages are polarized from the presence of lipopolysaccharide (LPS) and/or 
interferon-g (IFN-g) and M2 macrophages arise from IL-4 and IL-13 signaling (117, 118). 
Expression of specific transcription factors in M1 and M2 macrophages contribute to 
their polarization. Upon activation, M1 macrophages are more phagocytic, produce pro-
inflammatory cytokines such as IL-12, IL-1a/b, IL-6, TNFa, upregulate surface 
molecules, and have increased pathogen-killing capacity. In contrast, M2 macrophages 
are considered to be any macrophage that is not pro-inflammatory, which can include 
both wound healing and anti-inflammatory macrophages. These anti-inflammatory M2 
macrophages exert immunosuppression through production of cytokines such as IL-10 
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or transforming growth factor b (TGF-b) (119).  Besides immunosuppressive functions, 
other M2 macrophage roles can include promotion of allergic inflammation, aiding tumor 
growth, and also serving as reservoirs of pathogen survival. The M1 and M2 distinction 
of macrophages was proposed to mimic the T cell literature, as distinct classes of T 
cells are well characterized. However, the idea of defining macrophages as M1 or M2 is 
now regarded as too simplistic and narrow based on the varied roles that 
heterogeneous populations of macrophages can assume. Moreover, unlike other 
immune cells that upon differentiation are committed in lineage, macrophages are not 
irreversibly committed to a certain polarization state and can exert functions that 
encompass both M1 and M2 activities (120). Thus, some have proposed that due to the 
remarkable plasticity of macrophages, their classification should not be thought of as a 
linear scale, but rather representing a color wheel in which a blending of phenotypes 
leads to a larger spectrum that encompasses heterogeneous macrophage populations 
(90).  
S. aureus interaction with macrophages. Like neutrophils, macrophages are 
part of the initial cellular response to infection. As such, S. aureus and macrophages 
interact with each other during infection. Mice that are depleted of macrophages are 
exquisitely sensitive to S. aureus infection. For example, during S. aureus-induced 
peritonitis in mice, the absence of macrophages led to increased bacterial loads in 
organs as well as significantly higher mortality (121). Likewise, in a pulmonary model of 
infection, absence of alveolar macrophages significantly increased the mortality of mice 
but did not alter bacterial loads in the lung (122). S. aureus is readily internalized by 
macrophages, where it can survive and persist (123, 124). It is hypothesized that, as a 
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consequence of this persistence, S. aureus uses macrophages as a means of 
dissemination during infection (123, 124). In cystic fibrosis, S. aureus can cause 
recurrent pneumonia which is attributed to the intracellular persistence of S. aureus in 
alveolar macrophages (125). Thus, alveolar macrophages from the cystic fibrotic lung 
may serve as a reservoir of S. aureus leading to chronic pneumonia. Recently, it was 
reported that in a model of recurrent skin and soft-tissue infections by S. aureus that the 
host’s ability to mount a greater recall response to recurrent infections is mediated by 
the innate-like memory of macrophages (126). Altogether, the interactions between S. 
aureus and macrophages during infection are a critical determinant to the outcome of 
infection.  
Concluding Remarks. 
 In this section, we have introduced the main cellular components of the innate 
immune system that interface with S. aureus. These include eosinophils, basophils, 
mast cells, dendritic cells, neutrophils, and macrophages. We defined general features 
of these cells and highlighted some literature evidence that supports interactions of 
these innate cells with S. aureus. In the next section we will introduce how cells of the 
innate system detect S. aureus. 
Section 3: Innate Recognition of S. aureus 
 After breaching physical barriers, the innate immune system is the first line of 
defense against S. aureus. The recognition of S. aureus by the innate immune system 
is mediated through germline-encoded pattern recognition receptors (PRRs). PRRs are 
able to recognize microbial components like essential cell membrane and cell wall 
components of bacteria, bacterial toxins, DNA, RNA, bacterial lipoproteins, and 
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components of bacteria motility organelles. These microbial components are collectively 
known as pathogen-associated molecular patterns (PAMPs). PRRs are found either on 
the surface or reside within the cytosol of the cell. Interactions with cognate PAMPs 
leads to activation of specific signaling pathways that culminate in antimicrobial 
responses. PRRs modulate responses to various stimuli, are independent of 
immunological memory, and are present both internally and externally in cells that 
express PRRs (127). Almost every cell in the innate immune system, as well as 
endothelial and epithelial cells, and some cells of the adaptive immune system express 
PRRs. The first family of PRRs to be studied in detail is the Toll-like receptor (TLR) 
family. The name stems from the unanticipated role of the Toll protein in Drosophila 
melanogaster in responding to fungal infection (128). Currently there are 10 TLRs in 
humans and 13 known TLRs in mice that recognize a range of PAMPs. The primary 
ligands of these TLRs are summarized in Table 1. Other classes of PRRs include C-
type lectin receptors (CLRs), RIG-I-like helicases, formylated protein receptors (FPR1 
and FPR2) or the nucleotide binding-oligomerization domain (NOD)-like receptors. The 
diverse location, range of cell types, recognition of numerous PAMPs, and activation of 
antimicrobial signaling pathways of PRRs arm the innate immune system to mount rapid 
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Table 1. Toll-like Receptors and Ligands. 
 
Toll-like Receptor (TLR) 
(Location) 





























Viral single-stranded RNA (139, 140) 
8 
(Internal) 





CpG-containing DNA (142) 
10 (human only) N/A N/A 
11 (only in mice) 
(Internal) 
Profilin-like molecule; and 
unknown ligand from 
uropathogenic bacteria 
(143, 144) 
12 (only in mice) Profilin-like molecule (145) 
13 (only in mice) 
(Internal) 
23S ribosomal RNA (146) 
 
PRR Recognition of S. aureus. 
 Recognition of S. aureus by PRRs is rapidly achieved due its many PAMPs 
including: lipoteichoic acid (LTA), peptidoglycan, lipoproteins, DNA, and RNA. S. 
aureus-derived PAMPs include the cell wall, which is comprised of thick peptidoglycan 
layers embedded with LTA, as well as membrane anchored lipoproteins. S. aureus is 
considered to be an extracellular pathogen in that it does not depend on invading a host 
cell for its pathogenesis or replication. As such, the dominant PRRs that recognize S. 
aureus are found on the surface of PRR-expressing cells. This includes TLR2 that 
recognizes bacterial lipids, CLRs that sense carbohydrates, and formyl peptide 
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receptors that bind to secreted bacterial proteins containing a formylated methionine or 
to lytic small molecules made by S. aureus named phenol-soluble modulins (PSMs) 
(147). However, S. aureus can be internalized by professional phagocytes such as 
neutrophils, macrophages or dendritic cells, and by non-professional phagocytes 
including human keratinocytes. Internalized S. aureus is then recognized by endosomal 
and cytosolic PRRs including TLR8/9 that sense RNA and DNA respectively, and NLRs 
that detect peptidoglycan structures (141, 148, 149). 
TLR2 Recognition of S. aureus. 
The most important and well characterized PRR that recognizes S. aureus is 
TLR2. Like other surface TLRs, TLR2 is part of the type I integral membrane 
glycoprotein family (150). The extracellular N-terminal ectodomain is responsible for 
PAMP detection and consists of 16-28 leucine-rich repeats (LRR) (151). The conserved 
intracellular C-terminal domain bears homology to the IL-1 receptor and is known as the 
Toll/IL-1 receptor domain (TIR) (152). This intracellular TIR domain is necessary for the 
interaction of adaptor molecules, which aid in activating downstream signaling pathways 
upon receptor engagement (153). Recognition of TLR2 native ligands occurs through 
heterodimerization with either TLR1 or TLR6. Upon dimerization with a native ligand, 
crystallography studies with bound ligands reveal that the ectodomain of each monomer 
form a horse-shoe shaped structure containing the LRRs and the two monomers 
collectively form an “m” shaped complex with the ligand, stabilizing the two receptors 
(154-157). TLR1/2 heterodimers bind to triacylated lipoproteins and TLR2/6 
heterodimers primarily recognize diacylated lipoproteins and LTA (which is diacylated) 
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(158). Recognition of lipoproteins by TLR2 in the absence of TLR1 or TLR6 does not 
occur (159).  
S. aureus produces abundant amounts of lipoproteins that are both diacylated 
and triacylated, but under most growth conditions S. aureus lipoproteins are triacylated 
(160, 161). Therefore, recognition of S. aureus lipoproteins is most often mediated by 
TLR1/2. Co-crystallization of TLR1/2 heterodimer with a synthetic triacylated lipopeptide 
demonstrates that the ectodomain of TLR1 has a channel that binds the amide-linked 
lipid chain of the triacylated lipopeptide (157). This channel is blocked by phenylalanine 
residues in TLR6, providing a structural explanation for the specificity of diacylated or 
triacylated lipoproteins by TLRs (162). TLR2 has a hydrophobic pocket that interacts 
with the cysteine-linked diacylglycerol in a less specific manner that allows for functional 
plasticity in recognition of fatty acid chains with varying length or chemical structure 
(162).  
The cell wall of S. aureus is made up of thick layers of peptidoglycan. Countless 
studies and reviews list bacterial peptidoglycan as a TLR2 ligand (132, 163, 164). Many 
of the initial studies that determined peptidoglycan was a TLR2 ligand used 
commercially purified preparations of peptidoglycan. The use of commercial purified 
peptidoglycan may contain other TLR2 activating components. A study by Travassos et 
al. detailed that the TLR2-activating function of purified peptidoglycan stems from 
contaminating cell wall LTA and lipoproteins that are easily co-purified with 
peptidoglycan (165). Furthermore, they show that, with added steps in the procedure to 
isolate peptidoglycan by including treatments with amylase, trypsin, sodium dodecyl 
sulfate, acetone, and hydrofluoric acid, that peptidoglycan fails to activate cells through 
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TLR2 (165). Importantly, the hydrofluoric acid treatment step deactivates bacterial 
lipoproteins and LTA, which abrogates the TLR2 activating function of purified 
peptidoglycan. Treatment of S. aureus cell wall components with lipase, to hydrolyze 
the esterified lipids attached to lipoproteins also abrogates the TLR2 activating ability of 
the purified cell wall fractions (166, 167). Shortly after, another group reported that by 
treating bacteria with penicillin, which prevents peptidoglycan transpeptidation and 
allows for purification of soluble peptidoglycan fragments that are not incorporated into 
the cell wall or linked to other cell wall components, peptidoglycan still activates TLR2 
responses (168). A study using chemically synthesized fragments of peptidoglycan 
structure and surface plasma resonance found that only some but not all of the 
synthesized fragments could bind to TLR2 (169). However, these synthetic fragments 
were never put onto TLR2 expressing cells. Peptidoglycan isolated from Bacillus 
anthracis, which lacks LTA, needed to be internalized by cells in order to activate 
immune signaling cascades (170). In this instance, the cytosolic NLRs, which are 
definitive peptidoglycan receptors, are likely recognizing the internalized peptidoglycan. 
The variation in peptidoglycan structure from different bacterial species in conjunction 
with the slightly different methodologies of peptidoglycan purification compound the 
controversy of defining it as a TLR2 ligand (171). Thus, peptidoglycan is not likely to be 
a ligand of TLR2.  
TLR2 co-receptors. Besides working with TLR1 and TLR6 to increase the range 
of TLR2 substrate recognition, other molecules such as CD14, CD36 and asialo-GM1 
also interact with TLR2 to facilitate ligand recognition. These molecules are not 
necessary for TLR2 to recognize PAMPs, but instead function to enhance responses by 
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lowering the concentrations of ligand needed for receptor recognition (172, 173). CD14 
is a glycosylphosphatidylinositol-anchored membrane protein with no intracellular 
domain that can be found expressed on phagocytes such as macrophages. Besides 
being critical for facilitating TLR4 recognition of LPS, CD14 is an accessory molecule 
that helps to load both LTA and diacylated lipoproteins onto TLR2/6 heterodimers as 
well as deliver triacylated lipoproteins to TLR1/2 heterodimers (174-176). CD36, a 
membrane glycoprotein involved in scavenging, can load diacylated LTA or lipoproteins 
onto TLR2/6, but CD36 itself cannot bind to triacylated lipoproteins (177). CD36 plays a 
critical role during infection as CD36 knockout mice were found to be highly susceptible 
to S. aureus infection (172). Moreover, CD36 deficient macrophages could not produce 
cytokines after stimulation by LTA or different forms of diacylated lipoproteins, but other 
diacylated and triacylated lipoproteins were found to activate these CD36 deficient 
macrophages (178). Thus, CD36 may only recognize LTA and diacylated lipoproteins 
with certain structures. A study identified that CD36 may bind ligands and transfer them 
to CD14, which are both localized in lipid rafts that contain TLR1/2 or TLR2/6, and then 
load the ligands to the relevant TLR2 heterodimer (177). Besides CD14 and CD36, 
asialylated glycolipids like asialo-GM1, which are found in lung epithelial cells, are 
hypothesized to facilitate TLR2 recognition of S. aureus (179, 180). On the surface of 
airway epithelial cells, TLR2 and asialo-GM1 associate in lipid rafts and generate the 
synthesis of IL-8 after exposure to S. aureus (181).  Therefore, the association of TLR2 
with TLR1, TLR6, CD14, CD36 and asialo-GM1 help to generate a large variety of 
stimuli for TLR2. 
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 The TLR2 signaling pathway. Upon ligand binding to either heterodimer pair of 
TLR2, a signaling cascade induces nuclear translocation of the transcription factor 
nuclear factor kappa B (NF-kB), which controls the expression of pro-inflammatory 
genes. As diagramed in Figure 1, upon ligand recognition and dimerization of TLR2 the 
TIR domain of TIRAP/Mal proteins bind to the TIR domain of TLR2 and recruits the 
common adaptor molecule MyD88 (182). MyD88 then recruits IL-1R-associated kinase 
4 (IRAK-4) that then phosphorylates IRAK-1 to then initiate autophosphorylation (183). 
The phosphorylated IRAK-1 subsequently associates with TNFR-associated factor 6 
(TRAF6), which acts as an ubiquitin protein ligase (E3) to ubiquitinate itself in addition to 
the IKK-g/NF-kB essential modulator (NEMO) (184, 185). This ubiquitination activates a 
complex of TGF-b-activated kinase 1 (TAK1) and its associated proteins, leading to the 
phosphorylation of NEMO and activation of the inhibitor of nuclear factor-k (IKK) 
complex (186). Phosphorylated IkB undergoes K48-linked ubiquitination and 
degradation by the proteasome. This frees NF-kB to then translocate to the nucleus to 
initiative its transcriptional program of pro-inflammatory gene expression (187). At the 
same time, TAK1 activates the mitogen-activated protein kinases (MAPKs) cascades, 
leading to activation factor-1 (AP-1) induction, which also induces the expression of 
genes encoding pro-inflammatory factors (184). Together, NF-kB and AP-1 lead to the 
production of cytokines and chemokines such as IL-6, TNF, KC/IL-8, and Chemokine 
(C-C motif) ligand 3 or 4 (CCL3 and CCL4) also known as macrophage inflammatory 
protein 1-alpha or beta (MIP-1a and MIP-1b). This is just a very small sampling of the 
wide range of inflammatory changes mediated by these transcription factors.  
 




Figure 1. Model of TLR2 Signaling Pathway. After ligand recognition and dimerization 
of TLR2 with TLR1 or TLR6, the TIR domain of TLR2 recruits the common adaptor 
protein MyD88. MyD88 then recruits IRAK-4 which phosphorylates IRAK-1. The 
phosphorylated IRAK-1 subsequently associates with TRAF6, which ubiquitinates itself 
in addition to the IKK-g/NEMO complex. This ubiquitination activates a complex of TAK1 
and its associated proteins, leading to the phosphorylation of NEMO and activation of 
the IKK complex. Phosphorylated IkB undergoes K48-linked ubiquitination and 
degradation by the proteasome. This frees NF-kB to then translocate to the nucleus to 
initiative its transcription program of pro-inflammatory genes. At the same time, TAK1 
activates the MAP kinases cascades, leading to AP-1 induction, which also induces the 
expression of genes encoding pro-inflammatory factors. 
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Concluding Remarks.  
 In this section, we introduced how the host innate immune system recognizes S. 
aureus. This is carried out by the expression of various types of PRRs such as TLRs on 
innate cells as well as other non-innate immune cells including epithelial cells and 
keratinocytes in the skin. In particular, we focused on how S. aureus PAMPs are 
potently recognized by TLR2. PAMP recognition leads to a signaling cascade that 
culminates in the synthesis or activation of mediators of inflammation by innate immune 
cells. In this next section, we will introduce how the host controls or eliminates S. aureus 
upon recognition of the bacterium. 
Section 4: Host Control of S. aureus 
Extracellular Mechanisms of Host Defense. 
Antimicrobial peptides. A chemical defense strategy by innate cells and skin 
cells is the production of AMPs. AMPs are made by cells that are the primary defenders 
against S. aureus such as mast cells, eosinophils, dendritic cells, neutrophils, 
monocytes, macrophages, and keratinocytes. In total, there are over 1200 known or 
predicted AMPs with a diverse range of structure and activities (188). However, there 
are common features of these peptides, such as being small, containing positive 
charged residues, and having an amphipathic structure. Different types of AMPs 
including a-defensins, b-defensins, and cathelicidins are known to have antibacterial 
activity against S. aureus (189). The unique features of AMPs allow them to attach and 
insert into membrane bilayers to form pores through ‘barrel-stave’, ‘carpet’ or ‘toroidal-
pore’ mechanisms (190-192). The formation of transmembrane pores in bacteria lead to 
lysis and death of the targeted bacterium. However, pore formation is not the only 
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mechanism of bacterial killing, as AMPs can enter bacteria to inhibit cell-wall synthesis, 
or block DNA and protein synthesis. Besides the potent killing capacity of AMPs, they 
can also possess a variety of immune regulating functions (193). AMPs can serve as 
chemoattractants to promote leukocyte recruitment to the site of infection, induce 
production of chemokines and cytokines by innate immune cells, influence cell 
differentiation, modulate immune signaling pathways, and initiate adaptive immune 
responses. Thus, AMP production by the host in response to S. aureus infection is a 
broad defense mechanism.  
 Complement. Another critical mediator of innate immunity is the complement 
system, initially discovered for its ability to induce bacterial lysis. The complement 
system is a cascade of soluble proteins produced by the liver that function mainly in the 
serum as well as in tissues, on surfaces, or within the cell. There are three separate 
pathways of the complement system: classical pathway, lectin pathway, and the 
alternative pathway (194, 195). All of these pathways end in formation of surface-bound 
C3 convertases that cleave C3 to C3a and C3b.  
 The classical pathway is initiated when C1q, C1r, and C1s bind to the Fc portion 
of IgG or IgM that is bound to S. aureus. C1s is then activated to cleave C4 and C2 to 
yield the C3 convertase C4bC2a. This is similar to the lectin pathway which is activated 
when mannose binding lectin or Ficolin bind to carbohydrate moieties on pathogens 
(196, 197). Proteins associated with mannose binding lectin autoactivate upon binding 
to carbohydrate moieties on pathogens, cleaving C4 into C4a and C4b as well as C2 
into C2b and C2a. C4b and C2a form the C3 convertase C4bC2a. In the alternative 
pathway, C3 is constitutively hydrolyzed to form C3b which binds to bacteria. This 
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attracts factor B and factor D to form the C3 convertase C3bBb of the alternative 
pathway (198). Furthermore, cleavage of C3 by the C3 convertases forms C3a and 
C3b, which combine with other complement proteins to the generate two C5 
convertases, C4bC2aC3b and C3bBb. The cleavage of C5 by the C5 convertases 
produces C5a and C5b. 
 Activated complement leads to generation of three different types of immune 
effectors. First, C3a and C5a are anaphylatoxins that can attract and activate 
leukocytes through interaction with the C3a and C5a receptor (C3aR or C5aR) on 
leukocytes (199, 200). Second, C5b is part of the membrane attack complex that 
directly lyses Gram-negative bacteria. Last, the complement cascade produces 
opsonins like C3b, iC3b, and C3d that covalently bind to bacterial cells to facilitate 
phagocytosis by innate immune cells. In summary, the complement system is a large 
and complex cascade of cleavage and binding events that culminates in directly or 
indirectly killing invading bacteria like S. aureus. 
Cytokine and chemokine production. Another component of innate immune 
system control of S. aureus infection is the ability to produce and secrete cytokines and 
chemokines that help to regulate both the innate and adaptive immune system. 
Cytokines are small soluble proteins that initiate specific pro- and anti-inflammatory 
responses by binding to specific receptors on cells. There are over 100 proteins 
described as cytokines (201). In focusing on a small subset of the pro-inflammatory 
cytokines produced mainly by macrophages and/or neutrophils, the most common 
cytokines are IL-6, TNF, keratinocyte-derived cytokine (KC or IL-8 in humans), IL-1 
family, and IL-12. IL-6, TNF, and the IL-1 family (including IL-1a, IL-1b, and IL-1Ra) are 
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potent pyrogens and all cause a fever response (202).  IL-6 pro-inflammatory functions 
include recruitment of monocytes to the site of infection, maintenance of Th17 cells, and 
inhibition of T cell apoptosis (203, 204). TNF induces vasodilation and loss of vascular 
permeability, which aids immune cell tissue infiltration.  The IL-1 family of cytokines 
especially IL-1a and IL-1b are strongly pro-inflammatory and share overlapping 
functions. IL-1b stimulates histamine release from mast cells thereby causing 
vasodilation and increased local inflammation. Moreover, IL-1b assists in CD4 T cell 
differentiation and expansion, increases the surface expression of adhesion molecules 
on various cell types, and is a chemoattractant for granulocytes (205). KC is a potent 
chemoattractant for neutrophil recruitment (206, 207). IL-12, comprised of the p35 and 
p40 subunits, promotes inflammation through stimulation of Th1 cells resulting in 
production of IFN-g, which potently stimulates pro-inflammatory functions of 
macrophages (208).  
Chemokines are a type of cytokine, but they serve as chemoattractants to recruit 
specific cell types to the site of injury (209). Macrophages and neutrophils, among other 
cells, secrete CCL2, CCL3, and CCL4 in response to pro-inflammatory stimuli. After the 
binding of these chemokines to their cognate receptors, CCR2 for CCL2, and CCR5 for 
CCL3 and CCL4, monocytes and macrophages recruitment to the site of infection is 
enhanced. Altogether, the production of pro-inflammatory cytokines and chemokines in 
recognition of S. aureus infection serves to amplify the immune response to clear S. 
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Cellular Mediated Control of S. aureus. 
Phagocytosis and phagosome formation. Professional phagocytes of the 
innate immune system, including neutrophils, eosinophils, dendritic cells, macrophages, 
and monocytes work to ingest and eliminate invading pathogens like S. aureus. The 
process of phagocytosis and subsequent killing of internalized bacteria is best 
understood in neutrophils and macrophages. For neutrophils, initiation of phagocytosis 
requires the deposition of opsonins on the surface of the bacterium (210). In the serum, 
the predominant factors that serve as opsonins are immunoglobulins IgG and 
complement components such as C3b. Once deposited on the bacterial surface, 
receptors on neutrophils such as the Fc receptors, complement receptors, or other 
PRRs can then trigger phagocytosis. Macrophages generally do not need bacteria or 
other material to be opsonized to trigger phagocytosis. Macrophages are constitutively 
undergoing dynamic actin-based rearrangement to produce extracellular protrusions 
that probe the surrounding environments (211-213). Upon recognition of opsonized 
bacteria by different surface receptors, signal transduction in the interior of the cell 
works to promote localized lipid remodeling and rearrangement of the actin cytoskeleton 
within the plasma membrane (214, 215). Actin polymerization is required at the leading 
edge of the membrane pseudopodia to envelop the bacterium and concurrently actin 
depolymerization at the base of the pseudopod forms the phagocytic cup to allow entry 
of the newly internalized bacterium (216-218). The internalized bacterium is present in a 
structure called the phagosome, which is an outside-in compartment inside the cell. The 
phagosome then immediately undergoes a maturation process to become a highly 
localized site of bacterial killing. This process is driven by a series of sequential 
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interactions/fusions with different vesicles of the endocytic pathway, each transforming 
the phagosome in a unique way (219). Maturation of the phagosome is comprised of 
early, intermediate, and late stages. The final stage of phagosome maturation occurs 
when the maturing phagosome fuses with a lysosome, forming the phagolysosome. 
During the entire maturation process, the lumen of the phagosome becomes 
increasingly acidic from the activity of proton-pumping V-ATPases, which creates an 
unfavorable bacterial growth environment (220). The acidic environment in the lumen is 
not only important for inhibiting the growth of the resident bacteria but also provides the 
optimum pH in which many hydrolytic enzymes function (221, 222). 
Neutrophil mediated killing of S. aureus. Neutrophils, which are one the first 
immune cells recruited to the site of infection, can extracellularly kill S. aureus through 
neutrophil extracellular trap (NETs) formation in a process named NETosis or by 
degranulation. NETs are large, web-like extracellular structures that contain 
decondensed chromatin with embedded antimicrobial molecules that function to kill 
bacteria, viruses, fungi, and parasites (223). S. aureus is known to initiate two different 
types of NETosis, one that results in cell death and one that is independent of cell 
death. In the cell death version of NETosis, nucleus delobulation precedes disassembly 
of the nuclear envelope and loss of cellular polarization (224). Next, the chromatin 
decondenses and the plasma membrane ruptures leading to expelling of the NET and 
cell death. The non-lytic form of NETosis leads to expulsion of chromatin and granule 
contents. The remaining cell, called an anucleated cytoplast, can continue to ingest 
pathogens (225, 226). 
 
      
30 
Degranulation is another key killing mechanism of neutrophils. The process of 
degranulation occurs when PRR engagement stimulates neutrophils to translocate 
granules to the plasma membrane where they then can release their contents in the 
extracellular milieu through exocytosis (227). Four different types of granules exist in 
neutrophils: primary or azurophilic granules, secondary or specific granules, tertiary 
granules, and secretory vesicles (228). Of these granules, the primary granules contain 
the most reactive molecules such as elastase, myeloperoxidase (MPO), cathepsins, 
and defensins (229). Secondary and tertiary granules contain overlapping contents such 
as lactoferrin, matrix metalloprotease nine, and other materials (230). The release of 
these toxic granule contents by degranulation facilitate the strong bactericidal ability of 
neutrophils. In addition to the extracellular release of granules, they can be delivered to 
the phagosome. Lactoferrin in neutrophil secondary and tertiary granules acts as a 
scavenger of iron, aiding in bacterial growth restriction (231). A similar bacteriostatic 
activity is carried out by the membrane protein, named natural resistance-associate 
macrophage protein 1, which extrudes divalent metals such as Fe2+, Zn2+ and Mn2+ from 
the phagosomal lumen (232-234). Furthermore, neutrophils produce calprotectin, which 
can bind and sequester zinc and manganese from bacteria (231). This sequestration of 
essential metals or other trace nutrients is a general process called nutritional immunity 
(235).  
  Macrophage and neutrophil ROS production. A major antimicrobial activity of 
neutrophils and macrophages is a process known as respiratory burst, which generates 
potent reactive oxygen species (ROS) (236). The generation of ROS occurs through the 
nicotinamide adenine dinucleotide phosphate (NADPH) phagocyte oxidase complex 
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that is assembled on the phagosomal membrane (237). The NADPH oxidase complex 
is comprised of two transmembrane proteins, gp91phox and p22phox, in addition to four 
cytosolic proteins denoted as p47phox, p67phox, p40phox, and Rac1 or Rac2 (237-
240). Upon assembly and activation of the NADPH oxidase complex, it transfers 
electrons from NADPH to molecular oxygen releasing superoxide (O2-•) in the 
phagosome (239). Superoxide can undergo spontaneous dismutation into hydrogen 
peroxide (H2O2) or hydroxyl radical and other ROS (237, 239, 241-243). H2O2 can then 
be converted into hypochlorous acid and chloramines by MPO (229, 241). These ROS 
lead to oxidization of internalized bacterial DNA, mobilization of iron from iron-sulphur-
containing dehydratases promoting toxic Fenton chemistry, and oxidation of protein 
residues (237, 244, 245). All of these collectively facilitate killing of the internalized 
bacteria by ROS. NADPH oxidase dysfunction leads to chronic granulomatous disease 
(CGD) (246, 247). Patients with CGD commonly suffer from recurrent infections with S. 
aureus as well as the fungal pathogen Aspergillus, highlighting the importance of 
NADPH oxidase in host defense (246, 247). In addition to NADPH oxidase-derived 
ROS, mitochondrial respiration also generates ROS that contribute to the destruction of 
internalized bacteria (248). These mitochondrial ROS (mROS) are generated when 
electrons from the oxidative phosphorylation machinery escape and react with 
molecular oxygen (249, 250). Recent work demonstrates that mROS are packaged into 
mitochondrial-derived vesicles and delivered to the phagosome to facilitate the inhibition 
of internalized S. aureus (251, 252). Compared to macrophages, neutrophils are 
capable of producing higher amounts of ROS in response to bacterial pathogens. In 
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summary, the production of ROS by phagocytes is important for restricting S. aureus 
growth.  
 Macrophage and neutrophil RNS production. Synthesis of nitric oxide (NO•) 
also inhibits internalized bacterial pathogens and is produced in high amounts by 
macrophages (237). In response to engulfed pathogens, inducible nitric oxide 
synthetase (iNOS) is activated and leads to the formation of NO• and citrulline in large 
amounts from L-arginine and oxygen (253). It is known that NO• alone is not a highly 
reactive molecule and has an expansive range of cellular functions (254). Rather, NO• 
only becomes highly reactive when it is converted by the presence of oxygen into 
nitrogen dioxide, peroxynitrite (ONOO-), dinitrogen trioxide, and other nitrogen-based 
reactive species collectively forming reactive nitrogen species (RNS) (237, 255). The 
synthesized NO• and RNS inhibit bacterial respiration, perturb DNA replication, interfere 
with metal centers and tyrosine residues in proteins, and alter lipid integrity (237, 254, 
256). NO• and RNS are produced in higher abundance in activated macrophages rather 
than neutrophils. Given the similarities in the reactivity and formation of ROS and RNS, 
under certain conditions they can have synergistic antimicrobial activities (257). In 
particular, the production of the powerfully reactive RNS, ONOO-, is formed from 
NADPH oxidase-derived O2-• and iNOS-generated NO•, establishing a link between 
ROS and RNS production (237, 254).  
Concluding Remarks.  
 In this section, we introduced the various ways in which the innate immune 
system can kill pathogens like S. aureus. AMP production and activation of the 
complement system both contribute to the elimination of S. aureus. Also, production of 
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inflammatory cytokines and chemokines are necessary to coordinate innate and 
adaptive responses to S. aureus infection. The best studied antimicrobial functions of 
the innate system are the antibacterial activities of neutrophils and macrophages. Many 
of the antibacterial functions occur within neutrophils and macrophages, through a 
coordinated attack of S. aureus internalized by phagocytosis. In the next section, we 
cover the known virulence factors of S. aureus that work to counter these innate 
immune responses. 
Section 5: Innate Immune Evasion Mechanisms of S. aureus 
 S. aureus has acquired a vast array of virulence factors that inhibit innate 
responses and facilitate disease. Table 2 highlights many virulence factors encoded by 
S. aureus and the immune components they target.  
Table 2. Virulence Factors of S. aureus 
 
Virulence Factor Function Immune Target Reference 
Aureolysin Metalloprotease, cleaves C3 
and LL-37 
Complement System, blocks 
deposition of C3b; AMP 
function 









(260, 261)  
Staphylokinase (SAK) Activate plasminogen to 
generate plasmin 
Complement system, AMP 
production, and opsonization 
(262, 263)  




(264, 265)  
Staphylococcal binder 
of immunoglobin (Sbi) 




binding molecule (Efb) 
Binds to fibrinogen and C3d Phagocytosis; complement 
system 














migration; TLR2 signaling  
(270-276)  
coagulase and von 
Willebrand factor-
binding protein 
generate staphylothrombin Blocks agglutination and 
phagocytosis 
(277)  
DltABCD Modifies wall teichoic acids 
with d-alanine 
AMP  (278)  
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MprF Modification of 
phosphatidylglycerol with l-
lysine  
AMP (279)  
OatA Peptidoglycan acetylation Lysozyme activity (280)  
Extracellular 
adherence protein and 
homologs (Eap, EapH1, 
EapH2) 
Inhibition of serine proteases; 
bind to ICAM1 
Neutrophil antibacterial 
activity; Leukocyte migration 
(281, 282)  
SelX Bind to PSGL1 Leukocyte migration (274)  
Staphopain A Cleaves CXCR2 Neutrophil migration (283)  
chemotaxis inhibitory 
protein of S. aureus 
(CHIPS) 
Bind FPR1 and C5aR Neutrophil migration (284, 285) 
formyl peptide 
receptor-like 1 inhibitor 
and its homolog 
(FLIPr/FLIPrL) 






Lysis of immune cells Innate immune cells (287, 288)  
Alpha-hemolysin (Hla) Lysis of innate immune cells, 
erythrocytes, epithelial cells 




Lysis of immune cells and 
erythrocytes  
Cellular innate immunity and 
T-cells 
(291-293)  
adenosine synthase A 
(AdsA) 








antioxidant ROS detoxification   (296)  
SodA and SodM Superoxide dismutases ROS detoxification (297)  
methionine sulfoxide 
reductase (Msr) 
Repair oxidized methionine 
residues 
ROS detoxification  (298)  
surface factor 
promoting resistance 
to oxidative killing 
(Sok) 





NO• scavenger RNS detoxification (300)  
Lactate dehydrogenase 
(Ldh1) 
Maintain bacterial redox 
homeostasis  




Perturbation of Phagocytosis and Complement. 
Phagocytosis and the complement system are the targets of many S. aureus 
virulence factors. The presence of a thick peptidoglycan layer prevents the complement-
mediated membrane attack complex from lysing S. aureus. In addition, some clinical 
isolates of S. aureus contain genes that encode a polysaccharide capsule which can 
disrupt phagocytosis (302). One way that S. aureus targets the complement system 
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directly is through the activity of a zinc-dependent metalloprotease called Aureolysin 
(258). Aureolysin targets the complement system by cleaving C3 to form C3a and C3b. 
Then, the host complement factor I and factor H degrade C3b to prevent it from binding 
to S. aureus. The degradation of C3b also limits the release of C5a, interfering with 
production of opsonins. Staphylococcus complement inhibitor (SCIN) is a small protein 
that binds and stabilizes the C3bBb and C4b2a convertases preventing production of 
important complement mediators such as C3a, C3b, and C5a (260, 261). 
Staphylokinase (SAK), a secreted enzyme, activates host plasminogen attached on the 
bacterial surface to form plasmin, a potent serine protease (263). Plasmin is then able 
to cleave fibrin to break up blood clots and degrades C3b and human IgG. Collectively 
this blocks phagocytosis by eliminating potential complement-derived opsonins.  
Besides complement-derived opsonins, immunoglobins like IgG can serve as 
opsonins. Staphylococcal protein A (SpA) and Staphylococcal binder of immunoglobulin 
(Sbi) both bind to the Fc domain of IgG (264, 265, 268, 303). SpA and Sbi interfere with 
Fc receptor mediated phagocytosis and block the complement protein C1q from binding 
to IgG thereby disrupting complement activation (266, 267). Moreover, extracellular 
fibrinogen binding molecule (Efb) and extracellular complement-binding protein (Ecb) 
bind to the C3d region of cleaved C3b blocking complement-mediated opsonization 
(260, 269).  
Also involved in complement system inhibition are the staphylococcal 
superantigen-like proteins (SSLs) that are closely related to superantigens of S. aureus 
but lack the functional T cell receptor binding domain (304). The 14 ssl genes are 
arranged as tandem repeats in two different areas on the chromosome, in genomic 
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island-a and immune evasion cluster 2 (305). Most SSLs are only specific for humans 
and not animal host factors. SSL7 can interfere with the complement system by binding 
to human IgA and C5, leading to impaired IgA binding with its receptor FcaRI (270). 
Similarly, SSL10 binds to the Fc region of human IgG1 and blocks FcgR-mediated 
phagocytosis (306). Moreover, SSL3 can bind to the extracellular domain of TLR2, 
blocking macrophages from optimally recognizing native TLR2-activating ligands (276). 
Thus, many virulence factors of S. aureus function to block components of the 
complement system as well as interfere with phagocytosis. 
Disruption of Coagulation. 
Coagulation is another innate response mechanism by the host that is initiated by 
activated thrombin, converting fibrinogen to a crosslinked fibrin meshwork structure that 
can immobilize bacteria and attract phagocytic immune cells to clear the entrapped 
bacteria. All S. aureus isolates secrete coagulase and von Willebrand factor-binding 
protein, which are two coagulase degrading enzymes (305). These coagulases 
associate with prothrombin to generate staphylothrombin, which cleaves fibrinogen 
yielding fibrin without activating other host factors (277). The resulting fibrin begins to 
accumulate and assemble on the surface of S. aureus with the assistance of surface 
proteins clumping factor A, fibronectin-binding protein A and B, and bone sialoprotein 
binding protein. The agglutination of fibrin on the surface of S. aureus protects it from 
phagocytes. Lastly, SSL10 from S. aureus prevents prothrombin autoactivation, 
preventing activation of other host factors that stimulate the attraction of phagocytes to 
the entrapped bacteria (306). In summary, S. aureus is armed with different 
mechanisms to avoid coagulation by the host.  
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Interference with AMP Activity.  
Multiple virulence factors and adaptations of S. aureus contribute to a collective 
resistance against different AMPs and antibacterial proteins. Besides its ability to cleave 
complement proteins, Aureolysin also cleaves the cathelicidin AMP LL-37 and 
contributes to resistance to this AMP in vitro (259). As mentioned above, S. aureus SAK 
stimulates the protease plasmin to bind and inhibit the activity of a-defensin AMPs 
(262). Resistance to the antibacterial enzyme lysozyme, was attributed to the function a 
membrane bound O-acetyltransferase protein that modified the C6 hydroxyl group of 
muramic acid (280). Moreover, S. aureus secretes extracellular adherence protein (Eap) 
and its related homologs EapH1 and EapH2. Eap, EapH1, and EapH2 inhibit the activity 
of serine proteases neutrophil elastase, proteinase 3, and cathepsin G that are 
expressed by neutrophils (281). Furthermore, S. aureus uses modifications to wall 
teichoic acid, LTA, and membrane phospholipids to lower the net negative charge of its 
membrane. This prevents cationic AMPs from being able to effectively bind to S. aureus 
and cause cell death. The DltABCD proteins, encoded by the dlt operon, lead to d-
alanine substitutions into wall teichoic acids to reduce negative charge of this 
membrane component (278). In similar fashion, MprF works to increase the positive 
charge of phosphatidylglycerol exposed on the outer face of the cytoplasmic membrane 
by adding a positively charge l-lysine residue (279). In summary, S. aureus can either 
directly target AMPs through virulence factors or modifies its own cellular structures to 
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Blockade of Neutrophil Migration.  
 The migration and extravasation of activated neutrophils to the site of infection is 
a major barrier to S. aureus infection. These processes of neutrophils are inhibited by S. 
aureus through the secretion of SSLs, Eap, Staphopain A, chemotaxis inhibitory protein 
of S. aureus (CHIPS), and formyl peptide receptor-like 1 inhibitor (FLIPr) or its homolog 
(FLIPrL). SSL5, SSL11 and SelX (a staphylococcal enterotoxin-like protein) can bind to 
P-selectin glycoprotein ligand 1 (PSGL1) on leukocytes (272, 274, 275). PSGL-1 
regulates the adhesion and rolling steps of neutrophil extravasation through binding to 
P-selectin on activated endothelium. Thus, SSL5, SSL11, and SelX binding to PSGL1 
interferes with neutrophil extravasation, diminishing the number of neutrophils recruited 
to the site of infection. Eap blocks neutrophil and leukocyte migration by associating 
with intercellular adhesion molecule 1 (ICAM1) (282). SSL6 binds to the receptor CD47, 
which is a common receptor found on most tissues involved in migration, phagocytosis, 
and proliferation (274). Furthermore, SSL10 interferes with the chemoattraction of 
neutrophils through the blockade of the C-X-C chemokine receptor 4 (CXCR4) (307). 
The secreted protease Staphopain A cleaves the N-terminus of CXCR2 chemokines, 
blocking chemokine signaling and the migration of neutrophils (283). The binding of 
bacterial formylated proteins to FPR1 and C5a to the C5a receptor potentiate neutrophil 
chemotaxis and migration. CHIPS is a small protein that can bind to only human 
formylated peptide receptor 1 (FPR1) and the human complement protein C5a receptor, 
thereby blocking the neutrophil chemotaxis function induced by these receptors (285). A 
search for proteins homologous to CHIPS, identified both FLIPr and FLIPrL, which 
function as antagonists of FPR1 and contribute to blockade of neutrophil chemotaxis 
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(286). In conclusion, the interference of neutrophil migration is a target of many different 
S. aureus virulence factors. 
Toxins of S. aureus.  
 S. aureus directly induces the killing of innate immune cells via PSMs and 
different toxins. These toxins are arguably the most harmful virulence determinants of S. 
aureus. PSMs are a family of small amphipathic a-helical peptides with broad-range 
lytic activities. PSMs include both a- and b-type PSMs and the delta-toxin – a member 
of the a-PSMs. a-PSMs are 20-25 amino acids in length and are usually either neutral 
or positively charged. In contrast, b-PSMs are twice the size of a-PSMs at around 43-45 
amino acids and have a negative net charge. Focusing on just the PSM cell lysing 
activities, they are reported to lyse osteoblasts, endothelial cells, epithelial cells, 
monocytes, erythrocytes, and importantly PMNs. The targeting of all these diverse cell 
types is likely to be a receptor-independent process that relies on membrane insertion 
and pore formation (308). This is in contrast to other S. aureus cytolytic toxins, such as 
alpha-hemolysin (Hla) or the bicomponent leukotoxins, which are highly specific for a 
particular cell type and host species.  
Hla binds to the receptor A Disintegrin and Metalloproteinase Domain-containing 
protein 10 (ADAM10), which is expressed on the surface of myeloid cells, including 
neutrophils, epithelial cells and the vascular endothelium (289). Hla can lyse rabbit 
erythrocytes to a significantly greater degree compared to human erythrocytes. After 
binding to ADAM10, Hla assembles into a heptameric pore and through the 
metalloproteinase activity of ADAM10, triggers the lysis of epithelial cells or modulate 
the activity of innate immune cells (309).  
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Another highly destructive group of toxins are the bicomponent pore-forming 
leukotoxins, which have host species specific targets. These toxins consist of two 
monomeric subunits that target receptors on immune cells and kill by forming b-barrel 
pores that span the phospholipid bilayer (310). There are five known leukotoxins that 
associate with human infection, HlgAB, HlgCB, LukAB/HG, LukED, and Panton-
Valentine leukocidin (PVL) (311). All strains of S. aureus that infect humans produce at 
least three leukotoxins (HlgAB, HlgCB, and LukAB/HG), while the most highly virulent 
human isolates produce all five human-associated leukotoxins (311). LukMF’ and 
LukPQ are two other leukotoxins that are made by S. aureus but are only associated 
with zoonotic infections and rarely humans (312, 313). There are a diverse range of 
proteinaceous receptors that these leukotoxins bind to, conferring cell-specific targets 
for lysis. HlgAB binds to chemokine receptors CXCR1, CXCR2, and CCR2, as well as 
the Duffy antigen receptor for chemokines (DARC) (314, 315). HlgCB and PVL uses 
chemokine receptors C5aR1 and C5aR2 to associate with target cells (315). LukED 
also targets chemokine receptors, mainly CCR5, CXCR1, and CXCR2 on myeloid cells 
as well as DARC on erythrocytes (314, 316, 317). LukAB/HG binds to the myeloid 
marker CD11b and thus targets a range of phagocytic leukocytes (318). Receptor 
targeting by the five different human leukotoxins allows for lysis of a large number of 
immune cells, such as neutrophils, monocytes, macrophages, dendritic cells, T cells, 
and natural killer cells. In summary, S. aureus lytic molecules and toxins are collectively 
a major destructive group of virulence factors that have the potential to induce major 
host damage.  
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Mitigating Oxidative Stress in the Phagosome.  
 S. aureus withstands and survives an onslaught of host destructive mechanisms 
within the phagosome of neutrophils and macrophages through various adaptations and 
virulence factors. The host produces adenosine in response to hypoxia, ROS exposure 
or tissue damage. Adenosine recognition by the host during an active infection, signals 
that the level of inflammation to control disease is becoming self-harming. As a 
consequence of adenosine-based signaling, it can stop platelet aggregation and limit 
respiratory burst of neutrophils. S. aureus uses this system to its advantage and 
generates adenosine during infection through adenosine synthase A (294). The 
production of S. aureus-derived adenosine facilitates its survival within neutrophils likely 
through inhibition of respiratory burst (294) .  
Many virulence factors help S. aureus combat the antibacterial effects of ROS 
within the phagosome. The golden carotenoid pigment of S. aureus, staphyloxanthin, 
functions as an antioxidant protecting against damaging hydroxyl radicals (295). 
Furthermore, harmful effects by hydrogen peroxide are mitigated through the functions 
of S. aureus catalase and alkylhydroperoxide reductase (296). To withstand ROS 
toxicity, S. aureus also produces two superoxide dismutases, SodA and SodM, which 
work to eliminate superoxide production (297). Methionine residues in proteins can be 
targeted by ROS, leading to harmful oxidation. S. aureus encodes a methionine 
sulfoxide reductase or Msr that can repair the oxidized methionine residues (298). A 
surface protein of S. aureus named surface factor promoting resistance to oxidative 
killing or Sok is involved in resistance to ROS generated by neutrophils (299). Besides 
ROS, NO• and RNS induce nitrosative stress against S. aureus. One way that S. aureus 
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mediates NO• resistance is by the flavohemoglobin Hmp that scavenges NO• (300). 
Furthermore, a lactate dehydrogenase, Ldh1, is induced in response to NO• to 
circumvent the disruption of redox homeostasis within S. aureus and regenerate NADH 
and NAD+ (301). The mechanisms that facilitate the detoxification of ROS and 
avoidance of nitrosative stress within the phagosome clearly contribute to the ability of 
S. aureus to resist killing.  
S. aureus Survival in Immune Cells. 
 S. aureus is considered to be an extracellular pathogen, yet a growing body of 
evidence suggests that it is able to survive within various cell types including 
macrophages and neutrophils (123, 125, 291, 319, 320). To cope with the harsh 
environment within the phagosome, S. aureus can differentiate into small-colony 
variants (321). These small-colony variants are in a metabolically dormant state, can 
withstand stressors, and are highly resistant to antibiotics. Furthermore, residence in a 
host cell also can protect bacteria from antibiotics (322). Thus, the small-colony variant 
phenotype of intracellular S. aureus and the resulting protection from antibiotics may 
contribute to its survival within host cells. This has led to the hypothesis that S. aureus 
uses host cells such as neutrophils to support its dissemination during bloodstream 
infection to other parts of the host (323). Support for this hypothesis comes from a study 
that isolated neutrophils from the peritoneal cavity of mice infected with S. aureus that 
harbored viable bacteria and were able to cause disease when administered to naïve 
mice (324). To aid in the escape from within neutrophils, S. aureus increases the 
production of PSMs and LukAB/GH to mediate cell lysis and subsequent escape from 
neutrophils (325, 326). Although the immune system has dedicated cells such as 
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neutrophils to mediate bacterial-killing, S. aureus can hijack these cells with its virulence 
factors and use them for protection from other host defenses.  
Concluding Remarks. 
 S. aureus has a large array of virulence factors that can target numerous parts of 
the innate response to infection. As a consequence, S. aureus can often easily escape 
and disseminate causing severe disease. Furthermore, a vast majority of the evasion 
mechanisms introduced focus on how S. aureus counters neutrophil immune 
responses. Comparatively less is known about specific virulence factors that can 
subvert macrophage immune responses. A major goal of this thesis is to identify novel 
ways in which S. aureus evades macrophage immune responses.  
Section 6: S. aureus Metabolism and Pathogenesis 
Trace Metal Acquisition.  
 Besides the numerous innate immune evasion adaptations of S. aureus, it also 
harnesses a diverse repertoire of traits that aid in nutrient acquisition. The acquisition of 
trace metals such as iron, manganese, zinc, and copper during infection are crucial for 
survival of S. aureus, as numerous studies detail that deficiency in acquiring these 
metals leads to a defect in pathogenesis (327-336). As mentioned before, the host 
produces multiple metal binding proteins such as calprotectin, lactoferrin, or transferrin 
to outcompete bacterial sequestering mechanisms. Overcoming iron limitation is 
required to infect a host. S. aureus utilizes siderophores and a heme acquisition system 
to promote survival. Staphyloferrin A and staphyloferrin B are two siderophores 
secreted by S. aureus that bind to iron with high affinity, providing the bacterium with 
iron (337, 338). Both of these siderophores can remove and acquire iron from human 
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transferrin. Though siderophore-mediated iron acquisition supports growth of S. aureus, 
it prefers to use heme as a source of iron (339). Heme is the primary source of iron 
within vertebrate hosts, and S. aureus has a dedicated heme scavenging and heme 
uptake system (340, 341). Once heme enters the bacterial cell, the tetrapyrrole ring is 
degraded to liberate iron (342). Like iron, both manganese and zinc are required for S. 
aureus pathogenesis. Manganese is acquired through two transporters, MntABC and 
MntH, and zinc is imported through AdcABC and CntABCDF (327, 329). Loss of any of 
these transporters or importers in S. aureus compromises pathogenesis. Copper is a 
cofactor for various proteins in S. aureus. Currently the exact mechanism of copper 
acquisition in the host and the relevance of copper import to pathogenesis in S. aureus 
is unknown. However, two proteins CopA and CopZ are hypothesized to maintain 
copper homeostasis within S. aureus, as loss of these proteins leads to intracellular 
copper accumulation and toxicity (343). 
Acquisition of Other Nutrients.  
  In addition to trace metal acquisition adaptations by S. aureus, the bacterium 
also needs to import other molecules involved in metabolism such as carbohydrates 
and inorganic phosphate. Recent work identified 11 carbohydrate transporters in S. 
aureus, four of which can import glucose (344). Elimination of some of these 
carbohydrate transporters severely limits the amount of imported glucose and 
diminishes the pathogenesis of S. aureus during skin and soft-tissue infection. Similarly, 
S. aureus encodes three different inorganic phosphate transporters (PstSCAB, PitA, 
and NptA) and elimination of one is not sufficient to cause attenuation of disease (345, 
346). Rather, deletion of NptA and either remaining transporter conferred a defect 
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during S. aureus infection. These mechanisms facilitate the ability of S. aureus to 
overcome host imposed nutritional immunity. 
Moonlighting Proteins.   
 As described in detail above, S. aureus has a dedicated arsenal of virulence 
factors that perform distinct functions to promote microbial survival. However, a growing 
number of proteins outside this array of virulence factors have been identified that are 
able to carry out secondary activities, including the ability to promote virulence (347, 
348). Proteins possessing additional biological activities beyond their primary function 
are described as having moonlighting activity (349). These moonlighting proteins are 
emerging as important mediators of virulence in many bacterial pathogens. Proteins 
with moonlighting activity span all kingdoms of life. Most of the eukaryotic and 
prokaryotic moonlighting proteins are well-known metabolic enzymes or molecular 
chaperones. Many bacterial moonlighting proteins have primary functions as metabolic 
enzymes in the bacterial cytosol; however, inexplicably, these proteins are also 
commonly found in the extracellular environment where they contribute to bacterial 
virulence. For example, the glycolytic enzyme glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), which is present on the cell surface of streptococci and other 
bacteria, facilitates bacterial adhesion to a variety of ligands including the major host 
adhesive glycoprotein, fibronectin, as well as lysozyme, actin, and myosin (350). S. 
aureus GAPDH can bind to host transferrin, which sequesters iron away from bacteria 
(351). Enolase, an enzyme involved in glycolysis, is also found on the surface of S. 
aureus where it is hypothesized to bind to laminin (352). It is unknown whether the 
ability of GAPDH or enolase to bind transferrin or laminin has physiological relevance 
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during S. aureus infection. Moreover, as described with GAPDH of streptococci and S. 
aureus, the homologs of moonlighting proteins in other species are often found to retain 
their secondary functions highlighting their conservation. 
 Up to 25% of the secretome of Escherichia coli, Bacillus subtilis and S. aureus 
were identified as cytoplasmic proteins that function in metabolic pathways (353-356). 
What is so unusual, is that these extracellular cytoplasmic proteins do not contain any 
discernable secretion signals. This release of cytoplasmic proteins is specific, as not 
every cytoplasmic protein is found in the extracellular environment (357). Currently, the 
mechanism for surface display and/or secretion of cytoplasmic proteins is not well 
characterized.  What is known is that the presence of extracellular cytoplasmic proteins 
from S. aureus depends on the activity of the major autolysin, Atl (357). Atl is a 
peptidoglycan hydrolase and is involved in peptidoglycan remodeling of S. aureus. In 
the absence of Atl, there is a marked decrease in the amount of released cytoplasmic 
extracellular proteins. Another group concluded that the release of cytoplasmic proteins 
is not solely dependent on bacterial autolysis, as the abundances of released 
cytoplasmic proteins occur over time throughout growth and are in similar abundance 
compared to a naturally secreted protein (358). Furthermore, they show that some 
released cytoplasmic proteins congregate at the septum region of dividing cells. Also, in 
Listeria monocytogenes the surface display of certain cytoplasmic proteins partially 
depend on the SecA2 accessory secretion protein (359). Again, although the exact 
mechanism behind cytoplasmic protein release into the extracellular environment is 
unknown, it is appreciated that this is likely an active process.  
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Concluding Remarks. 
If S. aureus cannot acquire essential nutrients such as trace metals in the host, it 
cannot effectively replicate and cause disease. Moreover, metabolic proteins are found 
to be present in the extracellular environment and may facilitate pathogenesis.  The 
processes of trace nutrient acquisition and metabolic moonlighting proteins suggest that 
bacterial metabolism facilitates pathogenesis either directly or indirectly. In the next 
section, we will introduce a trace nutrient called lipoic acid that our laboratory has found 
to be essential for S. aureus pathogenesis. 
Section 7: Lipoic Acid and S. aureus 
Overview of Lipoic Acid.  
An essential trace nutrient that S. aureus must acquire is the metabolic cofactor 
lipoic acid. Lipoic acid is an organosulfur-containing molecule that is covalently linked to 
proteins in large multi-subunit enzymatic complexes and is involved in redox coupling 
during oxidative and one carbon metabolism (Figure 2A) (360). This cofactor is found in 
nearly all kingdoms of life, including bacteria, yeast, and higher order eukaryotes. Five 
multi-subunit complexes contain lipoic acid: pyruvate dehydrogenase complex (PDH), 2-
Oxoglutarate dehydrogenase (OGDH), branched-chain 2-Oxoacid dehydrogenase 
(BCODH), the glycine cleavage system (GCS) and acetoin dehydrogenase complex 
(AoDH) (361). S. aureus has all of these complexes except AoDH. In these complexes, 
lipoic acid serves as an electrophile that can bind reaction intermediates and shuttle 
substrates between the active sites of different subunits (362, 363). Due to this crucial 
function, without lipoic acid, these enzyme complexes do not work. The 2-oxoacid 
decarboxylases (PDH, OGDH, BCODH) are comprised of E1, E2, and E3 subunits 
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(361, 364). The core of the enzyme structure is provided by the E2 subunit, and often 
these 2-oxoacid decarboxylases carry multiple copies of the E2 component. In Gram-
positive bacteria, the core of PDH is comprised of 60 E2 subunits arranged with 
icosahedral symmetry (365). The GCS has four main subunits, the pyridoxal phosphate-
containing protein (P protein), hydrogen carrier protein (H protein), tetrahydrofolate-
containing protein (T protein), and lipoamide dehydrogenase (L protein). Lipoyl moieties 
are found covalently linked to a conserved lysine within the E2 or H subunit of these 
complexes. The number of lipoyl domains on PDH varies from one to three, while all 
OGDH and BCODH E2 subunits contain just one domain (361). PDH catalyzes the 
oxidative decarboxylation of pyruvate to form acetyl coenzyme A, feeding several 
metabolic pathways in the cells, including the tricarboxylic acid (TCA) cycle, fatty acid 
biosynthesis, and arms of isoprenoid biosynthesis. OGDH converts a-ketoglutarate to 
succinyl-coA, which is consumed by the TCA cycle or can be diverted for heme and 
amino acid biosynthesis. BCODH participates in the degradation of branched-chain 
amino acids to generate branched-chain coenzyme A intermediates needed for fatty 
acid synthesis. The GCS in bacteria degrades glycine and produces 5,19-methylene-
tetrahydrofolate, a one carbon donor involved in synthesis in serine, thymidine, and 
purines (366). In mammals, GCS prevents the buildup of toxic levels of glycine. Despite 
the conservation of lipoic acid, the mechanisms of lipoic acid acquisition show 
considerable diversity. 
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Figure 2. Lipoic Acid Acquisition in S. aureus. (A) Structure of lipoic acid. (B) Model 
of the S. aureus lipoic acid synthesis and salvage pathways. ACP, Acyl carrier protein; 
GcvH, H protein of the glycine cleavage system; E2s, E2 subunits of PDH, OGDH, and 
BCODH. LipM, octanoyl transferase; LipA, lipoyl synthetase; LipL, lipoyl transferase; 
LplA1/A2, lipoate protein ligases. (A) Reprinted with permission from Spalding and 
Prigge, 2010 (360). (Figure 42-Appendix A) 
  
Acquisition of Lipoic Acid. 
Bacteria acquire lipoic acid through the use of two different mechanisms: de novo 
synthesis or salvage from the environment. Though lipoic acid is an essential cofactor 
needed for viability, some bacteria such as Helicobacter pylori have adapted alternative 
non-lipoic acid dependent metabolic enzymes to facilitate cellular viability (367, 368). 
Lipoic acid acquisition and the proteins involved are best characterized in E. coli, B. 
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characterized lipoic acid acquisition schemes in S. aureus. Like B. subtilis, S. aureus 
engages in both de novo synthesis and salvage of lipoic acid (Figure 2B) (373, 374). 
Using genetic and biochemical studies, we have determined that synthesis of lipoic acid 
depends on the enzymes LipA, LipM, and LipL (373, 374). The salvage of lipoic acid 
occurs through the action of two ligases, LplA1 and LplA2. Lipoic acid synthesis starts 
with the transfer of octanoic acid, a medium chain fatty acid, from its acyl carrier protein 
(ACP) to GcvH by LipM, an octanoyl transferase. The lipoic acid synthase LipA then 
inserts two sulfur atoms into the octanoyl-precursor forming a dithiolane ring yielding 
lipoic acid. The amidotransferase LipL transfers the lipoyl moiety from GcvH to 
conserved lysine residues on the E2 subunits of PDH, OGDH, and BCODH (373, 374). 
In the scavenging pathway, the ligase LplA1 scavenges free lipoic acid from the 
environment and attaches it to GcvH where the lipoyl moiety is then transferred to its 
cognate E2 subunits (373, 374). Another ligase, LplA2, also scavenges free lipoic acid 
but it bypasses GcvH and directly attaches the lipoyl moiety to E2-PDH, E2-OGDH, and 
E2-BCODH (373, 374).   
Lipoic Acid in Pathogenesis. 
Given the significance of lipoic acid in bacterial metabolism, it is no surprise that 
acquisition of lipoic acid contributes to pathogenesis. For example, lipoic acid salvage 
enzymes promote the pathogenesis of Listeria monocytogenes and Chlamydia 
trachomatis (369, 375-377). In Plasmodium, the salvage enzyme ortholog LplA1 
contributes to the survival of the parasite during expansion within red blood cells during 
infection (378, 379). As of 2014, there was no data in the literature to suggest how lipoic 
acid acquisition in S. aureus contributes to virulence during infection. However 
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published work and preliminary studies from our laboratory indicate lipoic acid synthesis 
and salvage pathways are crucial for infection by S. aureus (373). We have found that 
in bloodstream infection, perturbations of lipoic acid synthesis and salvage can lead to 
tissue-specific defects where infection of the kidney depends on salvage, but infection 
of the heart requires de novo synthesis (373). These data suggest there is varied 
dependency on de novo lipoic acid synthesis or salvage for S. aureus survival that 
depends on the tissue site.  
Immunosuppressive Properties of Lipoic Acid. 
Aside from the central role of lipoic acid in metabolism, it also possesses 
immunosuppressive traits. High concentrations of free lipoic acid reduce the respiratory 
burst of neutrophils through its antioxidant properties and block the translocation of the 
transcription factor, NFkB, to the nucleus (380-383). Intriguingly, high concentrations of 
free lipoic acid also can activate Akt (384). This stimulates the phosphoinositide 3-
kinase/Akt signaling axis, which has a range of biological effects; but, in terms of lipoic 
acid activation, it was demonstrated to limit inflammatory cytokine production. Another 
described immunosuppressive activity of free lipoic acid, is the inhibition of iNOS activity 
at the protein level when induced by IL-1b (385). However, free lipoic acid is not a 
physiologically relevant form as lipoic acid is always bound to a protein via an amide 
bound. The relevance of lipoic acid immunosuppressive abilities has never been tested 
in vivo during the course of a bacterial infection.  
Summary 
 S. aureus is a human pathogen that can infect almost every tissue site in the host 
and cause significant disease. The innate immune system of the host is a fast-acting 
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initial line of defense that can recognize and utilize many diverse mechanisms to limit 
infection. However, S. aureus has evolved and acquired an array of virulence factors 
that can inhibit innate immune cell recruitment and antimicrobial activity, or directly 
target and kill phagocytic leukocytes thereby facilitating pathogenesis. In order to 
successfully infect the host, S. aureus must be able to acquire trace nutrients. How 
evasion of host innate responses and acquisition of trace nutrients in S. aureus dictates 
pathogenesis is largely understudied. Moreover, a majority of what is known about 
innate immune evasion and S. aureus focuses on countering neutrophil activity and not 
macrophages.  
Thus, this thesis sought to identify novel host innate evasion mechanisms of S. 
aureus that are directed at curbing macrophage immune responses. We found that the 
function of the lipoic acid synthetase, LipA, is necessary to dampen macrophage 
activation by S. aureus PAMPs. This occurs through the release of a metabolic protein 
into the extracellular environment, E2-PDH, which is modified with lipoic acid. The lipoic 
acid modified E2-PDH moonlights by restricting TLR1/2 activation of macrophages. 
During infection, the production of lipoic acid is crucial to dampen the inflammatory 
responses of macrophages. In the absence of this lipoic acid-based restriction of 
macrophage inflammatory responses during infection, macrophages are better able to 
control infection. In summary, this thesis has identified a novel innate immune evasion 
mechanism of S. aureus closely associated with bacterial metabolism. 
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CHAPTER TWO
MATERIALS AND EXPERIMENTAL METHODS 
Bacterial Strains and Culture Conditions 
All bacterial strains and oligonucleotides used in this thesis are listed in Table 3. 
The WT and parental strain used to generate all S. aureus mutants used in this study 
was the pulse field gel electrophoresis type USA300 isolate LAC cured of its plasmids 
(wild type – AH1263), unless noted otherwise. S. aureus RN4220 is a NCTC8325 
derivative which is restriction deficient for passage of plasmid. The T7 expressing 
Escherichia coli strain, lysY/Iq, was used as a host to overexpress and purify 
recombinant 6x-Histidine tagged S. aureus E2-PDH. All S. aureus strains were either 
grown in rich medium - Tryptic Soy Broth (TSB) (Criterion), or in defined medium lacking 
lipoic acid - Roswell Park Memorial Institute 1640 medium (RPMI) (Corning) 
supplemented with 1% casamino acids (Amresco). E. coli was cultivated in Lysogeny 
Broth, Miller formulation (LB) (BD Biosciences). Unless noted, all bacteria were grown 
at 37°C in a shaking incubator at 200 rpm in tubes kept at a 45° angle. When solid 
medium was required, agar (Amresco) was supplemented into TSB and LB at 1.5%. 
Where necessary, media was supplemented with antibiotics at the following final 
concentrations for S. aureus: erythromycin (Erm), 3 µg/mL (Amresco); kanamycin (Kan), 
50 µg/mL (Amresco); neomycin (Neo), 50 µg/mL (Amresco); and chloramphenicol 
(Cam), 10 µg/mL (Amresco). Antibiotics for E. coli were supplemented at the following 
final concentrations: ampicillin (Amp), 100 µg/mL (Gold Biotechnology); Kan, 10 or 25
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 µg/mL (Amresco); and Neo, 10 or 25 µg/mL (Amresco). RPMI medium used to bypass 
the requirement for lipoic acid (RPMI+BCFA) was supplemented with the following 
branched-chain carboxylic acids: 11.23 mM isobutyric acid (Sigma), 9.5 mM 2-
methylbutyric acid (Alfa Aesar), 9.69 mM isovaleric acid (Sigma), and 10 mM sodium 
acetate (Amresco), pH 7.4-7.5.  
Molecular Genetic Techniques 
S. aureus chromosomal DNA was isolated using the Wizard Genomic DNA 
purification kit (Promega) following the manufacturer’s protocol with minor modifications.  
1.2 mL of an overnight culture was pelleted by centrifugation at 14000 rpm for 3 minutes 
at room temperature and resuspended in 200 μL of TSM buffer (50 mM Tris, 0.5 M D-
Sucrose,10 mM MgCl2 pH 7.5) followed by addition of 2.5 µL of lysostaphin (Ambi 
Products, NY) stock solution (2 mg/mL in 20 mM sodium acetate, pH 4.5) and 
incubation at 37°C for 15 minutes to digest the cell wall. The bacteria were then pelleted 
by centrifugation at 14000 rpm for 5 minutes at room temperature and the chromosomal 
DNA was extracted as detailed by the manufacturer’s instructions. Recombinant 
plasmids and DNA from agarose gels were recovered using miniprep/midiprep and gel 
extraction kits from QIAGEN following the supplied protocol. Polymerase chain reaction 
was conducted using GoTaq polymerase (Promega) or Phusion High-Fidelity DNA 
polymerase (New England Biolabs) with oligonucleotide primers from Eurofin Genomics 
(Table 4), and dNTPs from Quanta Biosciences. DNA digestion was performed using 
restriction enzymes purchased from New England Biolabs. When digesting plasmids 
shrimp alkaline phosphatase (Amresco) was supplemented into the digests. Ligations 
were conducted using T4 DNA Ligase (New England Biolabs) at 16°C overnight.  
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Table 3. List of Strains  
Designation  Description Strain  
WT AH-LAC  S. aureus USA300 Strain LAC. Plasmid 
cured. 
USA300 AH-LAC 
WT LAC S. aureus USA300 Strain LAC USA300 WT LAC 
Transposon mutant library Nebraska Transposon Mutant Library of 
USA300 JE2 (386) 
USA300 JE2 
WT JE2 S. aureus USA300 Strain JE2 USA300 JE2 
DH5a E. coli strain used for propagating pIMAY in 
S. aureus   
DH5a 
lysY/Iq E. coli lysY/Iq strain used for expression of 
E2-PDH 
lysY/Iq 
RN4220 Restriction deficient S. aureus for plasmid 
propagation  
RN4220  
DlipA AH-LAC with in-frame deletion of lipA FA-S831* 
ΔlipA  + ΔlipA FA-S831 complemented with pJC1112-lipA FA-S877* 
ΔE2-PDH::kan   AH-LAC with gene replacement of e2-pdh 
with the kanamycin resistance cassette  
FA-S1041 
ΔE2-OGDH::kan   AH-LAC with gene replacement of e2-ogdh 
with the kanamycin resistance cassette  
FA-S1042 
ΔgcvH::kan AH-LAC with gene replacement of gcvH with 
the kanamycin resistance cassette 
FA-S1038 
ΔlipM AH-LAC with an in-frame deletion of lipM FA-S842* 
ΔlipL AH-LAC with an in-frame deletion of lipL FA-S1176* 
ΔlplA1 AH-LAC with an in-frame deletion of lplA1 FA-S841* 
ΔlplA2 AH-LAC with an in-frame deletion of lplA2 FA-S837* 
atl::erm  Transposon insertion into atl from the 
Nebraska Transposon Mutant Library of 
USA300 JE2 
NE460 
secA2::erm  Transposon insertion into secA2 from the 
Nebraska Transposon Mutant Library of 
USA300 JE2 
NE66 
ΔlipA::kan E.coli ΔlipA::kan LysY IQ E. coli FA-E1344 
6x-His-PDH  
 
pET15b encoding 6x-His-PDH transformed 
into ΔlipA::kan LysY IQ E. coli 
FA-S1359 
SitC-6x-His RN4220 with pOS1-PsarA-sodRbs-SitC-6x-His FA-S1424* 
*denotes strains generated by current and former members of the Alonzo Lab: Ryan 
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E. coli Competent Cell Preparation 
 A 5 mL O/N culture of E. coli in LB was grown at 37°C with shaking at 200 rpm. 
The overnight culture was diluted 1:55 into a 250 mL flask containing 200 mL of LB, and 
then grown at 37°C with shaking at 200 rpm until cultures reached an OD600 0.3-0.4 
(around 2.5 hours). The culture was divided equally into four pre-chilled 50 mL conical 
tubes and incubated on ice for 10 minutes. The tubes were centrifuged at 4000 rpm for 
10 minutes at 4°C. Supernatant was discarded and the pellets were resuspended in 10 
mL of Transformation Buffer 1 (30 mM KOAc, 100 mM RbCl2, 10 mM CaCl2, 50 mM 
MnCl2, 15% glycerol, pH to 5.8 using 0.2 M acetic acid) and incubated on ice for 10 
minutes. These washed cells were then centrifuged at 4000 rpm for 5 minutes at 4°C. 
Supernatant was discarded and the pellets were resuspended in 1 mL of 
Transformation Buffer 2 (10 mM MOPS, 75 mM CaCl2, 10 mM RbCl2, 15% glycerol, pH 
to 6.5 with KOH) and transferred to 1.5 mL microcentrifuge tubes. The competent cell 
preparations were stored at -80°C for future use. 
E. coli Transformation 
5 µL of a ligation reaction or 1 µL of purified plasmid were added to 50 µL of 
competent E. coli in microcentrifuge tubes on ice for 20 minutes. Bacterial cells were 
then heat-shocked for 45 seconds at 42°C and immediately placed on ice for 2 minutes. 
For recovery, 250 μL of SOC medium (0.5% tryptone, 0.5% yeast extract, 0.05% NaCl, 
250 mM KCl, adjusted to a pH 7.0 using 5M NaOH followed by addition of 20 mL 1M 
glucose) was added to the bacterial cells and incubated at 37°C with shaking at 200 
rpm for 2 hours.  After incubation, 100 µL of the transformation mixture was plated on 
LB plates with relevant antibiotics to select for transformants.  
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Preparation of S. aureus Electrocompetent Cells 
 A 5 mL O/N culture of S. aureus in TSB was grown at 37°C with shaking at 200 
rpm. The next day, 300 µL of the overnight culture was added to 30 mL of fresh TSB 
and grown for 3 hours at 37°C with shaking at 200 rpm. The culture was centrifuged for 
10 minutes at 8000 rpm for 10 minutes at 4°C. Supernatant was decanted and the 
bacterial pellet was washed in 30 mL ice-cold 10% glycerol, followed by another 
centrifugation at 8000 rpm for 10 minutes at 4°C. This washing step was repeated once 
more. Cells were then resuspended in 15 mL 10% glycerol followed by additional 
centrifugation at 8000 rpm for 10 minutes. Lastly, cells were suspended in 3 mL 10% 
glycerol and aliquoted into 1.5 mL microcentrifuge tubes and stored at -80°C until use. 
S. aureus Electroporation 
 To transform S. aureus, 50 μL of thawed S. aureus competent cells was mixed 
with ~1 μg of purified plasmid by gentle agitation and incubated at room temperature for 
30 minutes. The mixture was transferred to a 2 mm electroporation cuvette (VWR) and 
pulsed with a GenePulserXcell BioRad electroporator at 1800 V, 10 µF, 600 Ω. After 
pulsing, cells we allowed to recover in 750 µL of TSB for 1.5 hours at 30°C with shaking 
at 200 rpm. After incubation, 100 µL of the bacteria was plated onto TSA plates 
supplemented with appropriate antibiotics. The remaining bacteria were first pelleted by 
centrifugation at 10000 rpm for 2 minutes and the supernatant was removed until 100 
µL remained. The pellet was resuspended in this remaining 100 µL and plated onto TSA 
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Construction of Marked Deletion Mutants 
Two fragments corresponding to 500 base pairs upstream of the start codon and 
500 base pairs downstream of the stop codon of e2-pdh, e2-ogdh, and gcvH were 
amplified by polymerase chain reaction (PCR). The upstream fragment was PCR 
amplified from WT S. aureus genomic DNA using primer 0791SOE1-Kpn/0995SOE1-
Kpn/1305SOE1-Kpn and primer 0791SOE2-Kas/0995SOE2-Kas/1305SOE2-Kas (Table 
4). The downstream fragment was also PCR amplified from WT S. aureus genomic 
DNA using primer 0791SOE3-Kas/0995SOE3-Kas/1305SOE3-Kas and primer 
0791SOE4-Sac/0995SOE4-Sac/1305SOE4-Sac (Table 4). The resulting fragments 
were purified and used as templates in a splicing by overlap extension (SOEing) PCR 
reaction to generate the final amplicon for mutagenesis. This amplicon was then cloned 
into pIMAY using the KpnI and SacI restriction enzymes and propagated in E. coli.  
To construct pIMAY mutagenesis plasmids containing an antibiotic resistance 
marker, aphA3 (kanR) was PCR amplified from the plasmid pBTK with oligonucleotides 
KanF-Kas and KanR-Kas (Table 4). We then sub-cloned the kanR gene into a unique 
KasI site engineered between the upstream and downstream regions of homology 
previously cloned into pIMAY. Once constructed, the pIMAY gene replacement 
constructs were transformed into E. coli and selected for chloramphenicol (Cam) 
resistance. The pIMAY plasmids were propagated in E. coli and purified for 
electroporation into the restriction deficient S. aureus strain RN4220. The pIMAY 
plasmids were isolated from RN4220 and then electroporated into WT S. aureus LAC 
as described above. The pIMAY plasmid replicates at 28°C and integrates into the S. 
aureus chromosome at 37°C so it was maintained at 28°C until performing 
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mutagenesis. Allelic replacement was carried out by shifting to the non-permissive 
temperature for pIMAY replication (37°C) in the presence of Cam. This allows for pIMAY 
to integrate into the genome at the cloned homologous sites. The strains were then 
cultured at 28°C without Cam selection to facilitate a second recombination event and 
subsequent excision of the plasmid from the genome. To counter-select for bacteria that 
have lost the pIMAY plasmid, bacteria are plated on anhydrous tetracycline (AnTet). At 
the same time, the bacteria were selected on Kan/Neo plates to select for successful 
gene replacement events. Colonies that were Cam sensitive, AnTet resistant, and 
Kan/Neo resistant were analyzed by PCR for deletion of the relevant genes. This 
procedure was used to generate the following mutant strains: Δe2-pdh::kan, Δe2-
ogdh::kan, and ΔgcvH::kan. 
Bacterial Growth Curves 
Growth curves of WT, ΔlipA, or ΔlipA+lipA were carried out in TSB and RPMI, 
RPMI supplemented with 25 nM α-lipoic acid (Sigma), or RPMI supplemented with 
BCFA (RPMI+BCFA). Overnight cultures were prepared in triplicate in either TSB or 
RPMI+BCFA in a 96-well round-bottom polystyrene plate (CellTreat). The next day, 
cultures were washed three times in TSB or RPMI and the triplicate samples were 
subcultured 1:100 and grown in a 96-well flat-bottom polystyrene plate at 37°C with 
shaking at 200 rpm. Bacterial growth was assessed hourly for 10 hours by measuring 
optical density at 600 nm (OD600) using an ELx800 microplate reader (BioTek) until 
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Table 4. List of Primers  
 







































Isolation of Bone Marrow-Derived Macrophages 
Primary murine bone marrow macrophages (BMM) were derived from bone 
marrow progenitor cells isolated from the femurs and tibias of C57BL/6 (WT, TLR2-/-, 
TLR4-/-, MyD88-/-) mice. 5 x 106 progenitor cells were plated in 100 x 26-mm Petri dishes 
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containing 15 mL bone marrow macrophage medium (BMM medium - DMEM (CellGro) 
+ 1 mM Sodium Pyruvate (CellGro) + 1 mM HEPES Buffer (CellGro) + 2 mM L-
glutamine (CellGro) + 20% heat inactivated FBS (Seradigm) + 30% L929 fibroblast cell 
supernatant + 100 µg/ml Penicillin/Streptomycin (Pen/Strep) (CellGro) + 50 µM β-
mercaptoethanol (Amresco)). After 3 days at 37°C, 5% CO2, 10 mL of fresh BMM 
medium was added and macrophages were allowed to differentiate for 6 more days. To 
remove differentiated BMM from petri dishes, the cells were rinsed with 10 mL 1X PBS 
and incubated with 10 mL 1X PBS at 4°C for 30 minutes. Following incubation, cells 
were removed by manual pipetting and 1 x 107 cells were resuspended in BMM medium 
containing 10% DMSO (Sigma) for storage in liquid nitrogen. For experiments using 
frozen BMM, the frozen vial was thawed at 37°C and then slowly diluted dropwise into 
fresh BMM medium, pelleted by centrifugation at 1500 rpm at 4°C for 5 minutes, and 
then resuspended in 10 mL of fresh BMM medium. The cell suspension was 
subsequently split into two 100 x 26-mm Petri plates containing 10 mL BMM medium 
with 100 µg/mL penicillin/streptomycin and was cultured for 3 days at 37°C, 5% CO2 
before use.  
Isolation of Bone Marrow Neutrophils 
Murine bone marrow neutrophils were isolated from the femurs and tibias of 
C57BL/6 WT mice by flushing out the bone marrow cells with DMEM + 10% heat 
inactivated FBS. Cells were then centrifuged at 1500 rpm at 4°C for 5 minutes, the 
supernatant was decanted, and red blood cells were lysed with ACK lysing buffer 
(Lonza) by resuspending the pellet in 2 mL of lysis buffer and incubating for 2 minutes 
at room temperature. Cell lysis was stopped by adding 8 mL of 1X sterile PBS, mixing 
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gently, and pelleting by centrifugation at 1500 rpm, 4°C for 5 minutes. The cells were 
then resuspended in 10 mL of DMEM + 10% heat inactivated FBS, counted, and 
resuspended in 1 mL of 1X PBS after pelleting by centrifugation at 1500 rpm at 4°C for 
5 minutes. To isolate neutrophils, we used density gradient centrifugation. 3 mL of 
Histopaque 1077 (density 1.077 g/mL) (Sigma) was gently overlaid on 3 mL of 
Histopaque 1119 (density 1.119 g/mL) (Sigma) followed by addition of the bone marrow 
cell suspension on top of the Histopaque 1077 layer. The samples were then 
centrifuged for 30 minutes at 2000 rpm 25°C without brake and neutrophils were 
collected at the interface between the Histopaque 1119 and 1077 layers. Purified 
neutrophils were then washed twice by centrifugation at 1500 rpm at 4°C for 5 minutes 
and resuspending with DMEM + 10% heat inactivated FBS supplemented with 100 
µg/mL Pen/Strep (Corning) and 50 µg/mL gentamicin (Amresco). Neutrophils were then 
seeded at 65000 cells per well into 96-well flat-bottom tissue culture treated plates 
(Corning) in 90 µL DMEM + 10% heat inactivated FBS supplemented with 100 µg/mL 
Pen/Strep and 50 µg/mL gentamicin. The neutrophils were activated with 10 µL OD-
normalized supernatants from 9 hour S. aureus cultures followed by incubation at 37°C, 
5% CO2 for 12 hours.  Macrophage supernatants were then removed and either used 
immediately or stored at -80°C. To measure the levels of cytokines and chemokines in 
the neutrophil supernatants, a custom Cytometric Bead Array Flex set (BD Biosciences) 
was used according to manufacturer’s specifications. Bead and supernatant mixtures 
were incubated for 1.5 hours at 25°C at 600 rpm using a Thermo Mixer C (Eppendorf) in 
a 96-well V-bottom plate (Corning). Samples were then washed using FACS Wash 
Buffer (1X PBS + 2% heat inactivated FBS + 0.05% (w/v) Sodium Azide), data collected 
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on a LSRFortessa (BD Biosciences), and analyzed using FlowJo software (FlowJo, 
LLC) by gating on individual bead populations and calculating the geometric mean of 
fluorescence relative to protein standards. 
To measure the purity of the isolated bone marrow neutrophils, 100000 cells 
were transferred to a 96-well V-bottom plate (Corning) for cell surface staining. Prior to 
staining, immune cells were incubated with 50 μL of FACS Wash Buffer containing 0.2 
μg/mL of anti-CD16/CD32 (93) (BioLegend) for 30 minutes on ice to block Fc receptors 
followed by washing with FACS Wash Buffer and surface staining with the following 
antibodies from BioLegend: anti-CD11b-FITC (M1/70) and anti-Ly6G-APC (1A8) for 30 
minutes on ice and washed twice with FACS Wash Buffer. Samples were then washed 
twice and fixed using FACS Fixing Buffer (1X PBS + 2% heat inactivated FBS + 2% 
Paraformaldehyde + 0.05% (w/v) sodium azide). Data was collected on a LSRFortessa 
(BD Biosciences) and subsequently analyzed using FlowJo software (FlowJo, LLC). 
Isolated bone marrow neutrophils were 85-90% pure.  
Transposon Mutant Library Screen on BMM 
An annotated transposon mutant library generated in USA300 strain JE2 was 
used for screening (BEI resources repository) by Francis Alonzo. Overnight cultures 
were prepared by inoculating polystyrene plates (Corning) containing sterile TSB with 
transposon mutants that had been spot plated and grown on solid agar in 12x8 arrays 
(20 plates, each containing a single 12x8 array of mutant strains) the night prior. 
Following overnight growth at 37°C, the mutant library was subcultured 1:100 by 
inoculating 2 µL of a well-mixed overnight culture into 198 µL fresh TSB in 96-well 
polystyrene plates (Corning). The cultures were allowed to grow for 9 hours (OD600 = 
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1.2) at 37°C with shaking at 200 rpm. After 9 hours, the OD600 of the strains was 
measured using an Envision 2103 plate reader (Perkin-Elmer) and the bacteria were 
pelleted by centrifugation at 3700 rpm for 15 minutes at 4°C. Cell free supernatant was 
collected and used immediately for screening or stored at -80°C. 65000 BMM derived 
from bone marrow of 6-8 week old male and female C57BL/6 mice were seeded into 
96-well flat-bottom tissue culture treated plates (Corning) in BMM medium with 100 
µg/mL Pen/Strep (Corning) and 50 µg/mL gentamicin (Amresco) the day before use. 
The following day, supernatants isolated from 9 hour cultures of S. aureus transposon 
mutants were thawed from storage at -80°C on ice followed by addition of 10 µL OD 
normalized supernatants to macrophages in 90 µL BMM medium and incubation at 
37°C, 5% CO2 for 24 hours.  Macrophage supernatants were then removed and either 
used immediately in cytometric bead array or stored at -80°C for later analysis. 
To measure the levels of cytokines and chemokines in the macrophage supernatants, a 
custom Cytometric Bead Array Flex set (BD Biosciences) was used according to 
manufacturer’s specifications. Bead and supernatant mixtures were incubated for 1.5 
hours at 25°C at 600 rpm using a Thermo Mixer C (Eppendorf) in a 96-well V-bottom 
plate (Corning). Samples were then washed using FACS Wash Buffer (1X PBS + 2% 
heat inactivated FBS + 0.05% (w/v) Sodium Azide), data collected on a LSRFortessa 
(BD Biosciences), and analyzed using FlowJo software (FlowJo, LLC) by gating on 
individual bead populations and calculating the geometric mean of fluorescence relative 
to protein standards. From the 1920 mutants in the library, 96 were initially selected for 
rescreening based upon an altered abundance that fell at least 1 standard deviation 
outside the average response induced by all 1920 mutants. These 96 mutants were 
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rescreened. Those mutants whose cytokine abundance remained 1 standard deviation 
above or below that of wild type induction levels were selected and are displayed in 
Table 5. ++ and -- in Table 5 refers to those mutants whose cytokine levels fell one 
standard deviation beyond wild type in the positive or negative direction respectively. 
For an NE264 mutant, MCP1 and KC levels were highly variable between biological 
replicates, therefore these cytokine changes were designated ++/ND in Table 5. All 21 
mutants were rescreened in triplicate to confirm statistically significant enhancement or 
diminution of cytokine secretion relative to WT controls. After confirmation, the 
mutations were subsequently transduced into S. aureus USA300 strain LAC to confirm 
phenotypes before moving forward with prioritization of mutants for further studies. All 
transduced mutants were screened in triplicate and assessed for statistically significant 
differences in cytokine abundance compared to wildtype. This screen was conducted by 
Dr. Francis Alonzo.  
S. aureus Cell Free Supernatant Preparation 
S. aureus overnight cultures were prepared in triplicate by inoculating three wells 
with an individual bacterial colony in a 96-well round-bottom polystyrene plate 
containing RPMI+BCFA medium that was filtered sterilized using a 0.22 µM PES 
syringe filter (Corning) into a plastic conical tube. Following overnight growth at 37°C 
with shaking at 200 rpm, triplicate samples were subcultured by inoculating 3 µL of a 
well-mixed overnight culture into 147 µL RPMI+BCFA. The cultures were allowed to 
grow for 3, 5, or 9 hours at 37°C with shaking at 200 rpm. After 3, 5 or 9 hours, the 
OD600 of the strains were measured using an ELx800 microplate reader (BioTek) for 
OD normalization and the bacteria were pelleted by centrifugation at 3700 rpm for 15 
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minutes at 4°C. Cell free supernatant was collected and used immediately or stored at -
80°C.  
Purification of S. aureus Lipoyl-E2-PDH 
Recombinant E2-PDH was expressed and purified from E. coli lysY/Iq containing 
a ΔlipA::kan mutation. The ΔlipA::kan mutant was generated using lambda red 
mutagenesis. In brief, a primer pair (LipAP1F/LipAP2R) was designed containing 50 bp 
of homology upstream and downstream to the lipA gene in E. coli and homology to the 
priming regions of pKD4. These primers were then used to PCR amplify the kanamycin 
resistance cassette encoded in pKD4. Lambda red mutagenesis was carried out by 
electroporating this amplicon into competent lysY/Iq expressing pKD46 and plating on 
LB containing either 10 or 25 µg/mL of Kan and Neo. Antibiotic resistant colonies were 
patched and subsequently assessed for replacement of the lipA gene with the pKD4 
Kan resistance cassette using PCR with primer pair LipAF/LipAR. To generate a 6x-His-
Tagged E2-PDH expression plasmid, WT genomic DNA was isolated and amplified with 
the primer pair 0995hisN/CF/0995hisNR to generate an E2-PDH encoding amplicon 
flanked by NdeI and BamHI restriction sites. This amplicon was ligated into a pET15b 
expression plasmid which was subsequently transformed into the ΔlipA::kan lysY/Iq 
strain. To confirm expression of the N terminal 6x Histidine tagged E2-PDH, protein 
production was assessed after induction with 1 mM IPTG at 37°C for 3 hours (Gold 
Biotechnology).  
To purify E2-PDH, lysY/Iq ΔlipA::kan E. coli containing the pET15b-6x-His-E2-
PDH plasmid was grown overnight in 30 mL LB (BD Biosciences) supplemented with 
100 µg/mL ampicillin (Gold Biotechnology) at 37°C, 220 rpm. The following day, the 
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bacteria were subcultured 1:100 in 4 L fresh LB medium and grown for 20 hours at 37°C 
until reaching an OD600 of 0.25-0.3 followed by addition of IPTG (0.5 mM) (Gold 
Biotechnology) and incubation for 4 hours at 37°C at 220 rpm. Bacteria were pelleted by 
centrifugation at 8500 rpm for 10 minutes at 4°C followed by storage at -80°C. The 
following day, bacterial pellets were thawed at 37°C and resuspended in lysis buffer (25 
mM imidazole (Alfa Aesar), 50 mM Tris-HCL, 300 mM NaCl (Amresco), pH 8) 
supplemented with 1 mM dithiothreitol (DTT) (Amresco) and 1 mM phenylmethane 
sulfonyl fluoride (PMSF) (Acròs Organics). Bacteria were lysed on ice using a sonicator 
(Branson) at 20-second intervals with a rate of 0.8 seconds per pulse and an output of 
340 W for a total of 15 minutes. The bacterial debris was pelleted by centrifugation for 
45 minutes at 11000 rpm, filtered through a 0.45 μm filter followed by incubation of the 
clarified supernatant for 1 hour with 1 mL nickel-NTA resin (Qiagen). The resin was 
washed with 150 mL 50 mM imidazole, 1 mM DTT, 50 mM Tris-HCL, 300 mM NaCl, pH 
8 followed by elution in the same buffer containing 500 mM imidazole. The purified 
protein was dialyzed using snakeskin dialysis tubing (10 kDa MWCO, Thermo Scientific) 
into 100 mM imidazole + 50 mM Tris-HCL, 300 mM NaCl, pH 8.0 for 3 hours; 25 mM 
imidazole + 50 mM Tris-HCL, 300 mM NaCl, pH 8.0 overnight; and 50 mM Tris-HCL, 
300 mM NaCl, pH 8 for an additional 3 hours. The concentration of the purified protein 
was measured using a bicinchoninic acid (BCA) kit (Thermo Scientific) and stored at -
80°C. 
To lipoylate purified 6x-His-E2-PDH 4x50 µl reactions were set up in 50 mM Tris-
HCl, 300 mM NaCl, pH 8.0 supplemented with 6 mM ATP (Amresco), 1 mM DTT, 1 mM 
MgCl2 (Amresco), 1 µM recombinant purified lipoate protein ligase, 20 µM E2-PDH, and 
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2.4 mM lipoic acid. The reactions were incubated for 2 hours at 37°C shaking at 600 
rpm. After incubation, the reaction mixtures were loaded onto a Superdex 100 Increase 
3.2/300 Gel Filtration column and fractionated by size exclusion chromatography using 
an AKTA FPLC system (GE Healthcare) to purify lipoyl-E2-PDH in a final buffer 
containing 50 mM Tris-HCl, 300 mM NaCl, pH 8.0. Protein purity and lipoylation were 
confirmed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
and Coomassie staining with GelCode Blue stain reagent (Thermo Scientific), or via 
immunoblot with anti-lipoic acid antibody as described in detail below. The methods for 
purification and lipoylation of E2-PDH were devised by Irina Laczkovich.  
Purification of S. aureus Lipoprotein SitC 
Recombinant SitC was expressed and purified from S. aureus strain RN4220. To 
generate a plasmid capable of expressing SitC harboring a C-terminal 6x-His tag we 
first amplified the S. aureus sarA promoter (PsarA) linked to the ribosome binding site of 
the S. aureus superoxide dismutase (sodRbs) using primer pair SitC1/SitC2 and the 
plasmid pOS1-PsarA-sodRbs-sGFP as template. We then amplified the sitC from S. 
aureus LAC gDNA using primer pair SitC3/SitC4. SitC4 contains coding sequence for a 
6x-His tag embedded in the primer. The resulting amplicons from these PCRs were 
used in a SOEing PCR reaction to generate a single amplicon harboring PsarA-
sodRbsSitC-6xHis flanked by restriction endonuclease cut sites Pst1 and Sal1. The PsarA-
sodRbsSitC-6xHis was digested, ligated into the pOS1 plasmid, and transformed into 
DH5a E. coli. The pOS1- PsarA-sodRbsSitC-6xHis plasmid, was then purified from E. coli 
and electroporated into RN4220.  
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To purify SitC, S. aureus RN4220 containing the pOS1- PsarA-sodRbsSitC-6xHis 
plasmid was grown overnight at 37°C, 220 rpm in TSB supplemented with 10 μg of 
chloramphenicol (Amresco). The following day, the bacteria were subcultured 1:100 into 
2 liters of fresh TSB medium (Criterion) supplemented with 10 μg of chloramphenicol 
(Amresco) and grown for 8 hours at 37°C.  Bacteria were pelleted by centrifugation at 
8500 rpm for 10 minutes at 4°C and then stored at -80°C overnight. Bacteria pellets 
were thawed on ice and resuspended in lysis buffer (20mM Tris-HCL (Alfa Aesar), 
50mM NaCl (Amresco), pH 8.0). The resuspended cells were treated with 200 μl 
lysostaphin (Ambi Products, NY) (2mg/mL in 20mM sodium acetate pH 4.5) and 
incubated at 37°C for 1 hour. The cells were supplemented with 2 mM phenylmethane 
sulfonyl fluoride (PMSF) and lysed on ice via sonication (Branson) at 20-second 
intervals with a rate of 0.8 seconds per pulse and an output of 340W for a total of 30 
minutes. The bacterial debris was pelleted by centrifugation for 1 hour at 11000 rpm and 
cell-free supernatants were collected followed by isolation of membranes by 
ultracentrifugation at 39000 rpm for 1 hour. Membrane pellets were solubilized in 
extraction buffer (20mM Tris-HCl, 50mM NaCl, 2% TritonX-100 (Amresco), pH 8.0) for 
18 hours at 4°C. 1mL of Nickel-NTA resin (Qiagen) was equilibrated in the same 
extraction buffer for 18 hours at 4°C.  The following day, the solubilized membrane 
pellets were centrifuged at 11000 rpm for 1 hour to remove any insoluble debris, filtered 
through a 0.45 µM syringe filter, and incubated with Nickel-NTA resin for 1 hour at room 
temperature. The resin was washed four times with wash buffer (20mM Tris-HCl, 50mM 
NaCl, 0.25% TritonX-100, 40mM imidazole (Amresco)) prior to elution in the same 
buffer containing 400 mM imidazole. The purified protein was dialyzed using snakeskin 
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dialysis tubing (10kDa MWCO, Thermo Scientific) into 100mM imidazole, 20mM Tris-
HCl, 50mM NaCl ,0.25% TritonX-100 pH 8.0 3 hours at 4°C; 25mM imidazole, 20mM 
Tris-HCl, 50mM NaCl, 0.25% TritonX-100 pH 8.0 3 hours at 4°C; 20mM Tris-HCl, 50mM 
NaCl 0.25% TritonX-100 pH 8.0 overnight at 4°C.  The concentration of the purified SitC 
was measured using a bicinchoninic acid (BCA) kit (Thermo Scientific) and determined 
to be 2mg/mL. The purified protein was stored at -80°C until use where it was diluted 
20,000-fold before addition to cells so that the final TritonX-100 concentration was 
0.00001% with no adverse effects on mammalian cells. Protein purity was confirmed by 
SDS-PAGE and Coomassie staining. Purification of SitC was performed by Xi Chen. 
Exoprotein Isolation and Immunoblotting 
To isolate S. aureus exoproteins, strains were first grown overnight in 5 mL TSB 
or RPMI+BCFA in conical tubes. The following morning the bacteria were subcultured 
1:100 into conical tubes containing 5 mL fresh TSB or RPMI+BCFA and allowed to grow 
for 9 hours at 37°C with shaking at 200 rpm. After 9 hours, the OD600 was measured 
using a Genesys 10S UV-Vis spectrophotometer (Thermo Scientific). The cultures were 
pelleted by centrifugation at 4200 rpm at 4°C for 15 minutes. After pelleting the bacteria, 
1.3 mL cell free supernatant was removed followed by the addition of trichloroacetic 
acid (TCA) (Alfa Aesar) to 10% final volume and subsequent incubation at 4°C 
overnight. The following day, samples were centrifuged at 13000 rpm at 4°C for 15 
minutes and 1 mL of 100% EtOH was added followed by incubation at 4°C for 30 
minutes. The precipitated proteins were centrifuged at 13000 rpm at 4°C for 15 minutes 
and EtOH was removed, followed by an additional centrifugation at 15000 rpm for 2 
minutes at room temperature and removal of any excess ethanol. The pellets were then 
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left to air dry for 1 hour, followed by resuspension in 30 µL of TCA-SDS buffer (2X SDS 
buffer + β-mercaptoethanol diluted 1:1 with 0.5M Tris-HCl buffer (pH 8.0) + 4% SDS) 
and boiling for 10 minutes at 100°C. Samples were normalized to the highest OD600 
and separated by SDS-PAGE in 10% or 12% polyacrylamide gels followed by 
Coomassie staining with GelCode Blue stain reagent (Thermo Scientific). 
For immunoblotting, strains were first grown overnight in RPMI+BCFA. The 
following morning, overnights were subcultured 1:100 in 50 mL flasks containing 5 mL 
of RPMI+BCFA with reduced branched chain fatty acid precursors (1.123 mM isobutyric 
acid, 1.0 mM 2-methylbutyric acid, 1.0 mM isovaleric acid and 1.0 mM Na acetate) to 
reduce background on immunoblots. After 9 hours, the OD600 was measured and 
bacteria from 4 mL culture volume were pelleted by centrifugation at 4200 rpm at 4°C 
for 15 minutes. 1.3 mL cell free supernatant was removed followed by the addition of 
10% TCA and isolation of secreted proteins as described above. To detect lipoyl 
proteins in the supernatant, samples were loaded based on OD normalization to 
account for minor differences in final optical density, resolved on 10% or 8% SDS-
PAGE gels, followed by transfer to 0.2 µm PVDF membrane (EMD Millipore) at 200V for 
1.5 hours in a Quadra Mini-Vertical PAGE/Blotting System (CBS Scientific). Membranes 
were then incubated overnight in PBST (PBS + 0.1% Tween-20) with 5% Bovine Serum 
Albumin (BSA) (Amresco) or with 5% BSA in TBST (Tris-buffered saline + 1% Tween-
20) at 4°C overnight. The following day, membranes were blocked with 0.9 mg/mL 
human IgG (Sigma) for 1 hour to mitigate nonspecific binding to S. aureus antibody 
binding proteins. Membranes were washed three times in PBST or TBST for 15 minutes 
each followed by addition of a 1:5,000 dilution of rabbit anti-lipoic acid antibody (EMD 
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Millipore) in 10 mL of PBST + 5% BSA or TBST + 5% BSA. After 1 hour, membranes 
were washed three times with PBST or TBST for 15 minutes each, incubated with a 
1:400 dilution of goat anti-rabbit IgG (H+L) HRP conjugate (Thermo Scientific) in 10mL 
of PBST + 5% BSA for 1 hour or 1:5000 goat anti-rabbit IgG (H+L) Alkaline 
Phosphatase (Thermo Scientific) in 10mL of TBST + 5% BSA secondary antibodies 
depending on the detection method, followed by an additional three 15 minute washes 
in PBST or TBST. Immunoblots were visualized using a FluorChemE System (Protein 
Simple) or exposed to film (Dot Scientific), and developed using an Alphatek Ax390 SE 
autoprocessor using Pierce ECL Western Blotting Substrate (Thermo Scientific) or after 
addition of 35 µL of a 50 mg/mL stock of 5-bromo-4-chloro-3-indoyl phosphate 
(Amresco) and 66 µL of a 50mg/mL stock of nitro blue tetrazolium (Amresco) to 10mL of 
100 mM Tris pH 9.5 + 100 mM NaCl + 5 mM MgCl2 (AP Buffer) to membranes followed 
by incubation for 1-2 minutes.  
Isolation of Surface Proteins 
To isolate proteins on the surface of S. aureus, 5 mL cultures of strains were 
grown overnight in RPMI+BCFA. The following morning, the OD600 of the cultures were 
measured and then pelleted by centrifugation at 4200 rpm at 4°C for 15 minutes. The 
supernatant was decanted, and the cell pellets were resuspended in 200 µL of a 125 
mM Tris-HCL (pH 7.0) + 2% SDS solution. Samples were transferred to 1.5 mL 
microcentrifuge tubes, and boiled for 3 minutes at 95°C. After boiling, samples were 
spun at 10,000 g for 10 minutes. 180 µL of supernatant containing surface proteins was 
collected and boiled at 100°C for 10 minutes in 6X SDS sample buffer (30% (v/v) 
glycerol (Amresco) + 0.5M Tris (Amresco) + 10% (w/v) SDS (Amresco) + 5% (v/v) β-
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mercaptoethanol + 0.012% (w/v) bromophenol blue (Amresco)) followed by storage at -
20°C or immediate use in SDS-PAGE. Samples were loaded based on OD 
normalization to account for minor differences in final optical density and loaded onto 
12% SDS-PAGE gels followed either by Coomassie staining with GelCode Blue stain 
reagent or transfer to 0.2 µm PVDF membrane at 200V for 1 hour. Membranes were 
then blocked overnight with 5% BSA in TBST (Tris-buffered saline + 1% Tween-20) at 
4°C. Immunoblotting was conducted as described above using 0.9 mg/mL of human IgG 
for blocking, 1:3000 rabbit anti-lipoic acid primary antibody, and 1:5000 goat anti-rabbit 
IgG (H+L) Alkaline Phosphatase (Thermo Scientific) secondary antibody. Immunoblot 
were then developed after addition of 35 µL of a 50 mg/mL stock of 5-bromo-4-chloro-3-
indoyl phosphate (Amresco) and 66 µL of a 50mg/mL stock of nitro blue tetrazolium 
(Amresco) to 10mL of 100 mM Tris pH 9.5 + 100 mM NaCl + 5 mM MgCl2 (AP Buffer) to 
membranes followed by incubation for 1-2 minutes.  
Quantification of Lipoyl-E2-PDH 
To quantify the amount of lipoyl E2-PDH released by S. aureus, WT S. aureus 
was first grown overnight in RPMI+BCFA. The following morning, overnights were 
subcultured 1:100 in 50 mL flasks containing 5 mL of RPMI+BCFA with reduced 
branched chain fatty acid precursors. After 9 hours, the bacteria were pelleted by 
centrifugation at 4200 rpm at 4°C for 15 minutes. 1.3 mL cell free supernatant was 
removed followed by the addition of 10% TCA and secreted proteins were isolated as 
described above. 2.5 µL of WT TCA precipitated supernatant was loaded onto a 10% 
SDS-PAGE gel and resolved with a titration of purified recombinant lipoyl-E2-PDH. After 
performing an immunoblot to detect lipoyl-E2-PDH as described above, the amount of 
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lipoyl E2-PDH was estimated based on the intensity of the bands and found to be 
present in the range of approximately 25-50 nM. 
Immunoblotting for Cytosolic Lipoyl-Proteins 
To assess cytosolic lipoyl-protein profiles, strains were grown overnight in 
RPMI+BCFA. The next day cultures were diluted 1:100 in 5 mL RPMI+BCFA and grown 
for 9 hours at 37°C with shaking at 200 rpm. After 9 hours, OD600 was measured and 
the strains were pelleted by centrifugation at 4200 rpm for 15 minutes at 4°C. The spent 
culture medium was aspirated and the bacterial pellets were resuspended in 250 µL of 
sterile 1X PBS. The bacterial suspensions were transferred into screw-cap 
microcentrifuge lysing tubes (Fisher Scientific) containing 250 µL of 0.1 mm glass cell 
disruption beads (Scientific Industries, Inc.) and lysed using a Fast Prep-24 5G (MP 
Biomedicals) bead disruption system at setting 5.0 for 20 seconds followed by a 5 
minute incubation on ice and additional disruption at setting 4.5 for 20 seconds. Tubes 
were centrifuged at 13000 rpm for 15 minutes at 4°C  to pellet debris and 100 µL of 
clarified lysates were boiled at 100°C for 10 minutes in 6X SDS sample buffer (30% 
(v/v) glycerol (Amresco) + 0.5M Tris (Amresco) + 10% (w/v) SDS (Amresco) + 5% (v/v) 
β-mercaptoethanol + 0.012% (w/v) bromophenol blue (Amresco)) followed by storage at 
-20°C or immediate use in SDS-PAGE. Samples were loaded based on OD 
normalization to account for minor differences in final optical density and loaded onto 
12% SDS-PAGE gels followed either by Coomassie staining with GelCode Blue stain 
reagent (Thermo Scientific) or transfer to 0.2 µm PVDF membrane at 200V for 1 hour. 
Membranes were then blocked overnight with 5% BSA in PBST or with 5% BSA in 
TBST (Tris-buffered saline + 1% Tween-20) at 4°C. Immunoblotting was conducted as 
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described above using 0.9 mg/mL human IgG for blocking, 1:3000 rabbit anti-lipoic acid 
primary antibody, and either 1:200 goat anti-rabbit IgG (H+L) HRP conjugate or 1:5000 
goat anti-rabbit IgG (H+L) Alkaline Phosphatase (Thermo Scientific) secondary 
antibodies depending on the detection method. Immunoblots were developed after 
addition of Pierce ECL Western Blotting Substrate, exposure to film (Dot Scientific), and 
developed using an Alphatek Ax390 SE autoprocessor, or after addition of 35 µL of a 50 
mg/mL stock of 5-bromo-4-chloro-3-indoyl phosphate (Amresco) and 66 µL of a 
50mg/mL stock of nitro blue tetrazolium (Amresco) to 10mL of 100 mM Tris pH 9.5 + 
100 mM NaCl + 5 mM MgCl2 (AP Buffer) to membranes followed by incubation for 1-2 
minutes.  
In vitro Macrophage Experiments 
65000 macrophages were seeded into 96-well flat-bottom tissue culture treated 
plates (Corning) in 90 µL BMM medium supplemented with 100 µg/mL Pen/Strep and 
50 µg/mL gentamicin (Amresco) the day before use. The following day, supernatants 
isolated from 9 hour cultures of S. aureus were thawed from storage at -80°C on ice and 
10 µL was added to BMMs following OD normalization between strains to ensure 
equivalent content followed by incubation at 37°C, 5% CO2 for 24 hours. Macrophage 
supernatants were then removed and either used immediately or stored at -80°C. In 
experiments using either purified recombinant E2-PDH or synthetic DKA and DKLA 
(AnaSpec), proteins were pretreated with 20 µg/mL of Polymyxin B sulfate (Alfa Aesar) 
for 1-2 hours at 37°C to mitigate aberrant LPS activation. Treated protein samples were 
then added to the macrophages in triplicate along with the TLR agonists Pam2CSK4 (1 
ng/mL) or Pam3CKS4 (3 ng/mL) (Invivogen) where indicated. In the experiments with 
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SitC, the recombinant lipoprotein was treated with polymyxin B sulfate as described and 
added to the macrophages at a concentration 0.1 ng/mL for measurement of CCL3 and 
CCL4 production and 1 ng/mL for measurement of IL-6 and TNF production. In the 
indicated experiments 250 ng/mL of E. coli serotype 0111:B4 lipopolysaccharide (Enzo 
Life Sciences) or 250 ng/mL of flagellin isolated from the Gram-negative 
bacterium Salmonella enterica serovar Typhimurium (InvivoGen) was added to cells in 
the absence or presence of with 3 mM α-lipoic acid (Sigma). All BMMs were activated 
for 24 hours at 37°C, 5% CO2, followed by removal of macrophage supernatant and 
immediate use or storage at -80°C. 
To measure the levels of cytokines and chemokines in the macrophage 
supernatants, a custom Cytometric Bead Array Flex set (BD Biosciences) was used 
according to manufacturer’s specifications. Bead and supernatant mixtures were 
incubated for 1.5 hours at 25°C at 600 rpm using a Thermo Mixer C (Eppendorf) in a 
96-well V-bottom plate (Corning). Samples were then washed using FACS Wash Buffer 
(1X PBS + 2% heat inactivated FBS + 0.05% (w/v)  Sodium Azide), data collected on a 
LSRFortessa (BD Biosciences), and analyzed using FlowJo software (FlowJo, LLC) by 
gating on individual bead populations and calculating the geometric mean of 
fluorescence relative to protein standards.  
To measure bacterial survival upon infection of activated macrophages, 65000 
BMM were first seeded into 96-well flat-bottom plates in BMM-medium without 
antibiotic. The following day cells were treated with 10% S. aureus cell free supernatant 
and incubated for 16 hours to induce macrophage activation. The day after activation, 
overnight cultures of WT and ΔlipA S. aureus were normalized to an OD600 of 0.32-
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0.33 (1x108 CFU/mL) in PBS, added to macrophages at a multiplicity of infection of 1, 
and spun for 7 minutes at 1500 rpm to synchronize the infection. Infections were carried 
out at 37°C, 5% CO2 for 30 minutes, washed 3X with 1X PBS and incubated with 
gentamicin (50 μg/mL) at 37°C, 5% CO2 for an additional 30 minutes. Cells were 
washed 3X with 1X PBS and placed in BMM medium without antibiotic. After an 
additional hour of incubation, saponin (0.1%) was added to the wells and incubated on 
ice for 30 minutes, followed by plating onto BCFA-containing tryptic soy agar plates to 
enumerate bacterial CFU. 
Detection of Lipoyl-Peptide Binding 
A competition enzyme-linked immunosorbent assay (ELISA) plate-based assay 
was used to assess if lipoyl-peptides bound to TLR1/2 heterodimers. A 96-well EIA/RIA 
plate (Corning, cat# 3591) was coated with 50 µL containing 5 µg/mL of recombinant 
human TLR1/Fc chimera (R&D systems) and 4 µg/mL of recombinant mouse TLR2/Fc 
chimera (R&D systems). The ELISA plate was covered in parafilm and stored at 4°C to 
coat the wells overnight. The next day, the ELISA plate was washed three times in 200 
µL of 1X PBS + 0.05% Tween-20. After the final wash, wells were blocked in 
StartingBlock blocking buffer (Thermo Scientific) per manufacturers protocol. After 
blocking, the ELISA plate was washed three times in 200 µL of 1X PBS + 0.05% 
Tween-20. 100 µL of Pam3CSK4-biotin (Tocris Bioscience) was added to the wells in 
the presence of a serially diluted amount of synthetic DKA and DKLA (AnaSpec) in 100 
µL 1X PBS and incubated for 1 hour at 37°C 5% CO2. After incubation, the ELISA plate 
was washed five times in 200 µL of 1X PBS + 0.05% Tween-20 followed by addition of 
HRP Streptavidin (1:5000) (BioLegend) in 100 µL StartingBlock blocking buffer and 
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incubation at room temperature for 1 hour. After incubation, the ELISA plate was 
washed seven-eight times in 200 µL of 1X PBS + 0.05% Tween-20 and 100 µL of 
3,3’,5,5’-tetramethylbenzidine liquid substrate (Sigma) was added to the wells for 30 
minutes at room temperature, followed by addition of 2M sulfuric acid to stop the 
reaction. Color change was quantified by measuring the absorbance of the sample at 
450 nm using an ELx800 microplate reader (BioTek).  
NFkB Activation Assay 
To measure the activation of the transcription factor NFkB, the RAW-Blue 
macrophage cell line harboring an NFkB inducible chromosomally integrated secreted 
embryonic alkaline phosphatase (SEAP) reporter construct (Invivogen) was grown to 
about 50-70% confluency in DMEM (Corning) + 10% heat inactivated FBS in tissue 
culture treated T75 flasks (Corning). Media was removed from the flask and the cells 
were washed with 2mL of 0.05% trypsin + 0.53 mM EDTA (Corning). 2mL of fresh 
0.05% trypsin + 0.53 mM EDTA was added to the RAW cells for 5-10 minutes and cells 
were dissociated from the surface of the flasks by gentle agitation. Dissociated cells 
were then resuspended in DMEM + 10% heat inactivated FBS and centrifuged for 5 
minutes at 1500 rpm. Cells were then counted and seeded into 96-well flat-bottom 
tissue culture treated plates (Corning) at 50,000 cells per well in 90 µL of DMEM + 10% 
heat inactivated FBS supplemented with 100 µg/mL Pen/Strep (Corning) and 50 µg/mL 
gentamicin (Amresco) the day before use. The following day, supernatants isolated from 
9 hour cultures of S. aureus were thawed from storage at -80°C on ice and added to the 
RAW cells following OD normalization between strains to ensure equivalent loading 
followed by incubation at 37°C, 5% CO2 for 24 hours. Treated RAW-Blue cell 
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supernatants were collected and subsequently heated at 68°C for 30 minutes to 
deactivate endogenous phosphatases. 50 µL of the deactivated RAW cell supernatants 
were mixed with an equal volume of 1-Step PNPP (Thermo Scientific) in a 96-well 
polystyrene plate. After 2-3 hours of incubation, color change was quantified by 
measuring the absorbance of the sample at 450 nm using an ELx800 microplate reader 
(BioTek).  
Murine Infection Models 
Single colonies of freshly struck out bacteria were inoculated in TSB with shaking 
at 37°C and grown overnight. The overnight culture was subcultured 1:100 in 15mL 
fresh TSB and incubated at 200 rpm at 37°C for 3 hours. Cultures were then centrifuged 
for 5 minutes at 4200 rpm at 4°C, and the resulting cell pellets were washed 3 times in 
1X sterile PBS. Bacterial suspensions were then normalized to an OD600 of 1.1-1.2 (~1 
x 109 CFU/mL) for intraperitoneal infection or to an OD600 of 0.32-0.33 (~1 x 108 
CFU/mL) for intravenous infection. Five to eight week old female Swiss Webster mice 
(Envigo) were then injected intraperitoneally with 100 μL of PBS containing 1 x 108 CFU 
of S. aureus. For intravenous infection, five to eight week old female Swiss Webster 
mice were anesthetized with 2,2,2-tribromoethanol (Avertin) (250 mg/kg) (Sigma), via 
intraperitoneal injection followed by inoculation with 100 μL PBS containing 1 x 107 CFU 
of S. aureus directly into the bloodstream via retro-orbital sinus. After infection, the 
remaining bacterial suspensions were plated onto TSA plates to ensure accuracy of 
infection inoculums. Mice were monitored daily and after 16 or 72 hours for IP infection 
and 96 hours for IV infection, serum was collected via the facial vein and mice were 
immediately euthanized by CO2 narcosis followed by aseptic isolation of kidneys and 
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lavage samples. Lavage samples were isolated by flushing the peritoneal cavity with 7 
mL of 1x sterile PBS. Kidneys were homogenized, and lavage fluid and kidney 
homogenates were serially diluted onto TSA plates followed by incubation at 37°C 
overnight to enumerate CFU.  
To deplete mice of macrophages, dichloromethane bisphosphonate (clodronate) 
loaded into liposomes (Liposoma) was administered [1mL/100g (~150 μL/mouse)] by 
i.p. injection. After three days, bacteria were cultured as described above and 
normalized to an OD600 of 0.32-0.33 (~1 x 108 CFU/mL). Mice were injected i.p. with 
100 μL of PBS containing 1 x 107 CFU of S. aureus. Mice were monitored until 16 hours 
or 72 hours post-infection followed by enumeration of bacterial loads from the lavage 
and kidneys as described above.  
For S. aureus re-challenge models, six to eight week old male and female Swiss 
Webster mice were immunized by i.p. injection with 100 μL of PBS containing 1 x 108 
CFU of WT or DlipA S. aureus or sterile PBS. 7- or 14-days after immunization, mice 
were anesthetized with 2,2,2-tribromoethanol (Avertin) (250 mg/kg) (Sigma), via i.p. 
injection followed by inoculation with 100 μL PBS containing 1 x 107 CFU of S. aureus 
directly into the bloodstream via retro-orbital sinus. Mice were monitored daily and then 
euthanized either 24, 72, 96, or 120 hours post infection. Kidneys or hearts were 
isolated and bacterial loads in the kidneys or the hearts was quantified as described 
above.  
Flow Cytometry of Immune Cells 
Assessment of immune cell recruitment to the peritoneal cavity was determined 
by performing a lavage of the peritoneal cavity of euthanized mice 16- or 72-hours post-
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infection with 7 mL of 1X sterile PBS in a 10 mL sterile syringe with an 18-gauge 
needle. Isolated cells were pelleted by centrifugation at 1500 rpm at 4°C for 5 minutes, 
supernatant was decanted, and red blood cells were lysed with ACK lysing buffer 
(Lonza) by resuspending the pellet in 2 mL of lysing buffer and incubating for 2 minutes 
at room temperature. Cell lysis was stopped by adding 8 mL of 1X sterile PBS, mixing 
gently, and pelleting by centrifugation at 1500 rpm at 4°C for 5 minutes. Cells were then 
suspended in 1X sterile PBS and kept on ice while they were counted. 1-2 million cells 
were transferred to a 96-well V-bottom plate (Corning) for cell surface staining. Prior to 
staining, immune cells were incubated with 50 μL of FACS Wash Buffer containing 0.2 
μg/mL of anti-CD16/CD32 (93) (BioLegend) for 30 minutes on ice to block Fc receptors 
followed by washing with FACS Wash Buffer and surface staining with the following 
antibodies from BioLegend: anti-CD11b-Pacific Blue (M1/70), anti-Ly6G-PE (1A8), anti-
DX5-APC-Cy7 (DX5), anti-CD206-FITC (C068C2), anti-CD11c-Alexa700 (N418), anti-I-
A/I-E-Alexa647 (M5/114.15.2), anti-F4/80-PE-Cy7 (BM8), anti-CCR5-biotin (HM-CCR5) 
for 30 minutes on ice and washed twice with FACS Wash Buffer. To stain for CCR5, 
streptavidin conjugated PerCP-Cy5.5 was added on ice for 30 minutes. Samples were 
then washed twice and fixed using FACS Fixing Buffer (1X PBS + 2% heat inactivated 
FBS + 2% Paraformaldehyde + 0.05% (w/v) sodium azide). Data was collected on a 
LSRFortessa (BD Biosciences) and subsequently analyzed using FlowJo software 
(FlowJo, LLC).  
To assess the immune cells recruited to the kidneys in intravenously infected 
mice after 96 hours, immune cell suspensions were purified using a 40/80 Percoll (GE 
Healthcare) density gradient centrifugation. Kidneys were isolated and homogenized 
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using glass mortar and pestle homogenizers (Kontes Glass Co) in 5 mL of RPMI 
(Corning). Kidney homogenate was then transferred to a 50 mL conical tube and 
centrifuged at 1500 rpm, 4°C for 5 minutes. Supernatant was decanted and red blood 
cells were lysed with ACK lysing buffer (Lonza) by resuspending the pellet in 2 mL of 
lysis buffer and incubating for 2 minutes at room temperature. Cell lysis was stopped by 
adding 8 mL of RPMI (Corning), mixing gently, and pelleting by centrifugation at 1500 
rpm, 4°C for 5 minutes. Cells were resuspended in 10 mL RPMI (Corning) and passed 
through a 70 μM nylon mesh cell strainer (Corning). A 100% Percoll solution was made 
by mixing 9 parts Percoll with 1 part 10X PBS (Corning), and then diluted to 80% or 
40% in RPMI + 10% heat inactivated FBS. Cells were then centrifuged at 1500 rpm at 
4°C for 5 minutes, resuspended in 5 mL of 40% RPMI Percoll solution, and overlaid 
carefully on top of 5 mL of the 80% RPMI Percoll solution. Percoll gradients were rested 
at room temperature for 10 minutes and then centrifuged for 20 minutes 2500 rpm at 
room temperature with no brake. The top layer of parenchymal cells was aspirated off, 
and the immune cells present at the 40%/80% Percoll interface were collected. The 
immune cells were then washed twice in RPMI + 10% heat inactivated FBS and stained 
for flow cytometry as described above. 
Measurement of Macrophage Surface Marker Expression 
To assess the levels of various surface markers on BMMs, 300000 BMMs were 
seeded into 24-well non-tissue culture treated plate (Corning) in 300 µL BMM medium 
supplemented with 100 µg/mL Pen/Strep and 50 µg/mL gentamicin (Amresco) the day 
before use. The following day, supernatants isolated from 9 hour cultures of S. aureus 
were thawed from storage at -80°C on ice and 30 µL supernatant was added to BMMs 
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following OD normalization between strains to ensure administration of equivalent 
content followed by incubation at 37°C, 5% CO2 for 1, 2, 4, and 24 hours. In some 
instances 3mM α-lipoic acid (Sigma) was added to BMM for the same incubation times. 
Media was then removed from the BMMs and washed three times in 1 mL of sterile 1X 
PBS. After the last wash, 250 µL of sterile 1X PBS was added to the BMMs and 
incubated at 4°C for 30 minutes. Following incubation, cells were removed by manual 
pipetting and transferred to a 96-well V-bottom plate (Corning) for cell surface staining. 
Prior to staining, cells were incubated with 50 μL of sterile 1X PBS containing 0.2 μg/mL 
of anti-CD16/CD32 (93) (BioLegend) for 30 minutes on ice to block Fc receptors 
followed by washing with sterile 1X PBS and surface staining with the following 
antibodies from BioLegend: anti-CD11b-APC-Cy7 (M1/70), anti-F4/80-PE-Cy7 (BM8), 
anti-CD80- PerCP-Cy5.5 (16-10A1), anti-CD86-APC (GL-1), anti-TLR2-FITC (T2.5), 
and anti-TLR1-PE (TR23) (eBioscience). A fixable viability dye, eFluor 450, 
(eBioscience) was also included in the staining panel. Samples were incubated on ice 
for 30 minutes, washed twice with sterile 1X PBS, and fixed with FACS Fixing Buffer. 
Data was collected on a LSRFortessa (BD Biosciences) and subsequently analyzed 
using FlowJo software (FlowJo, LLC).  
S. aureus Survival in F4/80+ Sorted Cells 
Five to eight week old female Swiss Webster mice were infected via the 
peritoneal route as described previously with WT and ΔlipA S. aureus or sterile 1X PBS. 
72 hours post infection mice were euthanized and peritoneal cells were isolated by 
lavaging the peritoneal cavity with 7 mL of 1X sterile PBS in a 10 mL sterile syringe with 
an 18-gauge needle. Cells were then pelleted by centrifugation at 1500 rpm at 4°C for 5 
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minutes followed by decanting the supernatant and resuspending in 5 mL complete 
RPMI cell culture medium (Corning) (RPMI + 10% heat inactivated FBS) supplemented 
with 100 µg/mL Pen/Strep and 50 µg/mL gentamicin and incubated on ice for 30 
minutes to 1 hour. After incubation, cells were washed 3X in complete RPMI medium 
without antibiotics and incubated for 30 minutes in the antibiotic free medium. Cells 
were then washed once and resuspended in FACS wash buffer without sodium azide 
for magnetic bead sorting. F4/80+ cells were sorted from total peritoneal cells using BD 
Imag Cell Separation (BD Biosciences) after incubation with anti-CD16/CD32 (93) 
(BioLegend) and biotinylated anti-F4/80 antibody (BM8) (BioLegend). In brief, 
streptavidin-conjugated magnetic beads were added to cells and allowed to bind to a 
magnet for 8 minutes followed by removal of the unbound fraction. Bound beads were 
then resuspended in FACS wash buffer without sodium azide and allowed to re-bind to 
the magnet for 6 minutes. This washing step was repeated once more to ensure purity 
of the bound fraction. Sorted cells were stored in FACS wash buffer without sodium 
azide overnight at 4°C. The following day an overnight culture of WT LAC grown in TSB 
was washed 3 times in 5 mL sterile 1X PBS, normalized to an OD600 of ~0.32 
(~1.0x108 CFU/mL), and opsonized by incubation with 10% mouse serum for 30 
minutes at 37°C followed by washing 3 times in 1 mL sterile 1X PBS. The sorted F4/80+ 
cells were pelleted by centrifugation at 1500 rpm at 4°C for 5 minutes, resuspended in 
fresh complete RPMI medium, and counted. The opsonized bacteria were then used to 
infect sorted F4/80+ cells at a multiplicity of infection 1 or 0.1 for 30 minutes at 37°C in 
sterile 1.5 mL microcentrifuge tubes placed on a rotisserie. Following the 30-minute 
infection, samples were centrifuged at 1500 rpm at room temperature in a benchtop 
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centrifuge (Eppendorf) for 5 minutes and washed 3 times in sterile 1X PBS. Samples 
were then resuspended in 1 mL complete RPMI medium and placed at 37°C on a 
rotisserie. In certain experiments ROS production was blocked by addition of 2 µM 
diphenyleneiodonium (DPI; Sigma), mROS production was blocked by addition of 10 
µM Necrox5 (Cayman Chemical), iNOS was blocked by the addition of 500 µM N6-(1-
Iminoethyl)-lysine hydrochloride (L-NIL; Tocris), or vehicle controls were added to the 
culture medium. S. aureus CFU were enumerated hourly by removing 100 μl aliquots, 
lysing with 0.1% saponin (Sigma) for 20 minutes on ice, followed by serial diluting and 
plating the dilutions on TSA plates supplemented with 50 µg/mL of Kan and Neo.  
For experiments in which NADPH oxidase activity was blocked the following 
modifications were performed. Prior to infection, F4/80+ cells were treated with 50 µM 
gp91ds-tat (Anaspec) or vehicle control for 1 hour in RPMI serum free medium to allow 
for entry of the inhibitor into cells. Treated cells were then centrifuged at 1500 rpm at 
room temperature in a benchtop centrifuge for 5 minutes and washed 3 times in sterile 
1X PBS. Washed cells were resuspended in complete RPMI medium containing 
opsonized bacteria at a MOI of 1 and allowed to infect for 30 minutes at 37°C under 
constant rotation. The remainder of the experiment was conducted as described above. 
Assessment of ROS Production 
Three days after i.p. infection with WT, DlipA, or DlipA + lipA strains, peritoneal 
cells were isolated by lavage of the peritoneal cavity followed by magnetic sorting of 
F4/80+ macrophages as detailed above. To measure changes in the oxidative state of 
isolated peritoneal F4/80+ macrophages (ROS production), 5x105 F4/80+ cells were 
infected with WT S. aureus at a MOI of 0.1 for 30 minutes under constant rotation at 
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37°C. Cells were washed free of bacteria followed by incubation in medium containing 
1.25 µM CellROX deep red (Thermo Fisher Scientific) for 1 hour under constant rotation 
at 37°C. Cells were then washed 3X with 200 µL of sterile 1X PBS. Fluorescence was 
measured using a LSRFortessa (BD Biosciences) and data were analyzed using 
FlowJo software (FlowJo, LLC). Fold changes in the geometric means of CellROX 
fluorescence were assessed in infected cells and compared to uninfected F4/80+ cells.  
Griess Test for NO• Production 
Three days after i.p. infection with WT, DlipA, or DlipA + lipA strains, peritoneal 
cells were isolated by lavage of the peritoneal cavity followed by magnetic sorting of 
F4/80+ macrophages as described above. Immediately after sorting, isolated F4/80+ 
macrophages were counted and 100,000 cells were plated in a 96 well plate (Corning) 
in 100 µL complete RPMI medium. Heat-killed WT S. aureus was prepared by 
incubating a PBS-washed overnight culture for 1hr at 60°C. Sterility of the heat-killed 
bacteria was confirmed by enumeration of CFU on a TSA plate. Sorted F4/80+ 
macrophages were then stimulated with the heat-killed bacteria at a MOI of 10 or left 
unstimulated. After overnight incubation at 37°C in 5% CO2, 50 µL of supernatant was 
removed and a Griess test was performed to measure nitrite, which is a breakdown 
product of nitric oxide. 50 µL of 1% sulfanilic acid (Sigma) in 5% phosphoric acid 
(Fischer Scientific) was added to the supernatant samples followed by incubation for 5 
minutes followed by addition of 50 µL of 0.1% N-alpha-naphthyl-ehtylenediamine 
(Sigma) in sterile water and incubation for an additional 5 minutes. To quantify the 
amount of nitrite present in the cell culture medium 100mM sodium nitrate (Sigma) was 
diluted 1:1 and used to make a standard curve. After incubation, sample absorbance 
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was measured at OD550 using an ELx800 microplate reader (BioTek). Fold increase in 
nitrite (nitric oxide) levels of F4/80+ macrophages was determined by comparing nitrite 
production in heat-killed S. aureus stimulated cells compared to non-stimulated cells 
isolated from the same original infection condition (WT, DlipA, or DlipA + lipA).  
Quantification and Statistical Analysis 
All experiments were repeated at least three independent times. Statistical 
analysis was conducted using Prism software (GraphPad) and the specific tests used 
are indicated in the figure legends. Statistical significance was defined as P<0.05. The 
number of animals per treatment group is indicated as “n” in the figure legends. For any 
data without the use of animal models, we assumed a Gaussian distribution and used 1-
way ANOVA with Bonferonni-Sidak post-test for pair-wise comparison.  For any data 
with the use of animal models, we assumed a non-Gaussian distribution and used non-
parametric 1-way ANOVA (Kruskal-Wallis Test) with Dunn’s post-test unless otherwise 
noted. For S. aureus ex vivo survival/growth assays with F4/80+ sorted cells a 2-way 
ANOVA with Tukey’s multiple comparison test was used.
 








The innate immune system is a fast-acting initial line of defense to prevent 
infection. In order to withstand innate defenses, bacterial pathogens such as the Gram-
positive bacterium S. aureus, produce a wide array of virulence factors that inhibit 
innate immune cell recruitment and antimicrobial activity, or directly target and kill 
phagocytic leukocytes thereby facilitating pathogenesis. As previously introduced, a 
large amount of work has been done to understand how S. aureus evades neutrophil 
responses. Comparatively less is known about avoidance of macrophage responses.  
Macrophages are professional phagocytic leukocytes that are central to antimicrobial 
innate defenses. Besides the pathogen killing capacity of macrophages, they also 
produce and secrete a variety of cytokines and chemokines that help to regulate both 
the innate and adaptive immune system. Though less efficient than dendritic cells, 
activated macrophages are capable of presenting antigens to engage with T cells and 
promote their activation. Given their potent antimicrobial activities and critical immune 
signaling functions, macrophages are a significant mediator of the immune response to 
infection that S. aureus must overcome in order to cause disease. A growing body of 
work has begun to uncover mechanisms used by S. aureus to evade macrophages.
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Nevertheless, the repertoire of extracellular S. aureus virulence factors that disrupt 
macrophage functions remains understudied. 
Dr. Francis Alonzo conducted a forward genetic screen to identify S. aureus 
secreted factors that perturb macrophage inflammatory responses. To determine if S. 
aureus releases extracellular factors that perturb macrophage activation, Dr. Alonzo 
devised a forward genetic screen using cell free supernatants derived from 1920 
annotated transposon mutants of the epidemic S. aureus clone, USA300 (JE2) (386). 
Supernatants were added to murine bone marrow derived macrophages (BMM) 
followed by measuring pro-inflammatory cytokine production using multiplexed cytokine 
bead arrays as outlined in Figure 3. 21 mutants were identified that enhanced or 
reduced macrophage cytokine secretion, representing potential gene products that 
interact with macrophages (Table 5). In the screen, already known mechanisms that 
altered macrophage responses were identified, such as an insertion in the gene that 
encodes the lipoprotein signal peptidase (lspA), NE1757. Deletion of lspA led to 
reduced macrophage activation consistent with its role in processing lipoproteins – the 
bacterial PAMP recognized by TLR1/2 and TLR2/6 heterodimers – and therefore served 
as an internal validation of the screen (Figure 4) (388-390). 
 
Figure 3. Transposon Mutant Screen. Design of screen used to identify macrophage 
immunomodulatory factors. Transposon mutants were grown to an OD600 of ~1.2, 
followed by addition of cell free supernatants to BMM for 24 hours. BMM supernatants 
were collected and assessed for cytokine and chemokine secretion using cytometric bead 
array (CBA). 
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Table 5.  Identification of S. aureus Transposon Mutants that Enhance/Reduce 
Macrophage Activation 
 











Mutant # Accession # Gene Name Gene description IL1β IL6 KC MCP1 CCL3 CCL4 TNF 
NE95 SAUSA300_1989 agrB accessory gene 
regulator protein B 
++ -- -- -- -- -- ND 
NE1262 SAUSA300_1984 Hypothetical Hypothetical 
protein 
++ -- -- -- -- -- ND 
NE1908 SAUSA300_1911 -- ABC Transporter 
ATP-binding 
protein 
++ -- -- -- -- -- ND 
NE1714 SAUSA300_1590 -- GTP 
pyrophospokinase 
ND -- -- -- -- -- -- 
NE1757 SAUSA300_1089 lspA lipoprotein signal 
peptidase 
ND -- -- -- -- -- -- 
NE1684 SAUSA300_1308 arlR response regulator ++ ++ ++ ++ ND ++ ++ 
NE592 SAUSA300_2060 atpA ATP synthase F1, α 
subunit 
++ ++ ++ ++ ND ++ ++ 
NE481 SAUSA300_0645 -- DNA binding 
response regulator 
ND ++ ++ ++ ++ ++ ++ 
NE264 SAUSA300_0829 lipA lipoic acid 
synthetase 
ND ++ ++/ND ++/ND ++ ++ ++ 
NE1296 SAUSA300_0690 saeS sensor histidine 
kinase 
ND ++ ++ ++ ++ ++ ++ 
NE1622 SAUSA300_0691 saeR response regulator ND ++ ++ ++ ++ ++ ++ 
NE1775 SAUSA300_0320 geh triacylglycerol 
lipase 
ND ++ ++ ++ ++ ++ ++ 
NE1555 SAUSA300_1148 codY transcriptional 
repressor 
ND ND ND ND ++ ++ ND 
NE1607 SAUSA300_2025 rsbU sigma B regulation 
protein 
ND ND ND ND ++ ++ ND 
NE1833 SAUSA300_2026 -- PemK family 
protein 
ND ND ND ND ++ ++ ND 
NE1872 SAUSA300_2024 rsbV anti-sigma-B factor, 
antagonist 
ND ND ND ND ++ ++ ND 
NE229 SAUSA300_1119 Hypothetical Hypothetical 
protein 
++ ++ ND ++ ND ++ ++ 
NE292 SAUSA300_0539 ilvE branched chain 
amino acid amino-
transferase 
ND ND ND ++ ++ ++ ND 
NE912 SAUSA300_0752 clpP Clp protease ND ND ND ++ ND ++ ND 
NE1193 SAUSA300_0605 sarA accessory regulator 
A 
++ ++ ++ ++ ++ ++ ++ 
NE1909 SAUSA300_1720 Hypothetical Hypothetical 
protein 
ND ++ ND ND ND ++ ++ 
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Figure 4. Transposon Mutants Induce Higher or Lower BMM Cytokine and  
Chemokine Production. Relative abundance of IL-6, TNF, CCL3, and CCL4 produced 
by macrophages after addition of cell free supernatants from JE2 (WT), NE1757 
(lspA::erm), NE264 (lipA::erm).   
 
Of the other mutants identified, Dr. Alonzo found the transposon mutant NE264 
had a marked induction of IL-6, TNF, CCL3, and CCL4 relative to supernatant derived 
from the JE2 WT strain (Figure 4). Due to this increased macrophage response to the 
NE264 transposon mutant, this mutant was the selected for further assessment. NE264 
contains an insertion in the gene that encodes the lipoic acid synthetase, LipA, an 
enzyme required for synthesis of lipoic acid (361, 373). 
To confirm that disruption of lipA led to heightened macrophage activation, we 
used an in-frame deletion mutant (∆lipA) and complementation strain that harbors a 
chromosomally integrated plasmid with lipA under the control of its predicted native 
promoter (∆lipA+lipA). We assessed the growth dynamics of a ∆lipA mutant and found 
that a ∆lipA mutant grew identically to WT in tryptic soy broth (TSB), but not in Roswell 
Park Memorial Institute (RPMI) medium lacking free lipoic acid (Figure 5A and 5B). 
When free lipoic acid was supplemented into RPMI, a ∆lipA mutant grew identically to 
the WT strain bypassing the need for lipoic acid synthesis, as lipoic acid can be 
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acquired through the salvage pathway (Figure 2 and 5B) (373). The growth defect of a 
∆lipA mutant was rescued in RPMI bypass medium containing branched chain 
carboxylic acids and sodium acetate (RPMI + BCFA) (Figure 5C). The complementation 
strain, ∆lipA+lipA, fully complemented the growth defect of a ∆lipA mutant and mimicked 
WT growth (Figure 5A-C). To test if cell free supernatant from the ∆lipA mutant leads to 
hyper-activation of BMMs like the transposon insertion mutant, we added ∆lipA cell free 
supernatant derived from cultures grown in RPMI + BCFA medium to BMMs. The 
supernatant enhanced the secretion of the pro-inflammatory cytokines and chemokines 
IL-6, TNF, CCL3, and CCL4 (Figure 6), verifying the results from the screen. 
Furthermore, the enhanced activation of BMMs by ∆lipA mutant supernatant was 
complemented using the ∆lipA+lipA strain. Together, these data imply that LipA is 
required for synthesis of lipoic acid and suppresses BMM activation. 
 
 
Figure 5. Growth Dynamics of a ΔlipA Mutant in Various Media. (A-C) Growth 
curves of WT, ΔlipA, or ΔlipA+lipA in TSB, RPMI medium with and without 25 nM lipoic 
acid (LA), or RPMI medium supplemented with branched chain fatty acid precursors 









Figure 6. Lipoic Acid Synthesis is Required for Suppression of BMM Activation. 
IL-6, TNF, CCL3, and CCL4 production (pg/mL) by BMMs after addition of supernatant 
from WT, ΔlipA, or ΔlipA+lipA grown in RPMI+BCFA. Data shown are from one of at 
least three experiments conducted in triplicate. Means ± SD are shown (n = 3). *, 
P<0.05; **, P<0.01 by 1-way ANOVA with Bonferonni-Sidak post-test.  
 
The purpose of this thesis is to characterize and identify the mechanism behind 
the hyper-inflammatory macrophage response elicited by a ∆lipA mutant. In addition, we 
sought to elucidate if this modulation of macrophage immune responses imparted by 
LipA activity influences the pathogenesis of S. aureus using murine infection models. In 
summary, this dissertation reports on a novel innate immune evasion mechanism of S. 
aureus conferred through the function of the lipoic acid synthetase and adds to the 
growing body of work highlighting the crucial roles for bacterial metabolism in evasion of 
host immunity.  
LipA Restriction of Innate Immune Cell Activation Occurs through TLR2 
Immune cells sense and respond to S. aureus through TLR2-based recognition 
of lipoproteins and subsequent signaling through the adaptor protein MyD88 (391). To 
determine if lipA-mediated immune suppression occurs via a TLR2-dependent pathway, 
we evaluated activation of WT, TLR2-/-, TLR4-/- or MyD88-/- BMMs treated with 
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supernatant from WT, ΔlipA, or ΔlipA+lipA. Use of TLR2-/- and MyD88-/- BMMs 
abrogated the enhanced secretion of IL-6, TNF, CCL3, and CCL4 elicited by ΔlipA 
mutant supernatant (Figure 7). Signaling through TLR2 leads to NFκB activation and 
induction of pro-inflammatory cytokine and chemokine gene expression. We tested if 
macrophages treated with ΔlipA mutant supernatant have higher NFκB activation. The 
increased production of IL-6, TNF, CCL3, and CCL4 elicited by ΔlipA mutant 
supernatant correlated with increased NFκB dependent gene expression (Figure 8). 
These data suggest that LipA limits macrophage activation through a TLR2/MyD88 
dependent pathway.  
Neutrophils, like macrophages, express PRRs such as TLR2. To assess if other 
TLR2 expressing cells have enhanced activation in response to ΔlipA mutant 
supernatant, we tested the activation of neutrophils in response to ΔlipA mutant 
supernatant. We found that the enhanced activation caused by ΔlipA mutant 
supernatant is not limited to macrophages as murine neutrophils purified from the bone 
marrow also exhibited enhanced inflammatory chemokine secretion (Figure 9). These 
data indicate that other cells expressing TLR2-expressing cells respond better to 














Figure 7. TLR2 and MyD88 are Required for ΔlipA Hyper-Activation of BMMs. 
Production of IL-6, TNF, CCL3, and CCL4 (pg/mL) after addition of cell-free supernatant 
from WT, ΔlipA, or ΔlipA+lipA to WT, TLR2-/-, TLR4-/-, or MyD88-/- BMMs. Data shown 
are from one of at least three experiments conducted in triplicate. (-), media alone. 
Means ± SD are shown (n=3). NS, not significant; *, P<0.05; **, P<0.01; ***, P<0.001, 
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Figure 8. NFkB Activation is Induced by ΔlipA Mutant Supernatant. NFkB activation 
after treatment of RAW 264.7 cells, containing an NFkB-inducible secreted embryonic 
alkaline phosphatase reporter, with cell-free supernatant from WT, ΔlipA, or ΔlipA+lipA. 
Relative reporter activity (Absorbance 450 nm) from one of two experiments conducted 
in triplicate is shown. Means ± SD are shown. **, P<0.01; ****, P<0.0001, by 1-way 
ANOVA with Bonferonni-Sidak post-test. 
 
 
Figure 9. Neutrophils Secrete Greater Amounts of Cytokines in Response to  
ΔlipA Mutant Supernatant. KC and TNF production (pg/mL) of primary murine 
neutrophils after 24 hour stimulation with cell-free supernatant from the indicated 
strains. (-), media alone. Means ± SD are shown (n=3). **, P<0.01; ****, P<0.0001, by 1-
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S. aureus Release of Lipoyl-E2-PDH Coincides with Macrophage Suppression 
As cell free supernatants are used in all immune cell activation studies, we 
hypothesized that the secretome of S. aureus could be disrupted in a ΔlipA mutant 
leading to enhanced TLR2-dependent macrophage activation. However, we found that 
a ΔlipA mutant does not exhibit major alterations in its exoprotein profile when grown in 
either TSB or RPMI + BCFA compared to WT (Figure 10). Thus, the heightened 
activation of macrophages is not due to the hyper-secretion of TLR2 activating proteins 
as detected by Coomassie staining.  
There are four cytosolic lipoylated proteins (E2-PDH, E2-OGDH, E2-BCODH, 
and GcvH) produced by S. aureus that rely on the lipoic acid synthase activity of LipA 
for lipoylation when there is no available exogenous lipoic acid (Figure 11A). We 
wondered if one of these four lipoylated proteins in the cytosol of WT S. aureus may be 
released into the supernatant. Indeed, we found that of the four cytosolic lipoylated 
proteins produced by S. aureus, one 72 kilodalton protein is released into the 
supernatant and contains a lipoyl moiety, but is absent in a ΔlipA mutant. This protein is 
similar in size to E2-PDH and immunoblot of exoproteins from a ΔE2-pdh mutant 
indicated that this released lipoyl-protein is E2-PDH (Figure 11B). In summary, these 
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Figure 10. Exoprotein Profiles of WT, ΔlipA, and ΔlipA + lipA Strains. Coomassie 
stained SDS-PAGE gels of TCA precipitated exoproteins after 9 hours growth of the 
indicated strains in TSB or RPMI+BCFA. 
 
 
Figure 11. WT S. aureus Releases Lipoyl-E2-PDH into the Supernatant. 
Coomassie-blue stained SDS-PAGE gels (CB) or α-lipoic acid immunoblots (IB) of cell 
lysate (A) or TCA precipitated supernatant (B) proteins isolated after growing WT, ΔlipA, 
ΔlipA+lipA, and ΔE2-pdh in RPMI+BCFA for 9 hours. Other bands in supernatant IB 
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Lipoic acid acquisition by S. aureus occurs through either synthesis or salvage 
((373) and Figure 2). LipA, LipM, and LipL are required for synthesis, while LplA1 and 
LplA2 are involved in salvage. LipA and LipM contribute to the direct synthesis of the 
lipoyl moiety and LipL is required for its transfer to E2-PDH and E2-BCODH. We 
hypothesized that deletion of lipM or lipL would phenocopy the inflammatory response 
elicited by BMMs treated with ΔlipA supernatant. We found that all mutants lacking 
lipoyl-E2-PDH (ΔlipA, ΔlipM, and ΔlipL), but not mutants of the salvage pathway (ΔlplA1 
and ΔlplA2) elicited higher activation of BMMs (Figure 12A and B). A ΔlipL mutant 
enhanced macrophage activation even with lipoyl-E2-OGDH and lipoyl-GcvH present in 
the cytosol (Figure 12B). These data indicate that de novo lipoic acid synthesis is 
required to suppress BMM activation and specifically links the presence of lipoyl-E2-
PDH in the supernatant to suppression of macrophage activation.  
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Figure 12. Lipoic Acid Synthesis and Release of Lipoyl-E2-PDH Correlate with 
Dampening of BMM Activation. (A) IL-6, TNF, CCL3, and CCL4 production (pg/mL) 
by BMMs after addition of supernatant from the indicated strains. Data shown are from 
one of at least three experiments conducted in triplicate. Means ± SD are shown (n = 3). 
**, P<0.01; ***, P<0.001; ****, P<0.0001 by 1-way ANOVA with Bonferonni-Sidak post-
test. (B) Whole cell lysates or TCA precipitated exoproteins from the indicated S. aureus 
strains collected after growth in RPMI+BCFA followed by immunoblotting for lipoic acid-
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Lipoyl-E2-PDH is Released During S. aureus Growth 
The detection of cytosolic proteins in the extracellular environment, such as E2-
PDH, has been observed for numerous bacteria even though they do not contain a 
secretion signal (357, 359, 392, 393).To test if the release of lipoyl-E2-PDH is an active 
process or due to cell lysis during bacterial growth, we assessed lipoyl-E2-PDH release 
in the supernatant over various timepoints. We were able to detect E2-PDH in 
supernatant as early as 5 hours and by 9 or 24 hours we saw the highest levels of 
released E2-PDH (Figure 13A). Since the release of lipoyl-E2-PDH occurs earlier than 9 
hours during growth, we surmised that ΔlipA mutant supernatant harvested prior to 9 
hours, which lacks lipoyl-E2-PDH, could enhance the activation of macrophages. 
Macrophages treated with supernatants from ΔlipA mutant supernatant after 3, 5, and 9 
hours of culture in RPMI + BCFA enhanced macrophage activation (Figure 13B). 
Comparisons to purified recombinant lipoyl-E2-PDH suggest that S. aureus supernatant 
contains ~25-50 nM released lipoyl-E2-PDH (Figure 14). Thus, S. aureus releases 
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Figure 13. Release of Lipoyl-E2-PDH and Suppression of BMM Activation Occurs 
During Bacterial Growth. (A) Exoproteins were TCA precipitated from cell free 
supernatants of WT or ΔlipA S. aureus after 3, 5, 9, and 24 hours of growth in 
RPMI+BCFA followed by immunoblotting for lipoic acid-containing proteins. (B) CCL3 
and CCL4 production (pg/mL) by BMMs after addition of T3h, T5h, or T9h supernatant 
from the indicated strains. Data shown are from one out of at least three experiments 
conducted in triplicate. (-), media alone. Means ± SD are shown (n=3). *, P<0.05; ***, 
P<0.001; ****, P<0.0001 by 1-way ANOVA with Bonferonni-Sidak post-test. 
 
 
Figure 14. WT S. aureus Releases Nanomolar Amounts of Lipoyl-E2-PDH into  
the Supernatant. Immunoblot to quantify lipoyl-E2-PDH in S. aureus supernatant. To 
quantify the amount of lipoyl-E2-PDH released by S. aureus a titration of purified lipoyl-
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E2-PDH and GcvH are Detectable on the Bacterial Surface 
Extracellular detection of cytoplasmic proteins, though unusual, is not 
uncommon. A majority of these extracellular proteins are found to be expressed on the 
surface of bacteria. For example, E2-PDH has been detected on the surface of L. 
monocytogenes and Mycoplasma pneumonia (359, 391, 392).Therefore, we assessed if 
lipoyl-E2-PDH is also present on the surface of S. aureus. Visualization of surface 
extracted proteins show that E2-PDH and perhaps GcvH are present on the surface of 
WT S. aureus and its ΔlipA mutant (Figure 15). Furthermore, by immunoblot, we could 
see lipoyl-E2-PDH and lipoyl-GcvH in WT S. aureus, but not in a ΔlipA mutant (Figure 
15). This is surprising, as we did not see lipoyl-GcvH released into the supernatant of 
WT S. aureus by our detection methods. No lipoyl-E2-PDH was present on the surface 
of a ΔgcvH mutant, as GcvH is necessary to shuttle lipoic acid to E2-PDH (373, 374). 
Additionally, surface expression of E2-PDH and GcvH were not dependent on the lipoyl 
moiety, as we still saw both E2-PDH and GcvH on the surface of a ΔlipA mutant (Figure 
15). L. monocytogenes surface expression of E2-PDH is partially dependent on the 
secondary secretion system, SecA2 (359), whereas the autolysin Atl is required for the 
release of some cytosolic proteins in S. aureus (357). Using transposon mutants of atl 
and secA2, we found that SecA2 likely contributes to, while Atl may be necessary for 
the release of lipoyl-E2-PDH (Figure 16). All together, these data suggest lipoyl-E2-PDH 
is on the surface of S. aureus and potentially requires Atl-dependent lysis for release. 
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Figure 15. Surface Display of E2-PDH and GcvH. Coomassie-blue stained SDS-
PAGE gels (CB) or α-lipoic acid immunoblots (IB) of surface proteins isolated after 
growing WT, ΔlipA, ΔlipA+lipA, ΔgcvH, and ΔE2-pdh in RPMI+BCFA. Boxed regions in 





Figure 16. Release of Lipoyl-E2-PDH Likely Requires Atl and Potentially 
SecA2. Whole cell lysates or TCA precipitated exoproteins from the indicated S. aureus 
strains collected after growth in RPMI+BCFA followed by immunoblotting (IB) for lipoic 
acid-containing proteins. Other bands in supernatant IB appear to be non-specific. 
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Free Lipoic Acid Restricts the Activation of Macrophages 
Free lipoic acid suppresses the respiratory burst of innate cells when used at 
high concentrations (394, 395). Therefore, we hypothesized that release of lipoyl-E2-
PDH by S. aureus might confer immunosuppressive properties. We first determined if 
free lipoic acid suppresses BMM activation by S. aureus secreted factors. 
Supplementation of ΔlipA mutant supernatant with 3 mM free lipoic acid reduced BMM 
secretion of IL-6, TNF, CCL3, and CCL4 (Figure 17). 3 mM free lipoic acid also 
diminished the activation of BMMs by Pam2CSK4 and Pam3CSK4, synthetic diacylated 
or triacylated lipopeptides that induce TLR2/6 or TLR1/2 heterodimer signaling (Figures 
18). As free lipoic acid could suppress TLR2-based activation of macrophages, we 
wondered if lipoic acid also impairs recognition of other surface TLRs, such as TLR4 
and TLR5. Activation of BMMs with the TLR4 ligand lipopolysaccharide or the TLR5 
ligand flagellin in the presence of 3 mM free lipoic acid reduced the activation of BMMs, 
as determined by lower cytokine secretion (Figure 19). These data indicate free lipoic 
acid suppresses TLR2-dependent and other TLR-based activation pathways of BMMs 
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Figure 17. Free Lipoic Acid Diminishes BMM Activation by ΔlipA Mutant  
Supernatant IL-6, TNF, CCL3, and CCL4 production (pg/mL) after addition of ΔlipA 
supernatant to BMMs in the presence of free lipoic acid (LA) (3 mM or 0.3 mM). Data 
shown are from one of at least three experiments conducted in triplicate. Means ± SD 




Figure 18. Free Lipoic Acid Restricts TLR2-Dependent BMM Activation. IL-6, TNF, 
CCL3, and CCL4 production (pg/mL) after addition of 3 ng/mL Pam2CKS4 (Pam2) and 
30 ng/mL of Pam3CSK4 (Pam3) to BMMs in the presence of free lipoic acid (3 mM or 
0.3 mM). (-), media alone. Data shown are from one of at least three experiments 
conducted in triplicate. Means ± SD are shown (n=3). NS, not significant; *, P<0.05; ***, 
P<0.001; ****, P<0.0001 by 1-way ANOVA with Bonferonni-Sidak post-test. 
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Figure 19. Free Lipoic Acid Blunts TLR4- and TLR5-Dependent BMM Activation. 
IL-6 and CCL4 production (pg/mL) after addition of 250 ng/mL lipopolysaccharide (LPS) 
and 250 ng/mL of flagellin to BMMs in the presence of 3mM free lipoic acid. Data shown 
are from one of at least three experiments conducted in triplicate. Means ± SD are 
shown (n=3). ***, P<0.001; ****, P<0.0001 by 1-way ANOVA with Bonferonni-Sidak post-
test. 
 
Lipoyl-E2-PDH Diminishes the TLR1/2 Activation of Macrophages 
Since free lipoic acid suppresses macrophage activation, we wondered whether 
lipoylated proteins – the main form of lipoic acid in living systems – from S. aureus are 
sufficient to suppress BMM activation at physiologically meaningful concentrations. We 
tested if lipoyl-E2-PDH suppresses BMM activation by first purifying recombinant S. 
aureus lipoyl-E2-PDH and lipoylating it in vitro (purification and lipoylation technique 
devised by Irina Laczkovich) (Figure 20). Next, we activated BMMs with Pam2CSK4 
and Pam3CSK4 in the presence of recombinant lipoyl-E2-PDH and monitored cytokine 
secretion. We found that 10 nM lipoyl-E2-PDH suppressed TLR1/2 activation, but not 
TLR2/6 activation (Figure 21). To test if the lipoyl moiety is necessary for the restriction 
of BMM activation we used a synthetic tripeptide containing a lipoyl-lysine residue, 
DKLA, and found that it is sufficient to suppress TLR1/2 dependent macrophage 
activation at 10 nM concentration but not the unmodified tripeptide, DKA (Figure 22). 
DKLA also suppressed macrophage activation by SitC, a TLR1/2 activating triacylated 
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lipoprotein produced by S. aureus (160, 161) (Figures 23). These data indicate that 
lipoyl-E2-PDH is sufficient to suppress TLR1/2 activation of macrophages and that 
immune suppression is directly linked to the lipoyl modification.  
 
Figure 20. Purified Lipoyl-E2-PDH. S. aureus E2-PDH purified from E. coli. 
Coomassie-stained SDS-PAGE gel of 1 μg lipoyl-E2-PDH (CB) and lipoyl moiety 
detection by immunoblot with anti-lipoic acid antibody (α-LA IB). 
 
 
Figure 21. Purified Lipoyl-E2-PDH Dampens TLR1/2 Activation of BMMs. IL-6, TNF, 
CCL3, CCL4 production (pg/mL) after addition of 10 nM lipoyl-E2-PDH (LA-PDH) to 
BMMs in the presence of 1 ng/mL of Pam2 or 3 ng/mL of Pam3. Data shown are from 
one of at least three experiments conducted in triplicate. Means ± SD are shown (n=3).  
***, P<0.001; ****, P<0.0001 by 1-way ANOVA with Bonferonni-Sidak post-test.  
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Figure 22. The Lipoyl Moiety is Necessary for Restriction of TLR1/2 Activation 
BMMs. IL-6, TNF, CCL3, and CCL4 production (pg/mL) after addition of 10 nM 
synthetic tripeptides DKLA and DKA to BMMs in the presence of 1 ng/mL of Pam2 or 3 
ng/mL of Pam3. Data shown are from one of at least three experiments conducted in 
triplicate. Means ± SD are shown (n=3).  *, P<0.05; **, P<0.01; ***, P<0.001; ****, 
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Figure 23. Lipoyl-Peptide DKLA Dampens SitC Activation of BMMs. Coomassie-
stained SDS-PAGE gel of 500 ng purified SitC. IL-6, TNF, CCL3, and CCL4 production 
(pg/mL) after addition of SitC (0.1 ng/ml for CCL3/CCL4 and 1.0 ng/ml for IL-6/TNF) to 
BMM in the presence of 10 nM synthetic tripeptides DKLA and DKA. Data shown are 
from one of at least three experiments conducted in triplicate. Means ± SD are shown 
(n=3).  *, P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001 by 1-way ANOVA with 
Bonferonni-Sidak post-test.  
 
Mechanism of TLR1/2 Restriction by Lipoyl-Protein 
 Restriction of BMMs by lipoyl-E2-PDH only occurs through TLR1/2 and not 
TLR2/6, suggesting a mechanism of suppression specific to TLR1 or TLR2. We 
hypothesized that free lipoic acid or lipoyl-peptides either stimulates changes in TLR1 or 
TLR2 surface display, or directly interferes with the interaction of natural ligands with 
TLR1/2 by competing for similar binding sites. We tested this idea by assessing the 
levels of TLR1 or TLR2 on the surface of BMMs treated with supernatant derived from 
WT or ΔlipA S. aureus, as well as in the presence of free lipoic acid given that lipoyl-
proteins and free lipoic acid have different immunosuppressive functions. We found that 
there are no differences after treatment with supernatant from S. aureus that lack lipoyl 
proteins (ΔlipA) on the surface expression levels of TLR1 or TLR2 (Figure 24). 
Furthermore, we found that treatment of BMMs with free lipoic acid decreases the 
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amount of surface TLR2 on BMMs and not TLR1 (Figure 24). Next, we assessed if WT 
or ΔlipA supernatant or free lipoic acid could modulate the surface expression of other 
pro-inflammatory surface markers of BMMs such as CD80 and CD86. Again, there are 
no differences between surface CD80 or CD86 levels of BMMs treated with WT or ΔlipA 
supernatant. Interestingly, we found that free lipoic acid decreases the surface 
expression of CD86 but not CD80 relative to the media control condition (Figure 24). 
Like supernatant from S. aureus, free lipoic acid increased the surface levels of TLR1 
and CD80 (Figure 24). In summary, these data suggest that supernatant from a ΔlipA 
mutant does not modulate the levels of TLR1, TLR2, CD80, or CD86. Moreover, these 
data demonstrate that free lipoic acid reduces TLR2 and CD86 on BMMs, highlighting 
the broad immunosuppressive functions of free lipoic acid.  
 
 
Figure 24. Surface Expression of TLR1, TLR2, CD80, or CD86 are Not  
Modulated by ΔlipA Mutant Supernatant. BMMs were treated in the presence of WT 
or ΔlipA supernatant or 3 mM free lipoic acid (LA) for 18-24 hours followed by 
assessment of surface levels of TLR1 or TLR2, CD80, and CD86 by flow cytometry. 
Data shown are from one of at least three experiments conducted in triplicate. Means ± 
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To determine if lipoyl-peptides directly interfere with the interaction of natural 
ligands with TLR1/2 by competing for similar binding sites, we used an enzyme linked 
immunosorbent assay-based approach. Recombinant TLR1 and TLR2 were bound in a 
well overnight, followed by competing of binding for TLR1/2 between Pam3CSK4 and 
DKA or DKLA. If the lipoyl peptide DKLA binds to TLR1 or TLR2, then we expect to see 
a reduction in the binding of the native TLR1/2 ligand Pam3CSK4 in the presence of 
DKLA but not DKA. We found that an excess of DKLA, but not DKA, reduces the binding 
ability of Pam3CSK4 (Figure 25). However, as we titrated out the amounts of tripeptide, 
we observed high variability in the binding of Pam3CSK4. These data suggest that at 
high concentrations, the lipoyl moiety on DKLA may bind to TLR1/2 and compete for 
binding. However, this approach to determine if lipoyl-peptides bind to TLR1/2 to 
compete for binding sites with native ligands was limited and needs to be further 
refined.  
 
Figure 25. Binding of DKLA and DKA to Recombinant TLR1/2. 750 nM of 
biotinylated Pam3CSK4 binding to recombinant TLR1 and TLR2 in the presence of 
various amounts of the synthetic tripeptides DKA or DKLA. Percent binding determined 
by dividing the average absorbance of wells with Pam3CSK4 and titrated peptides by 
the absorbance of Pam3CSK4 binding alone. Pam3CSK4 binding to TLR1/2 alone was 
set as 100% binding. Means ± SD are shown (n=5). 
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Activity of the Lipoic Acid Synthetase Promotes S. aureus Pathogenesis 
Previous work in the lab conducted by Azul Zorzoli found that, during 
bloodstream infection, S. aureus mutants with defects in bacterial lipoic acid synthesis 
and salvage lead to tissue-specific virulence defects where infection of the kidney 
depends on lipoic acid salvage enzymes, but infection of the heart requires LipA (373). 
These observations suggest there is varied dependency on de novo lipoic acid 
synthesis for S. aureus survival in different tissue sites. Given the strong in vitro 
dampening of TLR1/2 activation of macrophages, we surmised that this 
immunosuppression could alter the host’s ability to limit infection by macrophage 
antimicrobial responses. To determine if lipoyl-protein immunosuppression occurs in 
vivo, we induced systemic infection in mice by intraperitoneal injection of WT, ΔlipA, or 
ΔlipA+lipA and determined the levels of macrophage chemokines in the serum. After 16 
hours, animals infected with a ΔlipA mutant had more CCL3 and CCL4 in the serum, 
whereas at 72 hours chemokine levels were similar (Figure 26). CCL3 and CCL4 are 
chemokines for macrophages and monocytes in addition to other innate immune cells 
through interaction with the CCR5 receptor. We then surveyed if the population of 
immune cells recruited to the site of infection were different between the infected 
animals. At 16 hours, the proportion of pro-inflammatory macrophages (CD11b+, F4/80+, 
CCR5+, I-A/I-Ehigh, Ly6G-) in the peritoneal cavity were identical among the infection 
groups (Figure 27). However, at 72 hours, ΔlipA mutant-infected animals had more I-
A/I-Ehigh/CCR5+ activated macrophages and I-A/I-Ehigh dendritic cells (Figure 27 and 28). 
Although CCL3 and CCL4 recruit other innate immune cells, the total number of 
recruited macrophages, neutrophils, and dendritic cells were the same in all infection 
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groups at both 16 hours and 72 hours post-infection (Figure 29). In summary, the 





Figure 26. Serum Levels of CCL3 and CCL4 Chemokines are Higher in ΔlipA 
Mutant-Infected Mice 16 Hours Post-Infection. Serum CCL3 and CCL4 levels 
(pg/mL) 16 hours or 72 hours post-infection. Means ± SD are shown (WT and ΔlipA 
n=10, ΔlipA+lipA n=7). NS, not significant; *, P<0.05 by 1-way ANOVA with Bonferonni-
Sidak post-test. 
 




Figure 27. Greater Amounts of Pro-Inflammatory Macrophages are Recruited to  
the Site of Infection with a ΔlipA Mutant 72 Hours Post-Infection. Pro-inflammatory 
macrophages in the peritoneal cavity at 16 hours and 72 hours post-infection. 
Macrophages were gated on CD11b+ F4/80+ Ly6G- cells followed by assessment of 
CCR5+ I-A/I-Ehi cells. Flow cytometry plots are representative of 4-8 animals per group. 
Scatter plots display percent CCR5+/I-A/I-Ehi cells within the CD11b+ F4/80+ Ly6G- gate. 
Bars display the median. NS, not significant; **, P<0.01; ***, P<0.001 by 1-way ANOVA 
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Figure 28. Greater Amounts of IA/IE+ Dendritic Cells are Recruited to the Site of 
Infection with a ΔlipA Mutant 72 Hours Post-Infection. Measurement of dendritic 
cells (CD11b+ CD11c+ F4/80- Ly6G-) expressing MHCII (I-A/I-Ehi) in the peritoneal cavity 
72 hours post-infection. Histogram is representative of 8 animals per group. Scatter 
plots display geometric mean of I-A/I-Ehi cells within the CD11b+ CD11c+ F4/80- Ly6G- 
gate for all animals - WT (n=8), ΔlipA (n=8), and ΔlipA + lipA (n=8). Means ± SD are 




Figure 29. The Total Number of Macrophages, Neutrophils, and Dendritic Cells 
are Not Different Between Infected Mice. Total cell numbers of macrophages, 
neutrophils, and dendritic cells in the peritoneal cavity of mice infected intraperitoneally 
with 1x108 CFU of WT, ΔlipA, or ΔlipA + lipA S. aureus 16- or 72-hours post-infection. 
Macrophages:CD11b+ F4/80+. Neutrophils: CD11b+ Ly6G+. Dendritic cells: CD11b+ 
CD11c+. Means ± SD are shown. 
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A ΔlipA Mutant is Attenuated During Infection 
Pro-inflammatory activated macrophages have a higher propensity to kill 
bacteria, and because we see higher proportions of activated macrophages recruited to 
the site of infection in animals infected with ΔlipA mutant-infected animals, we 
hypothesized there could be lower burdens of bacteria in the intraperitoneal infection 
model. Indeed, ΔlipA mutant-infected animals had significantly fewer bacteria at 16- and 
72-hours post-infection in the lavage fluid and kidney compared to WT or ΔlipA+lipA 
(Figure 30A). After 72 hours, a substantial number of the ΔlipA mutant-infected animals 
had undetectable bacteria in both the lavage fluid (N=7) and the kidneys (N=6) (Figure 
30A). By 72 hours, the median bacterial colony forming units (CFU) in ΔlipA mutant-
infected animals was near or at the limit of detection in both sites, while the median 
bacterial CFU of the WT and complement infected animals remained 1-2 logs higher, 
indicating LipA may promote bacterial survival during infection (Figure 30B). With these 
data, we cannot rule out the possibility that the attenuation of a DlipA mutant in vivo may 
stem either from observed metabolic deficiencies associated with lipoic acid limitation, 

















Figure 30. A ΔlipA Mutant is Attenuated During Infection. Bacterial burden (A) and 
medians of bacterial burden (B) in the peritoneal cavity and kidneys of mice 16 hours - 
WT (n=17), ΔlipA (n=19), ΔlipA+lipA (n=12), and 72 hours - WT (n=11), ΔlipA (n=12), 
ΔlipA+lipA (n=14) post IP infection. NS, not significant; *, P<0.05; **, P<0.01; ****, 
P<0.0001 by non-parametric 1-way ANOVA (Kruskal-Wallis Test) with Dunn’s post-test. 
Dashed lines, limit of detection. N=7 and N=6 in the 72 hour dataset are the number of 
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As mentioned earlier, during bloodstream infection, a ΔlipA mutant is not 
attenuated in the kidneys (373). In this bloodstream model, kidney abscesses readily 
form where phagocytic leukocytes are excluded from the abscess (396, 397). Therefore, 
we wondered if there are greater proportions of pro-inflammatory macrophages in 
kidneys during bloodstream infection with a ΔlipA mutant that cannot penetrate this 
abscess, leading to failure to clear a ΔlipA mutant. To test this, we systemically infected 
mice via injection into the bloodstream with WT or ΔlipA and assessed the proportion of 
pro-inflammatory macrophages in the kidneys. As expected, we found no differences in 
bacterial burdens in the kidney; however, we observed macrophages expressing higher 
amounts of IA/IE, suggesting greater macrophage activation in the kidneys of ΔlipA 
mutant-infected animals (Figure 31). These data imply that, in the absence of 
macrophage infiltration, a growth defect imparted by lack of LipA activity is likely not 
sufficient for attenuation. 
 
 
Figure 31. A ΔlipA Mutant is Not Attenuated in Kidneys During Bloodstream  
Infection, but Recruits Pro-Inflammatory Macrophages Bacterial burden (CFU/mL) 
in the kidneys of mice 96 hours post IV infection- WT (n=3) and ΔlipA (n=4). Pro-
inflammatory macrophages (CD11b+ F4/80+ Ly6G-) expressing I-A/I-E in kidneys of 
mice 96 hours post-infection. Histogram is representative of 3-4 animals per group. 
Scatter plots display geometric mean of I-A/I-Ehi cells within the CD11b+ F4/80+ Ly6G- 
gate for all animals. Means ± SD are shown. **, P<0.01 by 1-way ANOVA with 
Bonferonni-Sidak post-test. 
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Macrophages are Responsible for Attenuation of a DlipA Mutant During Systemic 
Infection 
To test if the observed attenuation of a DlipA mutant is due to the antimicrobial 
activity of activated macrophages, we depleted mice of macrophages and their 
precursors by administering clodronate-loaded liposomes three days prior to infection 
with 1x107 CFU of WT, DlipA, or DlipA + lipA strains. We first determined if clodronate 
treatment depleted macrophages in our infection model by assessing the proportion of 
macrophages recovered from S. aureus infected mice that were pre-treated with 
clodronate or PBS three days prior to infection. Clodronate treated mice had 
significantly reduced proportions of macrophages (CD11b+ Ly6G- Ly6C- Gr1- F4/80+) in 
the peritoneal cavity compared to non-treated mice (Figure 32A). We then infected 
clodronate-treated mice with WT, DlipA, or DlipA + lipA strains and enumerated CFU at 
16 hours and 72 hours post-infection. After 16 hours, we recovered near identical CFU 
from the peritoneal cavities or kidneys of macrophage-depleted mice despite a large 
distribution of bacterial loads (Figure 32B). At 72 hours post-infection, there were no 
discernable differences in CFU recovered from the lavage or the kidneys of infected 
clodronate-treated mice regardless of the strain used for infection (Figure 32C). We also 
observe a large distribution in CFU recovered from clodronate treated-mice at 72 hours 
post-infection; however, there were no differences in the average CFU recovered from 
infected animals. In summary, these data suggest that, in a peritonitis infection model, 
macrophages are a primary mediator of clearance in DlipA mutant-infected animals as 
opposed to a metabolic defect associated with lipoic acid limitation and macrophages 
are instrumental to control bacterial loads during infection.  
 




Figure 32. A DlipA Mutant is Not Attenuated in Macrophage-Depleted Mice. (A) 
Abundance of macrophages (CD11b+ Gr1- CD11c- Ly6G- F4/80+) in the peritoneal cavity 
of clodronate-treated mice or non-treated mice 72 hours post-intraperitoneal infection 
with WT S. aureus.  Bar represent medians. Data were analyzed using unpaired, two-
tailed Student’s t test. **, P<0.01. (B and C) the bacterial burden (Log10 CFU) in the 
peritoneal cavity and kidneys of clodronate treated mice 16 hours (B) post-
intraperitoneal infection with WT (n=18), DlipA (n=18), DlipA + lipA (n=18) or 72 hours 
(C) post-intraperitoneal infection with WT (n=13), DlipA (n=12), DlipA + lipA (n=11). Bars 
represent means. NS, not significant by non-parametric 1-way ANOVA (Kruskal-Wallis 
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Macrophages from ΔlipA Mutant-Infected Mice Control the Outgrowth of S. aureus 
Because a greater proportion of macrophages in ΔlipA-infected mice have 
enhanced pro-inflammatory characteristics, we reasoned that these macrophages might 
have greater bactericidal activity. To test this hypothesis, we isolated F4/80+ peritoneal 
cells elicited to the peritoneal cavity 72 hours after infection with WT and ΔlipA S. 
aureus, or mock infected with PBS. After antibiotic treatment to kill bacteria used for 
elicitation, we infected the sorted population of F4/80+ cells with WT S. aureus. The 
F4/80+ peritoneal cells elicited after infection with a ΔlipA mutant inhibited the growth of 
S. aureus better than F4/80+ peritoneal cells elicited from WT or PBS treated mice 
(Figure 33). Consistent with our in vitro findings, these data indicate macrophage 




Figure 33. Macrophages Isolated from ΔlipA Mutant-Infected Mice Control the  
Outgrowth of S. aureus. Survival/outgrowth of WT S. aureus after infecting WT (n=8), 
ΔlipA (n=8), or PBS (n=8) elicited F4/80+ cells.  *, P<0.05, ****; P<0.0001 by 2-way 
ANOVA with Tukey’s post-test.  
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Macrophages from DlipA Mutant-Infected Mice Produce More ROS to Restrict S. 
aureus Growth 
As the pro-inflammatory macrophages recruited to the site of infection with a 
DlipA mutant better restrict bacterial growth ex vivo and are instrumental to bacterial 
clearance, we sought to determine the mechanism by which these macrophages have 
an enhanced restrictive capacity. Macrophages generate ROS as one of a variety of 
mechanisms used to inhibit the growth of engulfed pathogens. To test if ROS production 
by macrophages is increased in DlipA mutant-infected mice, we elicited macrophages to 
the peritoneal cavity using WT, DlipA, or DlipA + lipA strains and re-infected the isolated 
macrophages ex vivo with WT S. aureus followed by quantitation of ROS, using an 
indicator dye that fluoresces upon oxidation. Upon re-infection, macrophages sourced 
from WT-infected mice had a net decrease in mean fluorescent intensity (MFI) (Figure 
34). In contrast, macrophages isolated from DlipA mutant-infected mice had, on 
average, a positive fold change in MFI, suggesting that these macrophages have a 
higher oxidative state (Figure 34). This was partially complemented by the DlipA + lipA 
strain (Figure 34). These data suggest that macrophages from DlipA mutant-infected 
mice produce greater amounts of ROS.  
To test if the increased ROS generation by macrophages isolated from DlipA 
mutant-infected mice is necessary to restrict S. aureus growth, we first inhibited ROS 
production using diphenyleneiodonium chloride (DPI) and compared the ability to 
restrict growth relative to macrophages isolated from WT-infected or mock-infected 
(PBS) mice. As seen previously, ROS replete cells from DlipA mutant-infected mice 
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slow the outgrowth of S. aureus compared to macrophages isolated from WT-infected 
mice (Figure 35). Upon inhibition of ROS production by DPI treatment, the 
macrophages isolated from DlipA-infected mice no longer restricted S. aureus outgrowth 
compared to WT-infected or mock-infected mice (Figure 35). These data suggest that 
increased ROS production contributes to the heightened ability of macrophages isolated 




Figure 34. Macrophages from DlipA Mutant-Infected Mice Produce Greater  
Amounts of ROS. F4/80+ macrophages were sorted from immune cells harvested from 
the peritoneal cavity of mice 72 hours post-intraperitoneal infection with WT (n=19), 
DlipA (n=20), DlipA + lipA (n=16) and infected ex vivo with WT S. aureus at a MOI of 
0.1. Macrophages were stained with the ROS indicator CellROX deep red and analyzed 
by flow cytometry. Fold changes in the geometric means of CellROX fluorescence were 
assessed in infected cells and compared to uninfected F4/80+ cells. **, P<0.01 by non-
parametric 1-way ANOVA (Kruskal-Wallis Test) with Dunn’s post-test. Dashed line is at 
zero, bars represent the median.  
 




Figure 35. ROS Production Contributes to the Heightened Ability of  
Macrophages Isolated from DlipA Mutant-Infected Mice to Control Bacterial  
Outgrowth. Outgrowth (Log10 CFU/mL) of WT S. aureus after infecting F4/80+ cells 
isolated from mice 72 hours post-intraperitoneal infection with WT (n=4), ΔlipA (n=4), or 
PBS (n=4) treated with DMSO vehicle control or ROS inhibitor DPI. Bars represent 
medians. NS, not significant; *, P<0.05; ***, P<0.001 by 2-way ANOVA with Tukey’s post-
test. Data shown are from one of at least three independent experiments. 
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DlipA Mutant-Induced Antibacterial ROS Are Generated by NADPH Oxidase 
Although DPI is commonly used to inhibit production of ROS, it can have off-
target effects that lead to the inhibition of mitochondrial respiration, which interferes with 
mROS generation (398). Therefore, DPI cannot conclusively determine whether ROS 
derived from the mitochondria or NADPH oxidase facilitates restriction of bacterial 
growth. However, recent studies have found that delivery of mROS to the phagosome is 
important for the antimicrobial response to internalized S. aureus, suggesting mROS 
are important in bacterial clearance (251, 252). We asked if macrophages from DlipA 
mutant-infected mice use mROS or NADPH oxidase-derived ROS to restrict bacterial 
growth. We inoculated mice with WT S. aureus or a DlipA mutant, isolated 
macrophages, and determined if inhibition of mROS using the inhibitor Necrox-5 
abrogated growth restriction. Generation of mROS facilitated the killing of S. aureus 
within macrophages, as S. aureus survival was greater in Necrox-5 treated 
macrophages compared to vehicle treated macrophages (Figure 36A). However, in the 
presence of Necrox-5, macrophages isolated from DlipA-infected mice still restricted the 
outgrowth of S. aureus to a greater degree than macrophages from WT- or mock-
infected mice (Figure 36B-C). These data suggest that, while production of mROS 
contributes to control of S. aureus within the macrophage, they are not involved in the 
improved restrictive capacity of macrophages isolated from DlipA mutant-infected mice.  
 




Figure 36. Macrophages Isolated from DlipA Mutant-Infected Mice Do Not Use 
mROS to Restrict Bacterial Outgrowth. (A) Percent survival of WT S. aureus 8 hours 
after infecting F4/80+ cells isolated from mice treated with DMSO vehicle control or 
mROS inhibitor Necrox-5. n=8, error bars represent SEM. Data were analyzed using 
unpaired, two-tailed Student’s t test. *, P<0.05. (B and C) Outgrowth (Log10 CFU/mL) of 
WT S. aureus after infecting F4/80+ cells isolated from mice 72 hours post-
intraperitoneal infection with WT (n=4), ΔlipA (n=4), or PBS (n=4) treated with (B) 
DMSO vehicle control or (C) Necrox-5. Bars represent medians. ***, P<0.001; ****, 
P<0.0001 by 2-way ANOVA with Tukey’s post-test. Data shown are from one of at least 
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Since mROS do not appear to play a role in the improved restrictive function, we 
wondered if NADPH oxidase-dependent ROS production contributes to the greater 
ability of macrophages sourced from DlipA mutant-infected mice to restrict bacterial 
growth. To test this, we used a specific peptide-based inhibitor of NADPH oxidase, 
gp91ds-tat (399). This NADPH oxidase assembly inhibitor is a chimeric peptide 
containing an amino acid sequence with high affinity for the gp91-phox subunit of 
NADPH oxidase linked with the tat peptide sequence from human immunodeficiency 
virus, which facilitates entry into cells (399, 400). We isolated macrophages from WT, 
DlipA, and mock (PBS) infected mice followed by re-infection with WT S. aureus ex vivo 
and monitored bacterial outgrowth hourly. Macrophages from DlipA mutant-infected 
mice better restricted the outgrowth of S. aureus compared to macrophages isolated 
from WT and mock-infected mice (Figure 37A). Treatment of macrophages sourced 
from WT, DlipA, or mock-infected mice with gp91ds-tat prevented enhanced growth 
restriction of S. aureus compared to macrophages isolated from WT and mock-infected 
mice (Figure 37B). In summary, these data suggest that the ROS generated from 
NADPH oxidase are necessary for the increased growth restriction of macrophages 












Figure 37. NADPH Oxidase Derived ROS Contributes to Improved Control of  
Bacterial Outgrowth by Macrophages Isolated from DlipA Mutant-Infected  
Mice. (A and B) Outgrowth (Log10 CFU/mL) of WT S. aureus after infecting F4/80+ cells 
isolated from mice 72 hours post-intraperitoneal infection with WT (n=8), ΔlipA (n=8), or 
PBS (n=8) treated with (A) water vehicle control or (B) NADPH oxidase inhibitor 
gp91ds-tat. Bars represent medians. NS, not significant; **, P<0.01; ***, P<0.001; ****, 
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RNS Contributes to the Enhanced Ability of Macrophages from DlipA Mutant-
infected Mice to Slow Bacterial Outgrowth 
Besides ROS, which forms in the phagosome to kill engulfed pathogens, the 
generation of NO• and RNS by iNOS also controls pathogen growth (237). Our data 
thus far suggest that blockade of NADPH oxidase activity abrogates the restrictive 
capacity of macrophages from DlipA mutant-infected mice, implicating ROS in this 
process. However, antimicrobial RNS such as ONOO- may depend on NADPH oxidase 
derived O2-• (254). Thus, macrophages treated with NADPH oxidase inhibitors may also 
generate fewer antimicrobial RNS. Therefore, we tested if macrophages recruited to the 
site of infection with a DlipA mutant produce greater amounts of NO• in addition to ROS 
that together might lead to growth restriction. We stimulated macrophages isolated from 
WT, DlipA, or DlipA + lipA infected mice ex vivo with heat-killed S. aureus and measured 
NO• production by the Griess test (401). Upon re-stimulation, macrophages from DlipA 
mutant-infected mice produced three times greater levels of nitrite, a stable breakdown 
product of NO• compared to WT or the complement strain (Figure 38). These data 
suggest that macrophages from DlipA mutant-infected mice produce greater amounts of 
NO•.  
Given the increased production of NO• in macrophages isolated from DlipA 
mutant-infected mice, we tested whether RNS contributes to growth restriction. We 
monitored the growth of WT S. aureus in macrophages isolated from WT, DlipA, or 
mock-infected mice in the presence of a specific iNOS inhibitor, N6-(1-Iminoethyl)-lysine 
hydrochloride (L-NIL), which prevents NO• production and thus RNS generation. We 
found that iNOS inhibition by L-NIL abrogated the improved growth restriction of S. 
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aureus by DlipA mutant-elicited macrophages compared to macrophages isolated from 
WT or mock-infected mice (Figure 39). Together, our data demonstrate that NO• 
production and iNOS activity are also necessary for macrophages isolated from DlipA 




Figure 38. Macrophages Isolated from DlipA Mutant-Infected Mice Produce  
Greater Levels of Nitric Oxide. F4/80+ macrophages were sorted from immune cells 
harvested from the peritoneal cavity of mice 72 hours post-intraperitoneal infection with 
WT (n=20), DlipA (n=19), DlipA + lipA (n=20) and stimulated overnight ex vivo with heat-
killed WT S. aureus at a MOI of 10. Nitrite levels, a breakdown of nitric oxide production, 
were measured by Griess test. Fold induction of nitric oxide production was determined 
by comparing levels of nitrite produced by infected cells to uninfected F4/80+ cells. *, 
P<0.05 by non-parametric 1-way ANOVA (Kruskal-Wallis Test) with Dunn’s post-test. 








Figure 39. RNS are Important for Restriction of Bacterial Growth by  
Macrophages Isolated from DlipA Mutant-Infected Mice. Outgrowth (Log10 CFU/mL) 
of WT S. aureus after infecting F4/80+ cells isolated from mice 72 hours post-
intraperitoneal infection with WT (n=8), ΔlipA (n=8), or PBS (n=8) treated with water 
vehicle control or iNOS inhibitor L-NIL. Bars represent medians. NS, not significant; *, 
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Primary Infection with a DlipA Mutant Fails to Protect Mice from Secondary S. 
aureus Challenge 
We have observed that a DlipA mutant not only increases macrophage ROS and 
RNS production to enhance bacterial killing, but also leads to (i) greater neutrophil 
cytokine and chemokine release (Figure 9) and (ii) elicits dendritic cells and 
macrophages with large amounts of the antigen presenting molecule major 
histocompatibility complex II (MHC-II) during infection (Figure 28). Thus, we wondered if 
infection with a DlipA mutant might improve protective recall responses upon S. aureus 
re-infection. We immunized mice with WT, a DlipA mutant, or PBS (mock) and allowed 
infection to clear over seven days. After seven days, mice were re-challenged with WT 
S. aureus and CFU were quantified in the kidney over time. Mice immunized with a 
DlipA mutant had equivalent CFU in the kidney compared to mice immunized with WT 
or mice that were not immunized at all time points (Figure 40A). Moreover, upon 
extension of the immunization time-course to two weeks, we noted that re-infection 
continues to yield identical CFU in the kidney regardless of whether or not the mice 
received primary immunization with WT or a DlipA mutant (Figure 40B). Interestingly, in 
mice immunized over the course of two weeks, we see higher levels of bacterial loads in 
the heart if mice received a primary immunization with a DlipA mutant (Figure 40B). In 
summary, these data suggest that despite the greater host innate response elicited 
during infection with a DlipA mutant, no improved response or potentially a worse recall 








Figure 40. Immunization of Mice with a DlipA Mutant Does Not Confer  
Protection from Secondary Challenge. (A and B) Mice were immunized by 
intraperitoneal injection with either 1 x 108 CFU of WT or DlipA S. aureus or sterile PBS 
(mock immunized). Either 7- (A) or 14- (B) days after immunization, mice were re-
challenged via injection into the retro-orbital sinus with 1 x 107 CFU of WT S. aureus. 
Bacterial burden (Log10 CFU) in the kidneys (A and B) or hearts (B) of mice assessed 
(A) 24 hours (WT: n=8, DlipA: n=8, PBS: n=8), 72 hours (WT: n=8, DlipA: n=6, PBS: 
n=8), 96 hours (WT: n=20, DlipA: n=23, PBS: n=23), 120 hours (WT: n=7, DlipA: n=6, 
PBS: n=8) or (B) 96 hours (WT: n=11, DlipA: n=9, PBS: n=8) post-secondary challenge. 
Bars represent medians and dashed lines represent the limit of detection. NS, not 









For a pathogen to infect and replicate in the host, it is often necessary to impede 
host immune defenses. The human pathogen S. aureus has armed itself with a 
repertoire of virulence factors to promote immune evasion. Many virulence factors 
counter neutrophil responses to infection, as these cells constitute the initial cellular 
response to S. aureus infection. Macrophages are another cellular component of the 
innate immune system with critical antimicrobial functions. In addition to their killing 
capacity, macrophages also produce cytokines and chemokines to promote key 
functions of both innate and adaptive immunity. Thus, macrophages are a key cell for S. 
aureus to overcome during infection. The goal of this thesis was to identify and 
characterize a novel extracellular virulence factor of S. aureus that counters 
macrophage immune responses.  
Using a transposon mutant library of the USA300 strain JE2, Dr. Alonzo found 
numerous mutants that elicited reduced or enhanced production of pro-inflammatory 
cytokines and chemokines by BMMs. Of interest, was the hyper-activation of BMMs 
caused by addition of supernatant from a S. aureus mutant with a mutation in the lipA 
gene. The lipA gene encodes for lipoic acid synthetase, which synthesizes the essential 
metabolic cofactor lipoic acid. In this work, we found that suppression of macrophage 
activation correlated with the ability of S. aureus to release a lipoic acid-modified 
metabolic enzyme subunit, E2 PDH, into the supernatant where it moonlights by
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restricting the TLR1/2 activation of macrophages. We show that dampening of 
macrophage function by LipA activity is necessary for optimal S. aureus pathogenesis. 
In the absence of lipoic acid synthesis in S. aureus, we saw that a DlipA mutant is more 
readily cleared by the host and elicits greater proportions of pro-inflammatory 
macrophages. Upon isolation of these macrophages, they restrict the outgrowth of S. 
aureus ex vivo better than macrophages from WT infected mice. The impedance of 
macrophage antimicrobial functions by LipA is mediated by reductions in the generation 
of ROS and RNS by NADPH oxidase and iNOS, respectively, leading to improved 
survival of S. aureus during infection. This suppressive function is lost upon infection 
with a DlipA mutant, whose clearance is dramatically improved due to enhanced 
production of ROS and RNS by macrophages at the site of infection. Despite the 
induction of a more robust antimicrobial immune response during infection with a DlipA 
mutant, the host is unable to mount a successful recall response, likely due to rapid 
clearance of the microbe. Figure 41 depicts a graphical model for how we imagine lipoic 
acid synthesis alters macrophage immune responses. On the whole, the work in this 
thesis demonstrates that synthesis of bacterial-derived lipoic acid by LipA confers 
immunosuppressive properties on macrophages and emphasizes the close associations 








Figure 41. Model of Lipoic Acid Synthesis Modulation of Macrophage  
Responses. WT S. aureus uses lipoic acid synthesis to attach a lipoyl moiety to E2-
PDH, which is released into the supernatant. Lipoyl-E2-PDH blocks TLR1/2 activation of 
macrophages, perhaps through binding competition with native ligands, leading to 
reduction in pro-inflammatory cytokines and chemokines IL-6, TNF, CCL3 and CCL4. 
As a result of LipA-mediated immunosuppression, macrophages produce less 
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Release of Lipoyl-E2-PDH 
 In order for S. aureus to dampen the activation of macrophages, it needs to 
release lipoyl-E2-PDH. Once outside of the bacterial cell, our data suggests that lipoyl-
E2-PDH can block TLR1/2 activation of macrophages. Normally, lipoyl-E2-PDH 
functions within the PDH complex present in the cytoplasm of S. aureus. The PDH 
complex catalyzes the oxidative decarboxylation of pyruvate to form acetyl coenzyme A, 
feeding several metabolic pathways in the cells, including the TCA cycle, fatty acid 
biosynthesis, and parts of isoprenoid biosynthesis. E2-PDH is not predicted to be 
secreted by S. aureus as it does not have a secretion sequence. Thus, it is unexpected 
to see a subunit of this cytoplasmic enzyme complex in the cell-free supernatant of S. 
aureus. In this section, we will discuss the release of lipoyl-E2-PDH by S. aureus. 
Excretion of Cytoplasmic Proteins.  
Our detection methods for identifying lipoylated proteins in the supernatant of S. 
aureus indicates that, of the four cytosolic lipoylated proteins, E2-PDH is the only 
subunit released by the bacterium (Figure 11). The extracellular detection of lipoyl-E2-
PDH is unusual, considering it lacks a discernable secretion sequence and is 
predominantly thought to function in the cytosol as a component of the PDH complex. 
However, metabolic enzymes and subunits of metabolic complexes, like PDH, are 
routinely found in the extracellular environment in numerous bacteria and eukaryotes 
(347, 348). E2-PDH was found on the surface of L. monocytogenes, where it depends 
on the SecA2 accessory secretion system for surface display (359). Furthermore, E2-
PDH is present on the surface of M. pneumoniae, where it is hypothesized to bind 
human plasminogen (392, 393). In prior studies, it was shown that S. aureus can 
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release cytoplasmic proteins into the extracellular environment including E2-PDH (357, 
358). This release of cytoplasmic proteins into the extracellular environment correlated 
with cell division and is linked to the activity of the peptidoglycan modifying enzyme, Atl 
(357). Not every cytoplasmic protein of S. aureus is found extracellularly, suggesting 
that this phenomenon is specific and not exclusively due to lysis of the bacterial cell. 
Indeed, our studies support data in literature, as we saw the release of lipoyl-E2-PDH 
requires Atl and to a lesser extent SecA2, despite the presence of cytosolic lipoyl-E2-
PDH in Datl and DsecA2 mutants (Figure 16). The roles of Atl and SecA2 in E2-PDH 
release are yet to be confirmed through genetic complementation of the Datl and 
DsecA2 mutant strains. The exact mechanism by which particular cytoplasmic proteins 
like lipoyl-E2-PDH are selected for extracellular release and then allowed to traverse 
across the bacterial membrane also needs to be studied. One way to approach this 
would be to fluorescently tag E2-PDH with a protein such as green fluorescent protein. 
Then, we could observe the localization dynamics of this tagged E2-PDH during phases 
of S. aureus growth with fluorescence microscopy. Furthermore, protein secretion in 
bacteria can require the assistance of chaperone proteins. Thus, it is possible that 
chaperone proteins or other proteins besides the other subunits of PDH interact with 
E2-PDH to facilitate its release into the extracellular environment.  
Surface Display of E2-PDH and GcvH.  
It is unknown how cytoplasmic proteins, like E2-PDH, that lack a discernable 
secretion sequence are released by bacteria. However, what we do know is that, as 
mentioned previously, other bacteria express cytoplasmic proteins on their surface. Our 
data confirm this happens in S. aureus, as we saw E2-PDH on the cell surface (Figure 
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15). In addition to E2-PDH, we find GcvH on the surface though we cannot detect it in 
the supernatant by immunoblot. It needs to be tested if the presence of E2-PDH and 
GcvH on the surface changes during the growth of S. aureus. Moreover, we wondered if 
the lipoyl moiety of E2-PDH is necessary for its release into the extracellular 
environment. However, our data indicates that the lipoyl moiety of E2-PDH and GcvH 
do not appear to be necessary for surface display, as we can detect both E2-PDH and 
GcvH on the surface a DlipA mutant (Figure 15). We surmise that both E2-PDH and 
GcvH on the surface of a DlipA mutant are modified with the medium chain fatty acid 
precursor to lipoic acid, octanoic acid. It is possible that the modification of octanoic acid 
on E2-PDH and GcvH facilitates their localization to the surface. We could test this 
possibility by substituting alanine for the conserved modified lysine residues of E2-PDH 
and GcvH and then assess the surface display of the non-modified E2-PDH and GcvH. 
If the modification of octanoic acid is necessary for the surface display of E2-PDH and 
GcvH, then we expect mutation of the modified conserved lysine residues would disrupt 
surface display. Along these lines, it remains to be explored if a DlipA mutant could 
release non-lipoyl-E2-PDH into the extracellular environment or if E2-PDH stays 
associated with the bacterial surface. More sensitive detection methods, such as mass 
spectrometry of exoproteins, could reveal if other lipoyl-proteins are present in the 
supernatant and if a DlipA mutant releases non-lipoyl modified versions of E2-PDH.  
Why E2-PDH?  
Out of the four lipoyl-proteins in the cytosol of S. aureus, we identified that only 
lipoyl-E2-PDH is released during growth in our conditions. PDH is one of the largest 
cellular machines in Gram-positive bacteria, as it contains 60 copies of E1 and E2 
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subunits, and 6-12 copies of the E3 subunit (365, 402). This is in contrast to the other 
lipoic acid modified subunits of enzyme complexes that contain fewer copies (~24 for 
E2-OGDH) of the lipoylated subunits (361). Thus, the high abundance of lipoyl-E2-PDH 
copies in the cytosol may explain why this protein is the primary released lipoyl-protein. 
The higher abundance of lipoyl-E2-PDH in the cytosol is evident in our immunoblots, as 
E2-PDH is the most intense band on the immunoblot (Figure 11A).  
Our studies determined that a synthetic tripeptide containing the lipoyl-lysine 
residue, DKLA, but not the unmodified tripeptide, DKA, is sufficient to restrict 
macrophage activation (Figure 22 and 23). This indicates the lipoyl moiety is required 
for immune suppression rather than a unique property of the lipoyl-E2-PDH protein 
itself. Since a lipoyl modification is sufficient for blunting macrophage activation, we 
believe that it is possible for any lipoyl protein, where the domain is accessible, to 
restrict macrophage activation. Future studies will need to test if any of the other three 
lipoyl-proteins of S. aureus (E2-OGDH, E2-BCODH, and GcvH) can confer 
immunosuppressive properties.  
Concluding Remarks. 
 In summary, S. aureus is able to release lipoyl-E2-PDH into the supernatant 
through an unknown mechanism. Because lipoyl-E2-PDH is an easily detectable 
protein, it can serve as a tool to more carefully delineate the process by which bacteria, 
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Lipoic Acid and Lipoyl-Protein Suppression of Macrophage Activation 
In this thesis, we provide data to support the hypothesis that bacterial derived 
lipoic acid can suppress the activation of innate immune cells. Lipoic acid derived from 
bacteria encounters immune cells in a form that is covalently attached to conserved 
lysine residues in the E2 subunit of PDH. Our data indicate that free lipoic acid and 
protein-linked lipoic acid confer different immunosuppressive properties on 
macrophages. Therefore, free lipoic acid and lipoyl-proteins may use different methods 
to exert their immunosuppressive functions on macrophages. In this section, we 
speculate on what the mechanisms for free lipoic acid and lipoyl-protein based 
immunosuppression could be. 
Lipoic Acid Suppression of BMM Activation.  
Millimolar concentrations of free lipoic are needed to suppress the activation of 
BMMs by either S. aureus supernatant, or TLR1/2, TLR2/6, TLR4, and TLR5 agonists 
(Figure 17-19). We only tested if free lipoic acid could block the activation of TLRs 
present on the surface of macrophages. However, due to the broad suppressive effects 
of lipoic acid, we expect that it could likely block other TLR activation pathways or other 
PRRs expressed by macrophages. To assess if free lipoic acid can limit the activation of 
other TLRs, such as TLR3, TLR7, TLR8, and TLR9, which are expressed intracellularly, 
one could stimulate macrophages with TLR3/7/8/9 agonists in the presence or absence 
of free lipoic acid and determine macrophage activation by cytokine secretion. 
Moreover, it would be valuable to test if free lipoic acid can block the activation of other 
inflammatory pathways, such as the inflammasome, by stimulating macrophages with 
inflammasome agonists in the presence of free lipoic acid.  
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Besides TLR based suppression, we found that free lipoic acid reduces the 
surface expression of TLR2 and CD86 on BMMs (Figure 24). Our data indicate that free 
lipoic acid reduced expression of only certain surface molecules, like TLR2 and CD86 
but not TLR1 nor CD80. Therefore, we hypothesize that there are other markers of 
BMMs that may be regulated by lipoic acid through an undetermined mechanism. 
RNAseq could be a useful approach to understand the broad modulatory effects of free 
lipoic acid on expression of the full range of BMM transcripts or those of other innate 
immune cells. Data from RNAseq could determine if free lipoic acid can polarize 
macrophages to a more pro-inflammatory or anti-inflammatory state. Moreover, others 
found that high concentrations of free lipoic acid reduce the respiratory burst of 
neutrophils through its antioxidant properties and block the translocation of the 
transcription factor, NFkB, to the nucleus (380-383). Also, free lipoic acid can activate 
the phosphoinositide 3-kinase/Akt signaling pathway to reduce inflammatory cytokine 
production (384). The perturbation of respiratory burst, blockade of NFkB translocation, 
and activation of the phosphoinositide 3-kinase/Akt signaling pathway all occur 
internally within immune cells. Because free lipoic acid can block these internal 
processes of inflammation, it must be able to enter eukaryotic cells to do so. Little 
insight has been made into how free lipoic acid or lipoyl proteins can enter into 
eukaryotic cells. In enterocytes and hepatocytes, the sodium-dependent multivitamin 
transport system (SMVT) transports biotin and patothenate and is reported to be used 
by lipoic acid or lipoyl proteins to enter these eukaryotic cells (403-405). It is unknown if 
macrophages express or utilize the SMVT system; thus, free lipoic acid may gain entry 
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into macrophages by other means, such as passive diffusion, which would necessitate 
the high concentrations needed for immunosuppression in our studies. 
Lipoyl-E2-PDH Restriction of BMM Activation.  
In contrast to free lipoic acid, which can limit the activation of BMMs through 
multiple TLRs, we found that purified lipoyl-E2-PDH limitsTLR1/2 activation of 
macrophages by Pam3CSK4 (Figure 22). For free lipoic acid to exert its TLR-restrictive 
function, millimolar quantities were needed. In contrast, nanomolar quantities of lipoyl-
E2-PDH or DKLA were sufficient to reduce TLR1/2 activation of BMMs. We hypothesize 
that a 1000-fold less lipoyl-protein is required for immunosuppression compared to free 
lipoic acid possibly due to the hydrophobic nature of free lipoic acid. The protein-bound 
form of lipoic acid would be more stable in solution and could access the macrophage 
more easily compared to hydrophobic free lipoic acid. Moreover, free lipoic acid could 
possibly diffuse across cellular membranes where it is then attached to host metabolic 
proteins, whereas the protein or peptide-bound form cannot readily do so.  
TLR2 Activation by S. aureus.  
To speculate about why lipoyl-E2-PDH only blocks TLR1/2 activation of BMMs, 
we need to revisit how the innate immune system mainly recognizes S. aureus. S. 
aureus produces numerous PAMPs that are recognized by TLR2 like peptidoglycan and 
lipoteichoic acid (132, 163, 164). However, the biological relevance of these PAMPs is 
questioned as the concentrations of peptidoglycan and lipoteichoic acid needed to 
activate TLR2 are not physiological (406). Treatment of peptidoglycan purification 
preparations with hydrofluoric acid to degrade LTA and lipoproteins completely 
abrogates the TLR2-activating effects of this purified peptidoglycan (165). Similarly, 
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treatment of S. aureus cell wall components with lipase to degrade the lipoproteins also 
abrogated the TLR2 activating ability of the purified cell wall fractions (166, 167). The 
consensus for S. aureus-based TLR2 activation is that lipoproteins are the most potent 
PAMPs that activate TLR2. These abundant lipoproteins from S. aureus can be 
diacylated or triacylated and are recognized by TLR1/2 and TLR2/6, respectively (158). 
S. aureus is reported to predominantly synthesize lipoproteins in their triacylated form in 
standard growth conditions (160, 161). Thus, TLR1/2 heterodimerization is a presumed 
major pathway of immune activation in S. aureus, necessitating adaptations by this 
pathogen to overcome TLR1/2 recognition.  
TLR1/2 Restriction by Lipoyl-E2-PDH.  
Triacylated lipoproteins and peptides bind to TLR1 and TLR2 via interactions of 
the amide-linked acyl chain with TLR1 and the cysteine-linked diacylglycerol with TLR2 
(157, 162). Lipoyl-PDH and lipoyl peptides suppress macrophage activation by 
Pam3CSK4, but not Pam2CSK4, suggesting a mechanism of blockade that is specific 
to TLR1/2. We found that the lipoyl moiety on DKLA is necessary to block the TLR1/2 
activation by the native triacylated lipoprotein SitC from S. aureus (Figure 23). The 
crystal structure of TLR1/2 with Pam3CSK4 revealed a hydrophobic binding pocket in 
TLR1 that interacts with the amide bound lipid of Pam3CSK4 (157). This hydrophobic 
interaction is reminiscent of how amide-linked lipoic acid binds within the hydrophobic 
pocket of E1 subunits (407, 408). This is in contrast to the binding pocket of TLR6, 
which is much shorter and is truncated by bulky phenylalanine side chains (162). 
Furthermore, TLR1 is thought to preferentially bind to peptide-bound medium chain fatty 
acids (> 6 carbons), resulting in activation of immune cells (409-411). We surmise that 
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the lipid-like structure of lipoic acid may facilitate E2-PDH and DKLA binding in the TLR1 
lipid binding pocket in order to compete with triacylated lipoproteins/peptides to prevent 
TLR1/2 activation. We tested this hypothesis by assessing if DKLA but not DKA could 
reduce the binding of Pam3CSK4 to TLR1/2. Using an enzyme-linked immunosorbent 
assay, we found that high molar excess concentrations (~20 times) of DKLA, but not 
DKA, were able to reproducibly block Pam3CSK4 binding to TLR1/2 (Figure 25). 
However, upon diluting out the competing tripeptides, we experienced variability 
between technical and biological replicates. This perhaps is due to lack of optimal 
dimerization between recombinant TLR1 and TLR2, which could lower the binding 
efficacy of Pam3CSK4 in the various replicates. Furthermore, this approach fails to 
distinguish if blocking of Pam3CKS4 binding is occurring in the ligand binding site of 
TLR1 or TLR2. We suggest that more sensitive biochemical approaches such as 
isothermal titration calorimetry, using only TLR1 or TLR2 with DKLA or DKA to measure 
binding events could decipher if the lipoyl moiety binds to TLR1 or TLR2. To determine 
if the lipoyl moiety binds within the pocket of TLR1, we could systematically mutate 
residues that comprise the binding pocket of TLR1 and assess by isothermal titration 
calorimetry if binding between DKLA with TLR1 still occurs. Also, if isothermal titration 
calorimetry indicates an interaction between TLR1 and DKLA, we could perform protein 
X-ray crystallography of TLR1 co-crystallized with DKLA to see where DKLA may be 
binding. 
The biologically active form of lipoic acid is not a linear fatty acid as it contains a 
dithiolane ring. This dithiolane ring may sterically hinder the insertion of lipoic acid within 
the TLR1 binding pocket. However, the disulfide bond in the dithiolane ring can be 
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reduced in certain conditions, breaking up the ring structure in the head group of lipoic 
acid (360). Although the extracellular environment is thought to be mainly oxidizing, the 
effect of the redox state of the lipoyl moiety on proteins to confer immunosuppressive 
functions needs to be considered. To test this, we could treat DKLA with a reducing 
agent such as dithiothreitol and assess by isothermal titration calorimetry the difference 
of binding between dithiothreitol treated and untreated DKLA with TLR1. 
Concluding Remarks. 
 Free lipoic acid and protein-bound lipoic acid derived from bacteria confer 
different immunosuppressive functions. We found that free lipoic acid can broadly 
suppress surface TLR activation by macrophages, as well as modulate the surface 
expression levels of certain markers on macrophages. This is in contrast to lipoyl-E2-
PDH, which we found only blocks TLR1/2 activation. Future studies will need to be 
conducted to determine how free lipoic acid can exert its broad anti-inflammatory 
activities on macrophages. Furthermore, we need to test how lipoyl-E2-PDH and the 
lipoyl-peptide DKLA only restricts TLR1/2 activation of macrophages. 
Breadth of Lipoic Acid Synthesis Dependent Suppression of Immune Cells 
 Though macrophages were used throughout this thesis, we observed that a DlipA 
mutant increased the activation of neutrophils as well as dendritic cells. Since lipoyl-
proteins restrict TLR1/2 activation, any cell that expresses TLR1/2, such as neutrophils 
and dendritic cells, may be modulated by LipA activity. Other innate immune cells that 
express TLR1/2 need to be tested to determine if their functions are also modulated by 
LipA-mediated mechanisms. Additionally, non-immune cells such as keratinocytes in 
the skin or epithelial cells can express TLR1/2 (412). Therefore, it would be interesting 
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to assess if activity of LipA modulates functions of these barrier cells that can encounter 
S. aureus during an infection. This could be tested by treating keratinocytes with 
supernatant from a DlipA mutant and then measure cytokine secretion as a readout of 
activation. 
Use of lipoic acid as cofactor in PDH is conserved in all kingdoms of life, though 
some bacterial species such as H. pylori do not use lipoic acid as a metabolic cofactor. 
It is unknown if lipoic acid synthesis in other Gram-positive or Gram-negative pathogens 
confers immunosuppressive functions to facilitate pathogenesis. Given the conservation 
of lipoic acid, we posit that any bacterial pathogen that activates the innate immune 
system through TLR1/2 and uses lipoic acid as a metabolic cofactor could use it a 
mechanism to evade TLR1/2 activation. However, the ability of lipoyl-E2-PDH or lipoyl-
proteins to moonlight depends on the extracellular presence of lipoylated metabolic 
proteins. As mentioned previously, E2-PDH is found on the surface of L. 
monocytogenes and M. pneumoniae. It is unknown if surface-associated E2-PDH is 
ever released from the surface of these bacteria into the extracellular environment, like 
we saw with S. aureus. Thus, we need to assess if other bacteria, such as L. 
monocytogenes and M. pneumoniae, release lipoylated-E2-PDH or other lipoyl-proteins 
into the extracellular environment during growth.  
Other TLR2-based Evasion Mechanisms.  
S. aureus has evolved in other ways to evade TLR2 recognition by the innate 
immune system. For example, the superantigen-like protein SSL3 is known to bind to 
the extracellular domain of TLR2 and function as an antagonist (276). Additionally, 
recent work conducted by Xi Chen in the Alonzo laboratory identified that the glycerol 
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ester hydrolase (Geh) of S. aureus prevents activation of macrophages by both 
diacylated and triacylated lipopeptides likely through cleavage of the two ester-bound 
lipid chains in the lipopeptides (413). The activity of SSL3, Geh, and LipA all seem to 
mask the TLR2-dependent activation of innate immune cells through slightly different 
mechanisms. For example, Geh only cleaves ester-bound lipid chains in triacylated 
lipoproteins, which are recognized by TLR2. We believe that the lipoyl moiety interferes 
with TLR1 recognition of the amide-linked lipid chain of the triacylated lipoprotein. 
Therefore, the activities of Geh and LipA are likely both important for blocking TLR2-
based recognition of S. aureus. Due to the broad immunosuppressive functions of lipoic 
acid, we believe that LipA could alter the pathogenesis of S. aureus in a non-TLR2 
dependent manner. We need to determine if a ΔlipA mutant is compromised for 
infection in TLR2 knockout animals as we know that a Δgeh mutant can colonize TLR2 
knockout animals to the same level as WT S. aureus (413). The combined contribution 
of all three known TLR2-based evasion mechanisms in S. aureus during infection needs 
to be further explored. This could be assessed by creating a triple mutant strain of S. 
aureus that contains deletions of the genes that encode for LipA, Geh, and SSL3 and 
assessing infection outcomes.   
Concluding Remarks. 
 In this thesis, we primarily focused on how lipoic acid synthesis in S. aureus 
suppresses the activation of macrophages. This finding could have broad implications in 
the sense that many bacterial species use lipoic acid as a metabolic cofactor. Thus it is 
possible that other bacteria could use lipoic acid as means to dampen macrophage 
activation. Furthermore, other cells in the innate immune system can recognize and 
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become activated by S. aureus. Though we predominantly use macrophages in this 
thesis, other cells that express TLR1/2 could be blocked by lipoyl protein production. 
Lastly, S. aureus has more than one way to block TLR2 activation by innate immunity. It 
needs to be considered how other TLR2 evasion of mechanisms work either individually 
or together in the context of infection to evade the innate immune system.  
Importance of Lipoic Acid Synthesis in S. aureus Pathogenesis 
 An important outcome of this thesis was our ability to demonstrate that lipoic acid 
synthesis can influence the virulence of S. aureus through its immunosuppressive 
abilities. Although lipoic acid synthesis is intimately linked to bacterial metabolism, the 
ability of lipoic acid to dampen macrophage antibacterial activities is crucial to the ability 
of S. aureus to survive in the host. In this section, we discuss the implications of lipoic 
acid synthesis in promoting S. aureus pathogenesis.  
Inflammation Dynamics in ΔlipA Mutant-Infected Mice.  
A ΔlipA mutant elicited heightened levels of CCL3 and CCL4 in the serum early 
in infection and greater proportions of activated macrophages (CCR5+ IA/IEhi) at the site 
of infection were not seen until later in the infection time-course (Figure 26 and 27). 
However, CCL3 and CCL4 levels were indistinguishable later in infection. We posit that 
the early increase in macrophage chemokines is likely a meaningful early signature that 
promotes the enhanced recruitment and activation of macrophages seen at 72 hours in 
ΔlipA-infected animals. At later time points of infection, when many ΔlipA-infected mice 
have undetectable infection, the effects of lipoyl-E2-PDH on chemokine secretion are 
less clear. 
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During infection, circulating monocytes in the blood are recruited into the 
peritoneal cavity and differentiate into F4/80-expressing macrophages (111). These 
recruited monocytes that differentiate into macrophages are recruited by the chemokine 
CCL2, and these cells also express the CCR2 receptor (114, 115). We did not test for 
CCL2 levels in the serum of ΔlipA mutant-infected animals nor assess CCR2 levels on 
the macrophage population at the site of infection. Though we see differences in the 
proportion of pro-inflammatory macrophages during infection, at both early and later 
stages of infection, the total number of macrophages, neutrophils, and dendritic cells 
were not different between the infection groups. These data are somewhat 
counterintuitive as presence of macrophage chemokines CCL3 and CCL4 in the serum 
would presumably recruit more macrophages and other innate immune cells to the site 
of infection with a ΔlipA mutant. Perhaps our assessment of immune cell numbers at 
16- or 72-hours post-infection failed to capture the proper timeframe in which increased 
cell numbers are present in ΔlipA mutant-infected animals if at all. We can test some of 
these ideas by assessing CCR2 levels on macrophages and CCL2 levels in the serum 
after infection with a ΔlipA mutant, and determine cell counts of the immune cells 
present earlier than 16 hours post-infection. 
Activated Macrophages by a ΔlipA Mutant Control Infection.  
Mice infected with a ΔlipA mutant of S. aureus more readily clear infection than 
mice infected with WT S. aureus (Figure 30). The clearance of bacteria in ΔlipA mutant-
infected animals correlated with the presence of greater proportions of activated 
macrophages. Upon isolation, these cells exhibited a greater ability to limit bacterial 
growth ex vivo (Figure 33). Using clodronate to deplete mice of macrophages, we 
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determined that the attenuation of a DlipA mutant during peritoneal infection is mediated 
almost exclusively by activated macrophages (Figure 32). This was surprising, as we 
surmised a proportion of the virulence defect of a DlipA mutant was derived from 
compromised metabolism due to lipoic acid limitation (373). During bloodstream 
infection, S. aureus mutants with defects in bacterial lipoic acid synthesis and salvage 
lead to tissue-specific virulence defects where infection of the kidney depends on lipoic 
acid salvage enzymes, but infection of the heart requires LipA (373). These 
observations suggest there is varied dependency on de novo lipoic acid synthesis for S. 
aureus survival in different tissue sites. Although virulence defects in the heart were 
previously attributed to lipoic acid auxotrophy, data in this thesis suggest the alternative 
possibility that LipA-dependent enhancement of antimicrobial innate immunity promotes 
infection persistence. To test this, we could systemically infect mice that are depleted of 
macrophages through treatment with liposomes containing clodronate and then 
measure the bacterial loads in the heart. We found that LipA is not necessary for 
bacterial survival in the peritoneal cavity in the absence of macrophages (Figure 32B 
and 32C).  We surmise that either an alternative metabolism takes over to allow survival 
in the absence of lipoic acid, or that sufficient trace lipoic acid is available to maintain 
metabolic activity (414-417). Incorporation of trace lipoic acid, while sufficient to 
maintain growth, appears to be insufficient to suppress immune responses in 
macrophage depleted mice. 
Clodronate Depletion.  
To deplete mice of macrophages, we administered clodronate-containing 
liposomes (86, 121, 122). At 72 hours post-infection in the peritoneal cavity of 
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macrophage depleted mice, we saw complete clearance of bacteria in some animals. 
Clodronate is used extensively to deplete macrophages, but other cells such as 
monocytes can also be depleted (418). Neutrophils, on the other hand, are still present 
in clodronate-treated mice, possibly in even greater amounts after S. aureus infection 
(121). The presence of neutrophils in the peritoneal cavity, given their crucial role in 
protection from S. aureus infection (86, 87), could account for clearance observed in 
some of the macrophage depleted mice. Though we have noted that lipoic acid 
synthesis interferes with neutrophil cytokine and chemokine secretion, this did not 
translate to enhanced clearance of a DlipA mutant compared to WT in macrophage 
depleted mice. To assess if neutrophils account for the clearance of bacteria in 
macrophage depleted mice, we could deplete mice of both macrophages and 
neutrophils and determine if mice are still able to clear bacteria after infection. 
Nonetheless, our studies show macrophage activity primarily leads to the virulence 
defect of a DlipA mutant.  
LipA Activity Modulates Macrophage ROS and RNS.  
Our data indicate that macrophages from DlipA mutant-infected mice are primed 
to produce higher amounts of ROS and NO•. Moreover, inhibition of NADPH oxidase 
activity by gp91ds-tat and iNOS activity by L-NIL abolished the greater restrictive 
capacity of macrophages from DlipA mutant-infected mice. Because both inhibitors 
abrogate bacterial growth defects when used separately, we assume that NADPH 
oxidase-derived ROS and iNOS-derived NO• are both required for S. aureus growth 
restriction. It is known that NO• alone is not a highly reactive molecule and has an 
expansive range of cellular functions (254). Rather, NO• becomes highly reactive when 
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it is converted to oxidative products such as ONOO- from superoxide (254). The 
resulting powerfully reactive ONOO- leads to microbial destruction by reacting with 
iron/sulfur metal centers, causing tyrosine nitration, triggering lipid peroxidation, and 
damaging DNA (237). As such, elimination of either ROS production or NO• production 
has the potential to compromise generation of potent antimicrobials, such as ONOO-. 
We propose a mechanism based on our data where the immunosuppressive effects of 
lipoic acid synthesis by S. aureus leads to reduced generation of the highly antimicrobial 
RNS derived from NADPH oxidase superoxide and NO•. The assessment of specific 
RNS species production using boronate-containing fluorescent probes (ESIPT) in 
macrophages isolated from WT and DlipA-infected animals needs to be tested, although 
this may be difficult due to the short half-life of species such as ONOO- (419, 420).  
TLR2 Activation of ROS.  
Lipoic acid synthesis is necessary to dampen TLR1/2 activation of BMMs through 
the release of lipoyl-E2-PDH by WT S. aureus. Besides leading to the production of pro-
inflammatory cytokines and chemokines, TLR2 can mediate the induction of ROS 
generation. Recognition of Mycobacterium tuberculosis by TLR2 leads to a direct 
interaction between TLR2 and NADPH oxidase to ultimately stimulate ROS production 
(421, 422). Similarly, activation of TLR2 by heat-killed L. monocytogenes induces an 
autophagy-associated protein, Rubicon, which interacts with the p22phox subunit of 
NADPH oxidase to aid in its phagosomal trafficking and subsequent superoxide 
production (423). Furthermore, TLR2 is necessary for efficient NADPH oxidase-
dependent killing of S. aureus in murine neutrophils (424). Indeed, our data aligns with 
these studies and suggests that LipA-dependent inhibition of TLR1/2 signaling by lipoyl-
 
        
155 
E2-PDH prevents activation of NADPH oxidase and thus ROS generation. This can be 
tested by treating macrophages with supernatant from a DlipA mutant and assessing 
levels of the NADPH oxidase complex proteins by immunoblot.  
Effects of Free Lipoic Acid on NADPH Oxidase and iNOS.  
In order to activate NADPH oxidase, Akt (protein kinase B) must phosphorylate 
p47phox (425). As mentioned before, high concentrations of free lipoic acid can activate 
Akt by increasing the levels of phosphorylated Akt (384). Because a DlipA mutant 
cannot synthesize lipoic acid, one might assume lower Akt activation and NADPH 
oxidase activity during infection. Our data does not support this assumption, as we see 
higher NADPH oxidase-derived ROS in macrophages from DlipA mutant-infected mice. 
We know that S. aureus derived lipoic acid is bound to proteins; thus, we believe the 
effects on Akt likely are not manifested in our infection system. In regard to iNOS 
activity, free lipoic acid can inhibit the induction of iNOS activity by IL-1b at the protein 
level (385). Thus, a DlipA mutant is likely more predisposed to activate iNOS activity 
leading to the observed higher NO• production. To test if a DlipA mutant may modulate 
Akt or iNOS activity, we can treat macrophages with supernatant from a DlipA mutant 
and then assess levels of phosphorylated Akt and the abundance of iNOS by 
immunoblot. Finally, free lipoic acid is known to have antioxidant activity that diminishes 
the respiratory burst of phagocytes (381, 383). Therefore, mice infected with a DlipA 
mutant may also be less likely to detoxify macrophage ROS or RNS. The detailed 
cellular mechanism behind how S. aureus lipoic acid synthesis interferes with ROS and 
RNS generation in macrophages during infection needs to be investigated. To test this, 
we can first activate macrophages with S. aureus supernatant to generate ROS and 
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RNS and treat these activated macrophages with free lipoic acid or lipoyl-E2-PDH. Then 
we could use fluorescent probes that measure ROS such as Cellrox or perform a Griess 
test to measure RNS production to determine if free lipoic acid or lipoyl-E2-PDH 
treatment modulates ROS or RNS levels.   
mROS Inhibition of S. aureus.  
Upon stimulation of macrophages through TLR1/2/4, mitochondria are recruited 
to the phagosome and can produce mROS which are known to contribute to the killing 
of S. aureus within the phagosome (248, 251, 252). Curiously, we found that mROS do 
not contribute to the ability of macrophages from DlipA-infected mice to restrict bacterial 
outgrowth. NO• and the resulting ONOO- are capable of interfering with the 
mitochondrial electron transport chain and perturb mitochondria respiration (254). 
However, this disruption of electron transfer by NO• can markedly increase the leakage 
of electrons resulting in enhanced formation of superoxide in the mitochondrial matrix 
(254). In a recent study, it was found that alpha-hemolysin activates the inflammasome 
in macrophages, leading to sequestration of mitochondria away from the phagosomes 
(252). These authors believe that the failure of mitochondria to localize and deliver 
mROS into the phagosome contributes to S. aureus survival in macrophages (252). 
Thus, it is possible the secretion of alpha-hemolysin could interfere with mROS-
mediated killing during infection in our ex vivo survival experiments. Nonetheless, we 
saw that mROS production in macrophages contributed to growth restriction of S. 
aureus (Figure 36A), but our data suggests that the greater ROS-related restrictive 
function of macrophages from DlipA-infected mice is mediated by NADPH oxidase 
derived ROS.  
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Macrophage Restriction of S. aureus. 
 Infection with WT or DlipA S. aureus elicits macrophages that possess a greater 
intrinsic ability to restrict growth compared to macrophages from mock-infected mice. 
Inhibition of mROS, NADPH oxidase or iNOS in macrophages from S. aureus-infected 
mice (WT or DlipA) still retain their greater restrictive capacity relative to the 
macrophages from mock-infected mice. Thus, S. aureus infection elicits macrophages 
that upon isolation and re-infection are more predisposed to produce greater ROS from 
the mitochondria or NADPH oxidase and RNS from iNOS activity that coalesce to 
hinder bacterial growth. In each instance where one main source of antimicrobial activity 
is blocked (ROS, mROS, or RNS), the other two pathways are sufficient to hinder 
bacteria growth. However, only upon treatment of macrophages with DPI, which blocks 
all ROS production and iNOS activity through off-target effects (398, 426), do we see no 
differences in growth restrictive function between S. aureus elicited macrophages or 
macrophages from mock-infected mice (Figure 35). These data highlight how S. aureus 
infection elicits macrophages that have ROS and RNS dependent restrictive functions.  
A DlipA Mutant Fails to Prime the Adaptive Immune System 
 Macrophages play a major role in the activation of the adaptive immune system 
through production of cytokines and chemokines that regulate T cell function and 
facilitate dendritic cell maturation, leading to antigen presentation and induction of 
adaptive immunity (90, 427). Despite the improved activation of innate immunity and 
microbial clearance after infection with a DlipA mutant, we found that prior infection 
failed to protect the host or even lead to more severe infection after secondary 
challenge. We suspect that the explanation for such poor immunity to infection centers 
 
        
158 
on the fact that S. aureus is destroyed too rapidly after infection with a DlipA mutant, a 
consequence of improved macrophage activation. The robust and destructive oxidative 
burst of macrophages interferes with optimal antigen presentation due to rapid 
phagolysosome fusion and destruction of antigenic peptides, lowering their ability to 
optimally present antigen (427). This contrasts with dendritic cells, which have 
drastically different phagosomal environments. Dendritic cell phagosomes are less 
destructive and can conserve antigenic information from engulfed pathogens thereby 
promoting efficient antigen presentation (427). Studies on early antibiotic intervention in 
Salmonella and Chlamydia infections found that early administration shortened the 
duration of antigen presentation, leading to poor protective memory (428). This 
observation supports our hypothesis that activated macrophages destroy antigen too 
quickly during infection with a DlipA mutant, leading to poor protective memory. Our 
data also demonstrate that NO• production is increased upon infection with a DlipA 
mutant, which is in part responsible for the antimicrobial function of recruited 
macrophages. Beyond its importance in the generation of RNS, NO• has diverse 
signaling functions that can dramatically affect adaptive immune responses such as 
inhibition of T cell proliferation (429-431). Thus, it is possible that the greater NO• 
produced by macrophages during infection with a DlipA mutant may interfere with 
optimal T cell proliferation. Whatever the ultimate mechanism, what seems clear is that 
improved activation of innate immune responses is unable to facilitate acquired 
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Summary 
 In this thesis, we provided evidence for a novel S. aureus macrophage evasion 
mechanism. We found that synthesis of the metabolic cofactor lipoic acid by LipA is 
necessary for the suppression of macrophage inflammatory responses. This is 
mediated by the release of lipoyl-E2-PDH by S. aureus where it moonlights by 
restricting the TLR1/2 activation by triacylated lipoproteins of macrophages. Moreover, 
S. aureus lipoyl-protein production in vivo results in impaired activation of inflammatory 
ROS and RNS responses of macrophages and leads to reduced host control of 
bacterial growth and dissemination. Additionally, increased macrophage responses do 
not necessarily translate to protection against reinfection. 
Bacterial pathogens are a significant cause of mortality and morbidity in human 
health. Modern medicine is faced with a crisis concerning the development of bacterial 
resistance to common treatment methods such as antibiotics. It is imperative to develop 
new therapeutics that target novel bacterial targets that do not lead to resistance. To 
begin to undercover novel therapeutics against bacterial pathogens, we must 
fundamentally understand how these pathogens interact with the host to cause disease. 
Thus, the scope of this thesis encompassed three main objectives: (1) to understand 
how bacteria cause disease; (2) to study how the host responds to bacterial disease; 
and (3) to uncover novel mechanisms by which bacterial pathogens evade the host 
response to infection. By understanding the interaction between the host and the 
pathogen, we can potentially identify new means to treat these infections. In line with 
these objectives, the work in this thesis has broadened our understanding that bacterial 
metabolism is closely linked with the evasion of innate immune responses by virtue of 
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the moonlighting activity of a metabolic protein. The metabolic disadvantage coupled 
with the observed heightened innate immune response associated with a S. aureus 
strain containing a mutation in the gene encoding for the lipoic acid synthetase, 
highlights a possibly lucrative therapeutic target for S. aureus infections that may cripple 
bacterial replication but still enhance host immunity. This work could have broad 
applications to other bacterial pathogens as well given that lipoic acid is a highly 
conserved metabolic cofactor in many human pathogens.
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Figure 42. Permission to Reproduce Copyrighted Content. Reprinted with 
permission from Spalding and Prigge, 2010 (360). See figure 2A.
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